

B/2

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
15 May 2003 (15.05.2003)

PCT

(10) International Publication Number  
WO 03/040373 A2(51) International Patent Classification<sup>7</sup>: C12N 15/52,  
15/53, 15/54, 15/60, C12P 13/08, C12N 1/21 // (C12P  
13/08, C12R 1:15)MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.

(21) International Application Number: PCT/EP02/08464

(22) International Filing Date: 30 July 2002 (30.07.2002)

(25) Filing Language: English

(26) Publication Language: English

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),  
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,  
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,  
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,  
GW, ML, MR, NE, SN, TD, TG).(30) Priority Data:  
60/309,878 6 August 2001 (06.08.2001) US(71) Applicant (*for all designated States except US*): DE-  
GUSSA AG [DE/DE]; Bennigsenplatz 1, 40474 Düssel-  
dorf (DE).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): BATHE,  
Brigitte [DE/DE]; Twieten 1, 33154 Salzkotten (DE).  
KREUTZER, Caroline [DE/DE]; Poststrasse 16, 49326  
Melle (DE). MÖCKEL, Bettina [DE/DE]; Benrode-  
strasse 35, 40597 Düsseldorf (DE). THIERBACH, Georg  
[DE/DE]; Gunststrasse 21, 33613 Bielefeld (DE).(74) Common Representative: DEGUSSA AG; Intellectual  
Property Management, Patents And Trademarks, Location  
Hanau, P.O. Box 13 45, 63403 Hanau (DE).(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

## Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW. ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)*
- *of inventorship (Rule 4.17(iv)) for US only*

## Published:

- *without international search report and to be republished upon receipt of that report*

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 03/040373 A2

(54) Title: CORYNEFORM BACTERIA WHICH PRODUCE CHEMICAL COMPOUNDS I

(57) Abstract: The invention relates to coryneform bacteria which have, in addition to at least one copy, present at the natural site (locus), of an open reading frame (ORF), gene or allele which codes for the synthesis of a protein or an RNA, in each case a second, optionally third or fourth copy of this open reading frame (ORF), gene or allele at in each case a second, optionally third or fourth site in a form integrated into the chromosome and processes for the preparation of chemical compounds by fermentation of these bacteria.

**Coryneform Bacteria which Produce Chemical Compounds I**

## Prior Art

Chemical compounds, which means, in particular, L-amino acids, vitamins, nucleosides and nucleotides and D-amino acids, are used in human medicine, in the pharmaceuticals industry, in cosmetics, in the foodstuffs industry and in animal nutrition.

Numerous of these compounds are prepared by fermentation from strains of coryneform bacteria, in particular Corynebacterium glutamicum. Because of their great importance, work is constantly being undertaken to improve the preparation processes. Improvements to the process can relate to fermentation measures, such as, for example, stirring and supply of oxygen, or the composition of the nutrient media, such as, for example, the sugar concentration during the fermentation, or the working up to the product form by, for example, ion exchange chromatography, or the intrinsic output properties of the microorganism itself.

Methods of mutagenesis, selection and mutant selection are used to improve the output properties of these microorganisms. Strains which are resistant to antimetabolites or are auxotrophic for metabolites of regulatory importance and which produce the particular compounds are obtained in this manner.

Methods of the recombinant DNA technique have also been employed for some years for improving the strain of Corynebacterium strains, by amplifying individual biosynthesis genes and investigating the effect on production.

A common method comprises amplification of certain biosynthesis genes in the particular microorganism by means of episomally replicating plasmids. This procedure has the

disadvantage that during the fermentation, which in industrial processes is in general associated with numerous generations, the plasmids are lost spontaneously (segregational instability).

- 5 Another method comprises duplicating certain biosynthesis genes by means of plasmids which do not replicate in the particular microorganism. In this method, the plasmid, including the cloned biosynthesis gene, is integrated into the chromosomal biosynthesis gene of the microorganism  
10 (Reinscheid et al., Applied and Environmental Microbiology 60(1), 126-132 (1994); Jetten et al., Applied Microbiology and Biotechnology 43(1):76-82 (1995)). A disadvantage of this method is that the nucleotide sequences of the plasmid and of the antibiotic resistance gene necessary for the  
15 selection remain in the microorganism. This is a disadvantage, for example, for the disposal and utilization of the biomass. Moreover, the expert expects such strains to be unstable as a result of disintegration by "Campbell type cross over" in a corresponding number of generations  
20 such as are usual in industrial fermentations.

#### Object of the Invention

The inventors had the object of providing new measures for improved fermentative preparation chemical compounds using coryneform bacteria.

#### 25 Summary of the Invention

- Coryneform bacteria which produce chemical compounds, characterised in that these have, in addition to at least one copy, present at the natural site (locus), of an open reading frame (ORF), gene or allele which codes for the  
30 synthesis of a protein or an RNA, a second, optionally third or fourth copy of the open reading frame (ORF), gene or allele in question at a second, optionally third or fourth site in a form integrated into the chromosome, no

nucleotide sequence which is capable of/enables episomal replication or transposition in microorganisms and no nucleotide sequence(s) which impart(s) resistance to antibiotics being present at the second, optionally third  
5 or fourth site, and the second, optionally third or fourth site not relating to open reading frames (ORF), genes or alleles which are essential for the growth of the bacteria and the production of the desired compound.

The invention also provides processes for the preparation  
10 of one or more chemical compounds, in which the following steps are carried out:

- a) fermentation of coryneform bacteria,
  - a1) which have, in addition to at least one copy, present at the natural site (locus), of an open  
15 reading frame (ORF), gene or allele which codes for the synthesis of a protein or an RNA, a second, optionally third or fourth copy of this open reading frame (ORF), gene or allele at a second, optionally third or fourth site in a form  
20 integrated into the chromosome, no nucleotide sequence which is capable of/enables episomal replication or transposition in microorganisms and no nucleotide sequence(s) which impart(s) resistance to antibiotics being present at the  
25 second, optionally third or fourth site, and the second, optionally third or fourth site not relating to open reading frames (ORF), genes or alleles which are essential for the growth of the bacteria and the production of the desired  
30 compound, and
  - a2) in which the intracellular activity of the corresponding protein is increased, in particular the nucleotide sequence which codes for this protein is over-expressed,

- b) concentration of the chemical compound(s) in the fermentation broth and/or in the cells of the bacteria,
- c) isolation of the chemical compound(s), optionally
- 5 d) with constituents from the fermentation broth and/or the biomass to the extent of > (greater than) 0 to 100 wt.%.

The invention also provides processes for the preparation of one or more chemical compounds, which comprise the  
10 following steps:

- a) fermentation of coryneform bacteria, in particular of the genus *Corynebacterium*, which have, in addition to the copy of an open reading frame (ORF), gene or allele present at the natural site (locus), in each  
15 case a second, optionally third or fourth copy of the open reading frame (ORF), gene or allele in question at in each case a second, optionally third or fourth site in integrated form, no nucleotide sequence which is capable of/enables episomal replication in  
20 microorganisms, no nucleotide sequence which is capable of/enables transposition and no nucleotide sequence which imparts resistance to antibiotics being present at the particular second, optionally third or fourth site,  
25 under conditions which allow expression of the said open reading frames (ORF), genes or alleles
- b) concentration of the chemical compound(s) in the fermentation broth and/or in the cells of the  
30 bacteria,
- c) isolation of the chemical compound(s), optionally

- d) with constituents from the fermentation broth and/or the biomass to the extent of > (greater than) 0 to 100%.

#### Detailed Description of the Invention

- 5 Chemical compounds are to be understood, in particular, as meaning amino acids, vitamins, nucleosides and nucleotides. The biosynthesis pathways of these compounds are known and are available in the prior art.

- Amino acids mean, preferably, L-amino acids, in particular  
10 the proteinogenic L-amino acids, chosen from the group consisting of L-aspartic acid, L-asparagine, L-threonine, L-serine, L-glutamic acid, L-glutamine, glycine, L-alanine, L-cysteine, L-valine, L-methionine, L-isoleucine, L-leucine, L-tyrosine, L-phenylalanine, L-histidine, L-lysine, L-tryptophan, L-proline and L-arginine and salts  
15 thereof, in particular L-lysine, L-methionine and L-threonine. L-Lysine is very particularly preferred.

- Proteinogenic amino acids are understood as meaning the amino acids which occur in natural proteins, that is to say  
20 in proteins of microorganisms, plants, animals and humans.

- Vitamins mean, in particular, vitamin B1 (thiamine), vitamin B2 (riboflavin), vitamin B5 (pantothenic acid), vitamin B6 (pyridoxines), vitamin B12 (cyanocobalamin), nicotinic acid/nicotinamide, vitamin M (folic acid) and  
25 vitamin E (tocopherol) and salts thereof, pantothenic acid being preferred.

Nucleosides and nucleotides mean, inter alia, S-adenosyl-methionine, inosine-5'-monophosphoric acid and guanosine-5'-monophosphoric acid and salts thereof.

- 30 The coryneform bacteria are, in particular, those of the genus *Corynebacterium*. Of the genus *Corynebacterium*, the species *Corynebacterium glutamicum*, *Corynebacterium*

ammoniogenes and *Corynebacterium thermoaminogenes* are preferred. Information on the taxonomic classification of strains of this group of bacteria is to be found, inter alia, in Kämpfer and Kroppenstedt (Canadian Journal of Microbiology 42, 989-1005 (1996)) and in US-A-5,250,434.

Suitable strains of the species *Corynebacterium glutamicum* (*C. glutamicum*) are, in particular, the known wild-type strains

10                    *Corynebacterium glutamicum* ATCC13032  
                    *Corynebacterium acetoglutamicum* ATCC15806  
                    *Corynebacterium acetoacidophilum* ATCC13870  
                    *Corynebacterium lilium* ATCC15990  
                    *Corynebacterium melassecola* ATCC17965  
                    *Corynebacterium herculis* ATCC13868  
15                    *Arthrobacter* sp. ATCC243  
                    *Brevibacterium chang-fua* ATCC14017  
                    *Brevibacterium flavum* ATCC14067  
                    *Brevibacterium lactofermentum* ATCC13869  
                    *Brevibacterium divaricatum* ATCC14020  
20                    *Brevibacterium taipei* ATCC13744 and  
                    *Microbacterium ammoniaphilum* ATCC21645

and mutants or strains, such as are known from the prior art, produced therefrom which produce chemical compounds.

Suitable strains of the species *Corynebacterium ammoniagenes* (*C. ammoniagenes*) are, in particular, the known wild-type strains

*Brevibacterium ammoniagenes* ATCC6871  
                    *Brevibacterium ammoniagenes* ATCC15137 and  
                    *Corynebacterium* sp. ATCC21084

30    and mutants or strains, such as are known from the prior art, produced therefrom which produce chemical compounds.

Suitable strains of the species *Corynebacterium thermoaminogenes* (*C. thermoaminogenes*) are, in particular, the known wild-type strains

- 5                    *Corynebacterium thermoaminogenes* FERM BP-1539  
                  *Corynebacterium thermoaminogenes* FERM BP-1540  
                  *Corynebacterium thermoaminogenes* FERM BP-1541 and  
                  *Corynebacterium thermoaminogenes* FERM BP-1542

and mutants or strains, such as are known from the prior art, produced therefrom which produce chemical compounds.

- 10    Strains with the designation "ATCC" can be obtained from the American Type Culture Collection (Manassas, VA, USA). Strains with the designation "FERM" can be obtained from the National Institute of Advanced Industrial Science and Technology (AIST Tsukuba Central 6, 1-1-1 Higashi, Tsukuba  
15    Ibaraki, Japan). The strains of *Corynebacterium thermoaminogenes* mentioned (FERM BP-1539, FERM BP-1540, FERM BP-1541 and FERM BP-1542) are described in US-A 5,250,434.

- 20    Open reading frame (ORF) describes a section of a nucleotide sequence which codes or can code for a protein or polypeptide or ribonucleic acid to which no function can be assigned according to the prior art.

- After assignment of a function to the nucleotide sequence section in question, it is in general referred to as a  
25    gene.

Alleles are in general understood as meaning alternative forms of a given gene. The forms are distinguished by differences in the nucleotide sequence.

- 30    In the context of the present invention, endogenous, that is to say species-characteristic, open reading frames, genes or alleles are preferably used. These are understood as meaning the open reading frames, genes or alleles or



nucleotide sequences thereof present in the population of a species, such as, for example, *Corynebacterium glutamicum*.

"A copy of an open reading frame (ORF), a gene or allele present at the natural site (locus)" in the context of this invention is understood as meaning the position or situation of the ORF or gene or allele in relation to the adjacent ORFs or genes or alleles such as exists in the corresponding wild-type or corresponding parent organism or starting organism.

Thus, for example, the natural site of the *lysC* gene or of an *lysC*<sup>FBR</sup> allele, which codes for a "feed back" resistant aspartate kinase from *Corynebacterium glutamicum* is the *lysC* site or *lysC* locus or *lysC* gene site with the directly adjacent genes or open reading frames *orfX* and *leuA* on one flank and the *asd* gene on the other flank.

"Feed back" resistant aspartate kinase is understood as meaning aspartate kinases which, compared with the wild-type form, have a lower sensitivity to inhibition by mixtures of lysine and threonine or mixtures of AEC (aminoethylcysteine) and threonine or lysine by itself or AEC by itself. Strains which produce L-lysine typically contain such "feed back" resistant or desensitized aspartate kinases.

The nucleotide sequence of the chromosome of *Corynebacterium glutamicum* is known and can be found in Patent Application EP-A-1108790 and Access Number (Accession No.) AX114121 of the nucleotide sequence databank of the European Molecular Biologies Laboratories (EMBL, Heidelberg, Germany and Cambridge, UK). The nucleotide sequences of *orfX*, the *leuA* gene and the *asd* gene have the Access Numbers AX120364 (*orfX*), AX123517 (*leuA*) and AX123519 (*asd*).

Further databanks, such as, for example, that of the National Center for Biotechnology Information (NCBI, Bethesda, MD, USA) or that of the Swiss Institute of Bioinformatics (Swissprot, Geneva, Switzerland) or that of  
5 the Protein Information Resource Database (PIR, Washington, DC, USA) can also be used.

"In each case a second, optionally third or fourth site" is understood as meaning a site which differs from the "natural site". It is also called a "target site" or  
10 "target sequence" in the following. It can also be called an "integration site" or "transformation site". This second, optionally third or fourth site, or the nucleotide sequence present at the corresponding sites, is preferably in the chromosome and is in general not essential for  
15 growth and for production of the desired chemical compounds.

To produce the coryneform bacteria according to the invention, the nucleotide sequence of the desired ORF, gene or allele, optionally including expression and/or  
20 regulation signals, is isolated and provided with nucleotide sequences of the target site at the ends, these are then transferred into the desired coryneform bacterium, preferably with the aid of vectors which do not replicate or replicate to only a limited extent in coryneform  
25 bacteria, and those bacteria in which the desired ORF, gene or allele is incorporated at the target site are isolated, no nucleotide sequence which is capable of/enables episomal replication in microorganisms, no nucleotide sequence which is capable of/enables transposition and no nucleotide  
30 sequence which imparts resistance to antibiotics remaining at the target site.

The invention accordingly also provides a process for the production of coryneform bacteria which produce one or more chemical compounds, which comprises

- a) isolating the nucleotide sequence of at least one desired ORF, gene or allele, optionally including the expression and/or regulation signals,
- 5 b) providing the 5' and the 3' end of the ORF, gene or allele with nucleotide sequences of the target site,
- c) preferably incorporating the nucleotide sequence of the desired ORF, gene or allele provided with nucleotide sequences of the target site into a vector which does not replicate or replicates to only a  
10 limited extent in coryneform bacteria,
- d) transferring the nucleotide sequence according to b) or c) into coryneform bacteria, and
- e) isolating coryneform bacteria in which the nucleotide sequence according to a) is incorporated at the  
15 target site, no nucleotide sequence which is capable of/enables episomal replication in microorganisms, no nucleotide sequence which is capable of/enables transposition and no nucleotide sequence which imparts resistance to antibiotics remaining at the  
20 target site.

Preferably, also, no residues of sequences of the vectors used or species-foreign DNA, such as, for example, restriction cleavage sites, remain at the target site. A maximum of 24, preferably a maximum of 12, particularly  
25 preferably a maximum of 6 nucleotides of such DNA upstream or downstream of the ORF, gene or allele incorporated optionally remain at the target site.

By the measures according to the invention, the productivity of the coryneform bacteria or of the  
30 fermentative processes for the preparation of chemical compounds is improved in respect of one or more of the features chosen from the group consisting of concentration (chemical compound formed, based on the unit volume), yield

(chemical compound formed, based on the source of carbon consumed) and product formation rate (chemical compound formed, based on the time) by at least 0.5 - 1.0% or at least 1.0 to 1.5% or at least 1.5 - 2.0%.

- 5 Instructions on conventional genetic engineering methods, such as, for example, isolation of chromosomal DNA, plasmid DNA, handling of restriction enzymes etc., are found in Sambrook et al. (Molecular Cloning - A Laboratory Manual (1989) Cold Spring Harbor Laboratory Press). Instructions  
10 on transformation and conjugation in coryneform bacteria are found, inter alia, in Thierbach et al. (Applied Microbiology and Biotechnology 29, 356-362 (1988)), in Schäfer et al. (Journal of Bacteriology 172, 1663-1666 (1990) and Gene 145, 69-73 (1994)) and in Schwarzer and  
15 Pühler (Bio/Technology 9, 84-87 (1991)).

- Vectors which replicate to only a limited extent are understood as meaning plasmid vectors which, as a function of the conditions under which the host or carrier is cultured, replicate or do not replicate. Thus, a  
20 temperature-sensitive plasmid for coryneform bacteria which can replicate only at temperatures below 31°C has been described by Nakamura et al. (US-A-6,303,383).

- The invention furthermore provides coryneform bacteria, in particular of the genus *Corynebacterium*, which produce L-  
25 lysine, characterized in that these have, in addition to at least one of the copy of an open reading frame (ORF), gene or allele of lysine production present at the natural site (locus), in each case a second, optionally third or fourth copy of the open reading frame (ORF), gene or allele in  
30 question at in each case a second, optionally third or fourth site in integrated form, no nucleotide sequence which is capable of/enables episomal replication in microorganisms, no nucleotide sequence which is capable of/enables transposition and no nucleotide sequence which

imparts resistance to antibiotics being present at the particular second, optionally third or fourth site.

The invention also furthermore provides a process for the preparation of L-lysine, which comprises the following

5 steps:

- a) fermentation of coryneform bacteria, in particular *Corynebacterium glutamicum*, characterized in that these have, in addition to at least one of the copy of an open reading frame (ORF), gene or allele of lysine production present at the natural site (locus), in each case a second, optionally third or fourth copy of the open reading frame (ORF), gene or allele in question at in each case a second, optionally third or fourth site in integrated form, no nucleotide sequence which is capable of/enables episomal replication in microorganisms, no nucleotide sequence which is capable of/enables transposition and no nucleotide sequence which imparts resistance to antibiotics being present at the particular second, optionally third or fourth site,

under conditions which allow expression of the said open reading frames (ORF), genes or alleles,

- b) concentration of the L-lysine in the fermentation broth,
- c) isolation of the L-lysine from the fermentation broth, optionally
- d) with constituents from the fermentation broth and/or the biomass to the extent of > (greater than) 0 to 100%.

A "copy of an open reading frame (ORF), gene or allele of lysine production" is to be understood as meaning all the, preferably endogenous, open reading frames, genes or

alleles of which enhancement/over-expression can have the effect of improving lysine production. Enhancement is understood as meaning an increase in the intracellular concentration or activity of the particular gene product,  
5 protein or enzyme.

These include, inter alia, the following open reading frames, genes or alleles: accBC, accDA, cstA, cysD, cysE, cysH, cysK, cysN, cysQ, dapA, dapB, dapC, dapD, dapE, dapF, ddh, dps, eno, gap, gap2, gdh, gnd, lysC, lysC<sup>FBR</sup>, lysE,  
10 msik, opcA, oxyR, ppc, ppc<sup>FBR</sup>, pgk, pknA, pknB, pknD, pknG, ppsA, ptsH, ptsI, ptsM, pyc, pyc P458S, sigC, sigD, sigE, sigH, sigM, tal, thyA, tkt, tpi, zwf and zwf A213T. These are summarized and explained in Table 1.

These include, in particular, the lysC<sup>FBR</sup> alleles which code  
15 for a "feed back" resistant aspartate kinase. Various lysC<sup>FBR</sup> alleles are summarized and explained in Table 2.

The following lysC<sup>FBR</sup> alleles are preferred: lysC A279T (replacement of alanine at position 279 of the aspartate kinase protein coded, according to SEQ ID NO: 2, by  
20 threonine), lysC A279V (replacement of alanine at position 279 of the aspartate kinase protein coded, according to SEQ ID NO: 2, by valine), lysC S301F (replacement of serine at position 301 of the aspartate kinase protein coded, according to SEQ ID NO: 2, by phenylalanine), lysC T308I  
25 (replacement of threonine at position 308 of the aspartate kinase protein coded, according to SEQ ID NO: 2, by isoleucine), lysC S301Y (replacement of serine at position 308 of the aspartate kinase protein coded, according to SEQ ID NO: 2, by tyrosine), lysC G345D (replacement of glycine  
30 at position 345 of the aspartate kinase protein coded, according to SEQ ID NO: 2, by aspartic acid), lysC R320G (replacement of arginine at position 320 of the aspartate kinase protein coded, according to SEQ ID NO: 2, by  
glycine), lysC T311I (replacement of threonine at position  
35 311 of the aspartate kinase protein coded, according to SEQ

ID NO: 2, by isoleucine), lysC S381F (replacement of serine at position 381 of the aspartate kinase protein coded, according to SEQ ID NO: 2, by phenylalanine).

5 The lysC<sup>FBR</sup> allele lysC T311I (replacement of threonine at position 311 of the aspartate kinase protein coded, according to SEQ ID NO: 2, by isoleucine), the nucleotide sequence of which is shown as SEQ ID NO:3, is particularly preferred; the amino acid sequence of the aspartate kinase protein coded is shown as SEQ ID NO:4.

10 The second, optionally third or fourth copy of the open reading frame (ORF), gene or allele of lysine production in question can be integrated at in each case a second, optionally third or fourth site. The following open reading frames, genes or nucleotide sequences, inter alia, can be  
15 used for this: aecD, ccpA1, ccpA2, citA, citB, citE, fda, gluA, gluB, gluC, gluD, luxR, luxS, lysR1, lysR2, lysR3, menE, mgo, pck, pgi, poxB and zwa2, in particular the genes aecD, gluA, gluB, gluC, gluD and pck. These are summarized and explained in Table 3.

20 The sites mentioned include, of course, not only the coding regions of the open reading frames or genes mentioned, but also the regions or nucleotide sequences lying upstream which are responsible for expression and regulation, such as, for example, ribosome binding sites, promoters, binding  
25 sites for regulatory proteins, binding sites for regulatory ribonucleic acids and attenuators. These regions in general lie in a range of 1-800, 1-600, 1-400, 1-200, 1-100 or 1-50 nucleotides upstream of the coding region. In the same way, regions lying downstream, such as, for example,  
30 transcription terminators, are also included. These regions in general lie in a range of 1-400, 1-200, 1-100, 1-50 or 1-25 nucleotides downstream of the coding region.

Intergenic regions in the chromosome, that is to say nucleotide sequences without a coding function, can

furthermore be used. Finally, prophages or defective phages contained in the chromosome can be used for this.

A prophage is understood as meaning a bacteriophage, in particular the genome thereof, where this is replicated  
5 together with the genome of the host and the formation of infectious particles does not take place. A defective phage is understood as meaning a prophage, in particular the genome thereof, which, as a result of various mutations, has lost the ability to form so-called infectious  
10 particles. Defective phages are also called cryptic. Prophages and defective phages are often present in integrated form in the chromosome of their host. Further details exist in the prior art, for example in the textbook by Edward A. Birge (Bacterial and Bacteriophage Genetics,  
15 3<sup>rd</sup> ed., Springer-Verlag, New York, USA, 1994) or in the textbook by S. Klaus et al. (Bakterienviren, Gustav Fischer Verlag, Jena, Germany, 1992).



Table 1

Open reading frames, genes and alleles of lysine production

Name	Description of the coded enzyme or protein	Reference	Access Number
accBC	Acyl-CoA Carboxylase EC 6.3.4.14 (acyl-CoA carboxylase)	Jäger et al. Archives of Microbiology (1996) 166:76-82 EP1108790; WO0100805	U35023  AX123524 AX066441
accDA	Acetyl-CoA Carboxylase EC 6.4.1.2 (acetyl-CoA carboxylase)	EP1055725 EP1108790 WO0100805	AX121013 AX066443
cstA	Carbon Starvation Protein A (carbon starvation protein A)	EP1108790 WO0100804	AX120811 AX066109
cysD	Sulfate Adenylyltransferase sub-unit II EC 2.7.7.4 (sulfate adenylyltransferase small chain)	EP1108790	AX123177
cysE	Serine Acetyltransferase EC 2.3.1.30 (serine acetyltransferase)	EP1108790 WO0100843	AX122902 AX063961
cysH	3'-Phosphoadenyl Sulfate Reductase EC 1.8.99.4 (3'-phosphoadenosine 5'-phosphosulfate reductase)	EP1108790 WO0100842	AX123178 AX066001
cysK	Cysteine Synthase EC 4.2.99.8 (cysteine synthase)	EP1108790 WO0100843	AX122901 AX063963
cysN	Sulfate Adenylyltransferase sub-unit I EC 2.7.7.4 (sulfate adenylyltransferase)	EP1108790	AX123176 AX127152
cysQ	Transport Protein CysQ (transporter cysQ)	EP1108790 WO0100805	AX127145 AX066423
dapA	Dihydrodipicolinate Synthase EC 4.2.1.52 (dihydrodipicolinate synthase)	Bonnassie et al. Nucleic Acids Research 18:6421 (1990) Pisabarro et al., Journal of Bacteriology 175:2743-2749 (1993) EP1108790 WO0100805 EP0435132 EP1067192 EP1067193	X53993  Z21502  AX123560 AX063773
dapB	Dihydrodipicolinate Reductase EC 1.3.1.26 (dihydrodipicolinate reductase)	EP1108790 WO0100843 EP1067192	AX127149 AX063753 AX137723

		EP1067193 Pisabarro et al., Journal of Bacteriology 175:2743-2749 (1993) JP1998215883 JP1997322774 JP1997070291 JP1995075578	AX137602 X67737 Z21502  E16749 E14520 E12773 E08900
dapC	N-Succinyl Aminoketopimelate Transaminase EC 2.6.1.17 (N-succinyl diaminopimelate transaminase)	EP1108790 WO0100843 EP1136559	AX127146 AX064219
dapD	Tetrahydrodipicolinate Succinylase EC 2.3.1.117 (tetrahydrodipicolinate succinylase)	EP1108790 WO0100843 Wehrmann et al. Journal of Bacteriology 180:3159-3165 (1998)	AX127146 AX063757 AJ004934
dapE	N-Succinyl Diaminopimelate Desuccinylase EC 3.5.1.18 (N-succinyl diaminopimelate desuccinylase)	EP1108790 WO0100843 Wehrmann et al. Microbiology 140:3349-3356 (1994)	AX127146 AX063749 X81379
dapF	Diaminopimelate Epimerase EC 5.1.1.7 (diaminopimelate epimerase)	EP1108790 WO0100843 EP1085094	AX127149 AX063719 AX137620
ddh	Diaminopimelate Dehydrogenase EC 1.4.1.16 (diaminopimelate dehydrogenase)	EP1108790 WO0100843 Ishino et al., Nucleic Acids Research 15:3917-3917 (1987) JP1997322774 JP1993284970 Kim et al., Journal of Microbiology and Biotechnology 5:250-256 (1995)	AX127152 AX063759 Y00151  E14511 E05776 D87976
dps	DNA Protection Protein (protection during starvation protein)	EP1108790	AX127153
eno	Enolase EC 4.2.1.11 (enolase)	EP1108790 WO0100844 EP1090998 Hermann et al., Electrophoresis 19:3217-3221 (1998)	AX127146 AX064945 AX136862
gap	Glyceraldehyde 3-Phosphate Dehydrogenase	EP1108790 WO0100844	AX127148 AX064941

	EC 1.2.1.12 (glyceraldehyde 3-phosphate dehydrogenase)	Eikmanns et al., Journal of Bacteriology 174:6076-6086(1992)	X59403
gap2	Glyceraldehyde 3-Phosphate Dehydrogenase EC 1.2.1.12 (glyceraldehyde 3-phosphate dehydrogenase 2)	EP1108790 WO0100844	AX127146 AX064939
gdh	Glutamate Dehydrogenase EC 1.4.1.4 (glutamate dehydrogenase)	EP1108790 WO0100844 Boermann et al., Molecular Microbiology 6:317-326 (1992). Guyonvarch et al., NCBI	AX127150 AX063811 X59404  X72855
gnd	6-Phosphogluconate Dehydrogenase EC 1.1.1.44 (6-phosphogluconate dehydrogenase)	EP1108790 WO0100844	AX127147 AX121689 AX065125
lysC	Aspartate Kinase EC 2.7.2.4 (aspartate kinase)	EP1108790 WO0100844 Kalinowski et al., Molecular Microbiology 5:1197-204 (1991)	AX120365 AX063743 X57226
lysC <sup>FBR</sup>	Aspartate Kinase feedback resistant (fbr) EC 2.7.2.4 (aspartate kinase fbr)	see Table 2	
lysE	Lysine Exporter (lysine exporter protein)	EP1108790 WO0100843 Vrljić et al., Molecular Microbiology 22:815-826 (1996)	AX123539 AX123539 X96471
msiK	Sugar Importer (multiple sugar import protein)	EP1108790	AX120892
opcA	Glucose 6-phosphate Dehydrogenase (subunit of glucose 6-phosphate dehydrogenase)	WO0104325	AX076272
oxyR	Transcription Regulator (transcriptional regulator)	EP1108790	AX122198 AX127149
ppc <sup>FBR</sup>	Phosphoenol Pyruvate Carboxylase feedback resistant EC 4.1.1.31 (phosphoenol pyruvate carboxylase feedback resistant)	EP0723011 WO0100852	
ppc	Phosphoenol Pyruvate Carboxylase EC 4.1.1.31 (phosphoenol pyruvate carboxylase)	EP1108790 O'Reagan et al., Gene 77(2):237-251(1989)	AX127148 AX123554 M25819

pgk	Phosphoglycerate Kinase EC 2.7.2.3 (phosphoglycerate kinase)	EP1108790  WO0100844 Eikmanns, Journal of Bacteriology 174:6076-6086 (1992)	AX121838 AX127148 AX064943 X59403
pknA	Protein Kinase A (protein kinase A)	EP1108790	AX120131 AX120085
pknB	Protein Kinase B (protein kinase B)	EP1108790	AX120130 AX120085
pknD	Protein Kinase D (protein kinase D)	EP1108790	AX127150 AX122469 AX122468
pknG	Protein Kinase G (protein kinase G)	EP1108790	AX127152 AX123109
ppsA	Phosphoenol Pyruvate Synthase EC 2.7.9.2 (phosphoenol pyruvate synthase)	EP1108790	AX127144 AX120700 AX122469
ptsH	Phosphotransferase System Protein H EC 2.7.1.69 (phosphotransferase system component H)	EP1108790  WO0100844	AX122210 AX127149 AX069154
ptsI	Phosphotransferase System Enzyme I EC 2.7.3.9 (phosphotransferase system enzyme I)	EP1108790	AX122206 AX127149
ptsM	Glucose-specific Phosphotransferase System Enzyme II EC 2.7.1.69 (glucose phosphotransferase system enzyme II)	Lee et al., FEMS Microbiology Letters 119 (1-2):137-145 (1994)	L18874
pyc	Pyruvate Carboxylase EC 6.4.1.1 (pyruvate carboxylase)	WO9918228 Peters-Wendisch et al., Microbiology 144:915-927 (1998)	A97276 Y09548
pyc P458S	Pyruvate Carboxylase EC 6.4.1.1 (pyruvate carboxylase) amino acid exchange P458S	EP1108790	
sigC	Sigma Factor C EC 2.7.7.6 (extracytoplasmic function alternative sigma factor C)	EP1108790	AX120368 AX120085
sigD	RNA Polymerase Sigma Factor D EC 2.7.7.6 (RNA polymerase sigma factor)	EP1108790	AX120753 AX127144
sigE	Sigma Factor E EC 2.7.7.6 (extracytoplasmic function alternative sigma factor E)	EP1108790	AX127146 AX121325
sigH	Sigma Factor H EC 2.7.7.6 (sigma factor SigH)	EP1108790	AX127145 AX120939

sigM	Sigma Factor M EC 2.7.7.6 (sigma factor SigM)	EP1108790	AX123500 AX127145
tal	Transaldolase EC 2.2.1.2 (transaldolase)	WO0104325	AX076272
thyA	Thymidylate Synthase EC 2.1.1.45 (thymidylate synthase)	EP1108790	AX121026 AX127145
tkt	Transketolase EC 2.2.1.1 (transketolase)	Ikeda et al., NCBI	AB023377
tpi	Triose Phosphate Isomerase EC 5.3.1.1 (triose phosphate isomerase)	Eikmanns, Journal of Bacteriology 174:6076-6086 (1992)	X59403
zwa1	Cell Growth Factor 1 (growth factor 1)	EP1111062	AX133781
zwf	Glucose 6-phosphate 1-Dehydrogenase EC 1.1.1.49 (glucose 6-phosphate 1- dehydrogenase)	EP1108790  WO0104325	AX127148 AX121827 AX076272
zwf A213T	Glucose 6-phosphate 1-Dehydrogenase EC 1.1.1.49 (glucose 6-phosphate 1- dehydrogenase) amino acid exchange A213T	EP1108790	

Table 2

lysC<sup>FBR</sup> alleles which code for feed back resistant aspartate kinases

Name of the allele	Further information	Reference	Access Number
lysC <sup>FBR</sup> -E05108		JP 1993184366-A (sequence 1)	E05108
lysC <sup>FBR</sup> -E06825	lysC A279T	JP 1994062866-A (sequence 1)	E06825
lysC <sup>FBR</sup> -E06826	lysC A279T	JP 1994062866-A (sequence 2)	E06826
lysC <sup>FBR</sup> -E06827		JP 1994062866-A (sequence 3)	E06827
lysC <sup>FBR</sup> -E08177		JP 1994261766-A (sequence 1)	E08177
lysC <sup>FBR</sup> -E08178	lysC A279T	JP 1994261766-A (sequence 2)	E08178
lysC <sup>FBR</sup> -E08179	lysC A279V	JP 1994261766-A (sequence 3)	E08179
lysC <sup>FBR</sup> -E08180	lysC S301F	JP 1994261766-A (sequence 4)	E08180
lysC <sup>FBR</sup> -E08181	lysC T308I	JP 1994261766-A (sequence 5)	E08181
lysC <sup>FBR</sup> -E08182		JP 1994261766-A (sequence 6)	E08182
lysC <sup>FBR</sup> -E12770		JP 1997070291-A (sequence 13)	E12770
lysC <sup>FBR</sup> -E14514		JP 1997322774-A (sequence 9)	E14514
lysC <sup>FBR</sup> -E16352		JP 1998165180-A (sequence 3)	E16352
lysC <sup>FBR</sup> -E16745		JP 1998215883-A (sequence 3)	E16745
lysC <sup>FBR</sup> -E16746		JP 1998215883-A (sequence 4)	E16746
lysC <sup>FBR</sup> -I74588		US 5688671-A (sequence 1)	I74588
lysC <sup>FBR</sup> -I74589	lysC A279T	US 5688671-A (sequence 2)	I74589
lysC <sup>FBR</sup> -I74590		US 5688671-A (sequence 7)	I74590
lysC <sup>FBR</sup> -I74591	lysC A279T	US 5688671-A (sequence 8)	I74591
lysC <sup>FBR</sup> -I74592		US 5688671-A (sequence 9)	I74592
lysC <sup>FBR</sup> -I74593	lysC A279T	US 5688671-A (sequence 10)	I74593
lysC <sup>FBR</sup> -I74594		US 5688671-A (sequence 11)	I74594
lysC <sup>FBR</sup> -I74595	lysC A279T	US 5688671-A (sequence 12)	I74595
lysC <sup>FBR</sup> -I74596		US 5688671-A (sequence 13)	I74596

lysC <sup>FBR</sup> -I74597	lysC A279T	US 5688671-A (sequence 14)	I74597
lysC <sup>FBR</sup> -X57226	lysC S301Y	EP0387527 Kalinowski et al., Molecular and General Genetics 224:317-324 (1990)	X57226
lysC <sup>FBR</sup> -L16848	lysC G345D	Follettie and Sinskey NCBI Nucleotide Database (1990)	L16848
lysC <sup>FBR</sup> -L27125	lysC R320G lysC G345D	Jetten et al., Applied Microbiology Biotechnology 43:76- 82 (1995)	L27125
lysC <sup>FBR</sup>	lysC T311I	WO0063388 (sequence 17)	
lysC <sup>FBR</sup>	lysC S301F	US3732144	
lysC <sup>FBR</sup>	lysC S381F		
lysC <sup>FBR</sup>		JP6261766 (sequence 1)	
lysC <sup>FBR</sup>	lysC A279T	JP6261766 (sequence 2)	
lysC <sup>FBR</sup>	lysC A279V	JP6261766 (sequence 3)	
lysC <sup>FBR</sup>	lysC S301F	JP6261766 (sequence 4)	
lysC <sup>FBR</sup>	lysC T308I	JP6261766 (sequence 5)	

Table 3

Target sites for integration of open reading frames, genes  
and alleles of lysine production

Gene name	Description of the coded enzyme or protein	Reference	Access Number
aecD	beta C-S Lyase EC 2.6.1.1 (beta C-S lyase)	Rossol et al., Journal of Bacteriology 174(9):2968-77 (1992)	M89931
ccpA1	Catabolite Control Protein (catabolite control protein A1)	WO0100844 EP1108790	AX065267 AX127147
ccpA2	Catabolite Control Protein (catabolite control protein A2)	WO0100844 EP1108790	AX065267 AX121594
citA	Sensor Kinase CitA (sensor kinase CitA)	EP1108790	AX120161
citB	Transcription Regulator CitB (transcription regulator CitB)	EP1108790	AX120163
citE	Citrate Lyase EC 4.1.3.6 (citrate lyase)	WO0100844 EP1108790	AX065421 AX127146
fda	Fructose Bisphosphate Aldolase EC 4.1.2.13 (fructose 1,6- bisphosphate aldolase)	von der Osten et al., Molecular Microbiology 3(11):1625-37 (1989)	X17313
gluA	Glutamate Transport ATP- binding Protein (glutamate transport ATP-binding protein)	Kronemeyer et al., Journal of Bacteriology 177(5):1152-8 (1995)	X81191
gluB	Glutamate-binding Protein (glutamate-binding protein)	Kronemeyer et al., Journal of Bacteriology 177(5):1152-8 (1995)	X81191
gluC	Glutamate Transport Permease (glutamate transport system permease)	Kronemeyer et al., Journal of Bacteriology 177(5):1152-8 (1995)	X81191
gluD	Glutamate Transport Permease (glutamate transport system permease)	Kronemeyer et al., Journal of Bacteriology 177(5):1152-8 (1995)	X81191
luxR	Transcription Regulator LuxR (transcription regulator LuxR)	WO0100842 EP1108790	AX065953 AX123320
luxS	Histidine Kinase LuxS (histidine kinase LuxS)	EP1108790	AX123323 AX127145
lysR1	Transcription Regulator LysR1	EP1108790	AX064673 AX127144



	(transcription regulator LysR1)		
lysR2	Transcription Activator LysR2 (transcription regulator LysR2)	EP1108790	AX123312
lysR3	Transcription Regulator LysR3 (transcription regulator LysR3)	WO0100842 EP1108790	AX065957 AX127150
menE	O-Succinylbenzoic Acid CoA Ligase EC 6.2.1.26 (O-succinylbenzoate CoA ligase)	WO0100843 EP1108790	AX064599 AX064193 AX127144
mgo	Malate-Quinone Oxidoreductase (malate-quinone- oxidoreductase)	Molenaar et al., Eur. Journal of Biochemistry 1;254(2):395-403 (1998)	AJ224946
pck	Phosphoenol Pyruvate Carboxykinase (phosphoenol pyruvate carboxykinase)	WO0100844	AJ269506 AX065053
pgi	Glucose 6-phosphate Isomerase EC 5.3.1.9 (glucose 6-phosphate isomerase)	EP1087015 EP1108790	AX136015 AX127146
poxB	Pyruvate Oxidase EC 1.2.3.3 (pyruvate oxidase)	WO0100844 EP1096013	AX064959 AX137665
zwa2	Cell Growth Factor 2 (growth factor 2)	EP1106693 EP1108790	AX113822 AX127146

The invention accordingly also provides a process for the production of coryneform bacteria which produce L-lysine,  
 5 which comprises

- a) isolating the nucleotide sequence of at least one desired ORF, gene or allele of lysine production, optionally including the expression and/or regulation signals,
- 10 b) providing the 5' and the 3' end of the ORF, gene or allele of lysine production with nucleotide sequences of the target site,
- c) preferably incorporating the nucleotide sequence of the desired ORF, gene or allele provided with

nucleotide sequences of the target site into a vector which does not replicate or replicates to only a limited extent in coryneform bacteria,

- 5 d) transferring the nucleotide sequence according to b) or c) into coryneform bacteria, and
- e) isolating coryneform bacteria in which the nucleotide sequence according to a) is incorporated at the target site, no nucleotide sequence which is capable of/enables episomal replication in microorganisms, no  
10 nucleotide sequence which is capable of/enables transposition and no nucleotide sequence which imparts resistance to antibiotics remaining at the target site.

The invention furthermore provides coryneform bacteria, in  
15 particular of the genus *Corynebacterium*, which produce L-methionine and/or L-threonine, characterized in that these have, in addition to at least one of the copy of an open reading frame (ORF), gene or allele of methionine production or threonine production present at the natural  
20 site (locus), in each case a second, optionally third or fourth copy of the open reading frame (ORF), gene or allele in question at in each case a second, optionally third or fourth site in integrated form, no nucleotide sequence which is capable of/enables episomal replication in  
25 microorganisms, no nucleotide sequence which is capable of/enables transposition and no nucleotide sequence which imparts resistance to antibiotics being present at the particular second, optionally third or fourth site.

The invention also furthermore provides a process for the  
30 preparation of L-methionine and/or L-threonine, which comprises the following steps:

- a) fermentation of coryneform bacteria, in particular *Corynebacterium glutamicum*, characterized in that

these have, in addition to at least one of the copy of  
an open reading frame (ORF), gene or allele of  
methionine production or threonine production present  
at the natural site (locus), in each case a second,  
5 optionally third or fourth copy of the open reading  
frame (ORF), gene or allele in question at in each  
case a second, optionally third or fourth site in  
integrated form, no nucleotide sequence which is  
capable of/enables episomal replication in  
10 microorganisms, no nucleotide sequence which is  
capable of/enables transposition and no nucleotide  
sequence which imparts resistance to antibiotics being  
present at the particular second, optionally third or  
fourth site,

15

under conditions which allow expression of the said  
open reading frames (ORF), genes or alleles,

- b) concentration of the L-methionine and/or L-threonine  
in the fermentation broth,
- 20 c) isolation of the L-methionine and/or L-threonine from  
the fermentation broth, optionally
- d) with constituents from the fermentation broth and/or  
the biomass to the extent of > (greater than) 0 to  
100%.

25 A "copy of an open reading frame (ORF), gene or allele of  
methionine production" is to be understood as meaning all  
the, preferably endogenous, open reading frames, genes or  
alleles of which enhancement/over-expression can have the  
effect of improving methionine production.

30 These include, inter alia, the following open reading  
frames, genes or alleles: accBC, accDA, aecD, cstA, cysD,  
cysE, cysH, cysK, cysN, cysQ, dps, eno, fda, gap, gap2,  
gdh, gnd, glyA, hom, hom<sup>FBR</sup>, lysC, lysC<sup>FBR</sup>, metA, metB, metE,

methH, metY, msik, opcA, oxyR, ppc, ppc<sup>FBR</sup>, pgk, pknA, pknB, pknD, pknG, ppsA, ptsH, ptsI, ptsM, pyc, pyc P458S, sigC, sigD, sigE, sigH, sigM, tal, thyA, tkt, tpi, zwf, zwf A213T. These are summarized and explained in Table 4.

- 5 These include, in particular, the lysC<sup>FBR</sup> alleles which code for a "feed back" resistant aspartate kinase (see Table 2) and the hom<sup>FBR</sup> alleles which code for a "feed back" resistant homoserine dehydrogenase.

The second, optionally third or fourth copy of the open  
10 reading frame (ORF), gene or allele of methionine production in question can be integrated at in each case a second, optionally third or fourth site. The following open reading frames, genes or nucleotide sequences, inter alia, can be used for this: brnE, brnF, brnQ, ccpA1, ccpA2, citA,  
15 citB, citE, ddh, gluD, gluC, gluD, luxR, luxS, lysR1, lysR2, lysR3, menE, metD, metK, pck, pgi, poxB and zwa2. These are summarized and explained in Table 5.

The sites mentioned include, of course, not only the coding regions of the open reading frames or genes mentioned, but  
20 also the regions or nucleotide sequences lying upstream which are responsible for expression and regulation, such as, for example, ribosome binding sites, promoters, binding sites for regulatory proteins, binding sites for regulatory ribonucleic acids and attenuators. These regions in general  
25 lie in a range of 1-800, 1-600, 1-400, 1-200, 1-100 or 1-50 nucleotides upstream of the coding region. In the same way, regions lying downstream, such as, for example, transcription terminators, are also included. These regions  
30 in general lie in a range of 1-400, 1-200, 1-100, 1-50 or 1-25 nucleotides downstream of the coding region.

Intergenic regions in the chromosome, that is to say nucleotide sequences without a coding function, can furthermore be used. Finally, prophages or defective phages contained in the chromosome can be used for this.

Table 4

Open reading frames, genes and alleles of methionine production

Name	Description of the coded enzyme or protein	Reference	Access Number
AccBC	Acyl-CoA Carboxylase EC 6.3.4.14 (acyl-CoA carboxylase)	Jäger et al. Archives of Microbiology (1996) 166:76-82 EP1108790; WO0100805	U35023  AX123524 AX066441
AccDA	Acetyl-CoA Carboxylase EC 6.4.1.2 (acetyl-CoA carboxylase)	EP1055725 EP1108790 WO0100805	AX121013 AX066443
AecD	Cystathionine beta-Lyase EC 4.4.1.8 (cystathionine beta-lyase)	Rossol et al., Journal of Bacteriology 174:2968-2977 (1992)	M89931
CstA	Carbon Starvation Protein A (carbon starvation protein A)	EP1108790 WO0100804	AX120811 AX066109
CysD	Sulfate Adenylyltransferase sub-unit II EC 2.7.7.4 (sulfate adenylyltransferase small chain)	EP1108790	AX123177
CysE	Serine Acetyltransferase EC 2.3.1.30 (serine acetyltransferase)	EP1108790 WO0100843	AX122902 AX063961
CysH	3'-Phosphoadenyl Sulfate Reductase EC 1.8.99.4 (3'-phosphoadenosine 5'-phosphosulfate reductase)	EP1108790 WO0100842	AX123178 AX066001
CysK	Cysteine Synthase EC 4.2.99.8 (cysteine synthase)	EP1108790 WO0100843	AX122901 AX063963
CysN	Sulfate Adenylyltransferase sub-unit I EC 2.7.7.4 (sulfate adenylyltransferase)	EP1108790	AX123176 AX127152
CysQ	Transport protein CysQ (transporter cysQ)	EP1108790 WO0100805	AX127145 AX066423
Dps	DNA Protection Protein (protection during starvation protein)	EP1108790	AX127153
Eno	Enolase EC 4.2.1.11 (enolase)	EP1108790 WO0100844 EP1090998 Hermann et al., Electrophoresis 19:3217-3221 (1998)	AX127146 AX064945 AX136862

Fda	Fructose Bisphosphate Aldolase EC 4.1.2.13 (fructose bisphosphate aldolase)	van der Osten et al., Molecular Microbiology 3:1625-1637 (1989)	X17313
Gap	Glyceraldehyde 3-Phosphate Dehydrogenase EC 1.2.1.12 (glyceraldehyde 3-phosphate dehydrogenase)	EP1108790 WO0100844 Eikmanns et al., Journal of Bacteriology 174:6076-6086 (1992)	AX127148 AX064941 X59403
gap2	Glyceraldehyde 3-Phosphate Dehydrogenase EC 1.2.1.12 (glyceraldehyde 3-phosphate dehydrogenase 2)	EP1108790 WO0100844	AX127146 AX064939
Gdh	Glutamate Dehydrogenase EC 1.4.1.4 (glutamate dehydrogenase)	EP1108790 WO0100844 Boermann et al., Molecular Microbiology 6:317-326 (1992); Guyonvarch et al., NCBI	AX127150 AX063811 X59404  X72855
GlyA	Glycine/Serine Hydroxymethyltransferase EC 2.1.2.1 (glycine/serine hydroxymethyltransferase)	EP1108790	AX127146 AX121194
Gnd	6-Phosphogluconate Dehydrogenase EC 1.1.1.44 (6-phosphogluconate dehydrogenase)	EP1108790 WO0100844	AX127147 AX121689 AX065125
Hom	Homoserine Dehydrogenase EC 1.1.1.3 (homoserine dehydrogenase)	Peoples et al., Molecular Microbiology 2:63-72 (1988)	Y00546
hom <sup>FBR</sup>	Homoserine Dehydrogenase feedback resistant (fbr) EC 1.1.1.3 (homoserine dehydrogenase fbr)	Reinscheid et al., Journal of Bacteriology 173:3228-30 (1991)	
LysC	Aspartate Kinase EC 2.7.2.4 (aspartate kinase)	EP1108790 WO0100844 Kalinowski et al., Molecular Microbiology 5:1197-204 (1991)	AX120365 AX063743 X57226
lysC <sup>FBR</sup>	Aspartate Kinase feedback resistant (fbr) EC 2.7.2.4 (aspartate kinase fbr)	see Table 2	
MetA	Homoserine Acetyltransferase EC 2.3.1.31 (homoserine acetyltransferase)	Park et al., Molecular Cells 8:286-94 (1998)	AF052652
MetB	Cystathionine $\gamma$ -Lyase	Hwang et al.,	AF126953

	EC 4.4.1.1 (cystathionine gamma-synthase)	Molecular Cells 9:300-308 (1999)	
MetE	Homocysteine Methyltransferase EC 2.1.1.14 (homocysteine methyltransferase)	EP1108790	AX127146 AX121345
MetH	Homocysteine Methyltransferase (Vitamin B12-dependent) EC 2.1.1.14 (homocysteine methyltransferase)	EP1108790	AX127148 AX121747
MetY	Acetylhomoserine Sulfhydrolase (acetylhomoserine sulfhydrolase)	EP1108790	AX120810 AX127145
MsiK	Sugar Importer (multiple sugar import protein)	EP1108790	AX120892
OpcA	Glucose 6-phosphate Dehydrogenase (subunit of glucose 6-phosphate dehydrogenase)	WO0104325	AX076272
OxyR	Transcription Regulator (transcriptional regulator)	EP1108790	AX122198 AX127149
ppc <sup>FBR</sup>	Phosphoenol Pyruvate Carboxylase feedback resistant EC 4.1.1.31 (phosphoenol pyruvate carboxylase feedback resistant)	EP0723011 WO0100852	
Ppc	Phosphoenol Pyruvate Carboxylase EC 4.1.1.31 (phosphoenol pyruvate carboxylase)	EP1108790  O'Reagan et al., Gene 77(2):237- 251 (1989)	AX127148 AX123554 M25819
Pgk	Phosphoglycerate Kinase EC 2.7.2.3 (phosphoglycerate kinase)	EP1108790  WO0100844 Eikmanns, Journal of Bacteriology 174:6076-6086 (1992)	AX121838 AX127148 AX064943 X59403
PknA	Protein Kinase A (protein kinase A)	EP1108790	AX120131 AX120085
PknB	Protein Kinase B (protein kinase B)	EP1108790	AX120130 AX120085
PknD	Protein Kinase D (protein Kinase D)	EP1108790	AX127150 AX122469 AX122468
PknG	Protein Kinase G (protein kinase G)	EP1108790	AX127152 AX123109
PpsA	Phosphoenol Pyruvate Synthase EC 2.7.9.2 (phosphoenol pyruvate synthase)	EP1108790	AX127144 AX120700 AX122469
PtsH	Phosphotransferase System Protein H EC 2.7.1.69 (phosphotransferase system component H)	EP1108790  WO0100844	AX122210 AX127149 AX069154
PtsI	Phosphotransferase System Enzyme I EC 2.7.3.9 (phosphotransferase system enzyme I)	EP1108790	AX122206 AX127149
PtsM	Glucose-specific Phosphotransferase System Enzyme II	Lee et al., FEMS Microbiology	L18874

	EC 2.7.1.69 (glucose phosphotransferase system enzyme II)	Letters 119 (1-2):137-145 (1994)	
Pyc	Pyruvate Carboxylase EC 6.4.1.1 (pyruvate carboxylase)	W09918228 Peters-Wendisch et al., Microbiology 144:915-927 (1998)	A97276 Y09548
Pyc P458s	Pyruvate Carboxylase EC 6.4.1.1 (pyruvate carboxylase) amino acid exchange P458S	EP1108790	
SigC	Sigma Factor C EC 2.7.7.6 (extracytoplasmic function alternative sigma factor C)	EP1108790	AX120368 AX120085
SigD	RNA Polymerase Sigma Factor D EC 2.7.7.6 (RNA polymerase sigma factor)	EP1108790	AX120753 AX127144
SigE	Sigma Factor E EC 2.7.7.6 (extracytoplasmic function alternative sigma factor E)	EP1108790	AX127146 AX121325
SigH	Sigma Factor H EC 2.7.7.6 (sigma factor SigH)	EP1108790	AX127145 AX120939
SigM	Sigma Factor M EC 2.7.7.6 (sigma factor SigM)	EP1108790	AX123500 AX127153
Tal	Transaldolase EC 2.2.1.2 (transaldolase)	W00104325	AX076272
ThyA	Thymidylate Synthase EC 2.1.1.45 (thymidylate synthase)	EP1108790	AX121026 AX127145
Tkt	Transketolase EC 2.2.1.1 (transketolase)	Ikeda et al., NCBI	AB023377
Tpi	Triose Phosphate Isomerase EC 5.3.1.1 (triose phosphate isomerase)	Eikmanns, Journal of Bacteriology 174:6076-6086 (1992)	X59403
zwf1	Cell Growth Factor 1 (growth factor 1)	EP1111062	AX133781
Zwf	Glucose 6-phosphate 1-Dehydrogenase EC 1.1.1.49 (glucose 6-phosphate 1- dehydrogenase)	EP1108790  W00104325	AX127148 AX121827 AX076272
Zwf A213T	Glucose 6-phosphate 1-Dehydrogenase EC 1.1.1.49 (glucose 6-phosphate 1- dehydrogenase) amino acid exchange A213T	EP1108790	



Table 5

Target sites for integration of open reading frames, genes  
and alleles of methionine production

Gene name	Description of the coded enzyme or protein	Reference	Access Number
BrnE	Transporter of branched-chain amino acids (branched-chain amino acid transporter)	EP1096010	AX137709 AX137714
BrnF	Transporter of branched-chain amino acids (branched-chain amino acid transporter)	EP1096010	AX137709 AX137714
BrnQ	Carrier protein of branched-chain amino acids (branched-chain amino acid transport system carrier protein)	Tauch et al., Archives of Microbiology 169(4):303-12 (1998) WO0100805 EP1108790	M89931 AX066841 AX127150
ccpA1	Catabolite Control Protein (catabolite control protein A1)	WO0100844 EP1108790	AX065267 AX127147
ccpA2	Catabolite Control Protein (catabolite control protein A2)	WO0100844 EP1108790	AX065267 AX121594
citA	Sensor Kinase Cita (sensor kinase Cita)	EP1108790	AX120161
citB	Transcription Regulator CitB (transcription regulator CitB)	EP1108790	AX120163
citE	Citrate Lyase EC 4.1.3.6 (citrate lyase)	WO0100844 EP1108790	AX065421 AX127146
ddh	Diaminopimelate Dehydrogenase EC 1.4.1.16 (diaminopimelate dehydrogenase)	Ishino et al., Nucleic Acids Research 15: 3917 (1987) EP1108790	S07384 AX127152
gluA	Glutamate Transport ATP-binding Protein (glutamate transport ATP-binding protein)	Kronmeyer et al., Journal of Bacteriology 177(5):1152-8 (1995)	X81191
gluB	Glutamate-binding Protein (glutamate-binding protein)	Kronmeyer et al., Journal of Bacteriology 177(5):1152-8 (1995)	X81191
gluC	Glutamate Transport Permease (glutamate transport	Kronmeyer et al., Journal of Bacteriology 177(5):1152-8 (1995)	X81191

	system permease)		
gluD	Glutamate Transport Permease (glutamate transport system permease)	Kronemeyer et al., Journal of Bacteriology 177(5):1152-8 (1995)	X81191
luxR	Transcription Regulator LuxR (transcription regulator LuxR)	WO0100842 EP1108790	AX065953 AX123320
luxS	Histidine Kinase LuxS (histidine kinase LuxS)	EP1108790	AX123323 AX127145
lysR1	Transcription Regulator LysR1 (transcription regulator LysR1)	EP1108790	AX064673 AX127144
lysR2	Transcription Activator LysR2 (transcription regulator LysR2)	EP1108790	AX123312
lysR3	Transcription Regulator LysR3 (transcription regulator LysR3)	WO0100842 EP1108790	AX065957 AX127150
menE	O-Succinylbenzoic Acid CoA Ligase EC 6.2.1.26 (O-succinylbenzoate CoA ligase)	WO0100843 EP1108790	AX064599 AX064193 AX127144
metD	Transcription Regulator MetD (transcription regulator MetD)	EP1108790	AX123327 AX127153
metK	Methionine Adenosyl Transferase EC 2.5.1.6 (S-adenosylmethionine synthetase)	WO0100843 EP1108790	AX063959 AX127148
pck	Phosphoenol Pyruvate Carboxykinase (phosphoenol pyruvate carboxykinase)	WO0100844	AJ269506 AX065053
pgi	Glucose 6-Phosphate Isomerase EC 5.3.1.9 (glucose-6-phosphate isomerase)	EP1087015 EP1108790	AX136015 AX127146
poxB	Pyruvate Oxidase EC 1.2.3.3 (pyruvate oxidase)	WO0100844 EP1096013	AX064959 AX137665
zwa2	Cell Growth Factor 2 (growth factor 2)	EP1106693 EP1108790	AX113822 AX127146

A "copy of an open reading frame (ORF), gene or allele of threonine production" is to be understood as meaning all the open reading frames, genes or alleles of which enhancement/over-expression can have the effect of  
 5 improving threonine production.

These include, inter alia, the following open reading frames, genes or alleles: accBC, accDA, cstA, cysD, cysE, cysH, cysI, cysN, cysQ, dps, eno, fda, gap, gap2, gdh, gnd, hom, hom<sup>FBR</sup>, lysC, lysC<sup>FBR</sup>, msik, opcA, oxyR, ppc, ppc<sup>FBR</sup>,  
 10 pgk, pknA, pknB, pknD, pknG, ppsA, ptsH, ptsI, ptsM, pyc, pyc P458S, sigC, sigD, sigE, sigH, sigM, tal, thyA, tkt, tpi, thrB, thrC, thrE, zwf, zwf A213T. These are summarized and explained in Table 6. These include, in particular, the lysC<sup>FBR</sup> alleles which code for a "feed back"  
 15 resistant aspartate kinase (See Table 2) and the hom<sup>FBR</sup> alleles which code for a "feed back" resistant homoserine dehydrogenase.

The second, optionally third or fourth copy of the open reading frame (ORF), gene or allele of threonine production  
 20 in question can be integrated at in each case a second, optionally third or fourth site. The following open reading frames, genes or nucleotide sequences, inter alia, can be used for this: ccpA1, ccpA2, citA, citB, citE, ddh, gluA, gluB, gluC, gluD, glyA, ilvA, ilvBN, ilvC, ilvD, luxR,  
 25 luxS, lysR1, lysR2, lysR3, mdh, menE, metA, metD, pck, poxB, sigB and zwa2. These are summarized and explained in Table 7.

The sites mentioned include, of course, not only the coding regions of the open reading frames or genes mentioned, but  
 30 also the regions or nucleotide sequences lying upstream which are responsible for expression and regulation, such as, for example, ribosome binding sites, promoters, binding sites for regulatory proteins, binding sites for regulatory ribonucleic acids and attenuators. These regions in general  
 35 lie in a range of 1-800, 1-600, 1-400, 1-200, 1-100 or 1-50

nucleotides upstream of the coding region. In the same way, regions lying downstream, such as, for example, transcription terminators, are also included. These regions in general lie in a range of 1-400, 1-200, 1-100, 1-50 or  
5 1-25 nucleotides downstream of the coding region.

Intergenic regions in the chromosome, that is to say nucleotide sequences without a coding function, can furthermore be used. Finally, prophages or defective phages contained in the chromosome can be used for this.

Table 6

Open reading frames, genes and alleles of threonine production

Name	Description of the coded enzyme or protein	Reference	Access Number
accBC	Acyl-CoA Carboxylase EC 6.3.4.14 (acyl-CoA carboxylase)	Jäger et al. Archives of Microbiology 166:76-82 (1996) EP1108790 WO0100805	U35023  AX123524 AX066441
accDA	Acetyl-CoA Carboxylase EC 6.4.1.2 (acetyl-CoA carboxylase)	EP1055725 EP1108790 WO0100805	AX121013 AX066443
cstA	Carbon Starvation Protein A (carbon starvation protein A)	EP1108790 WO0100804	AX120811 AX066109
cysD	Sulfate Adenylyltransferase sub-unit II EC 2.7.7.4 (sulfate adenylyltransferase small chain)	EP1108790	AX123177
cysE	Serine Acetyltransferase EC 2.3.1.30 (serine acetyltransferase)	EP1108790 WO0100843	AX122902 AX063961
cysH	3'-Phosphoadenyl Sulfate Reductase EC 1.8.99.4 (3'-phosphoadenosine 5'-phosphosulfate reductase)	EP1108790 WO0100842	AX123178 AX066001
cysK	Cysteine Synthase EC 4.2.99.8 (cysteine synthase)	EP1108790 WO0100843	AX122901 AX063963
cysN	Sulfate Adenylyltransferase sub-unit I EC 2.7.7.4 (sulfate adenylyltransferase)	EP1108790	AX123176 AX127152
cysQ	Transport protein CysQ (transporter cysQ)	EP1108790 WO0100805	AX127145 AX066423
dps	DNA Protection Protein (protection during starvation protein)	EP1108790	AX127153
eno	Enolase EC 4.2.1.11 (enolase)	EP1108790 WO0100844 EP1090998 Hermann et al., Electrophoresis 19:3217-3221 (1998)	AX127146 AX064945 AX136862
fda	Fructose Bisphosphate Aldolase EC 4.1.2.13 (fructose bisphosphate aldolase)	van der Osten et al., Molecular Microbiology 3:1625-1637 (1989)	X17313
gap	Glyceraldehyde 3-Phosphate Dehydrogenase EC 1.2.1.12	EP1108790 WO0100844 Eikmanns et al.,	AX127148 AX064941 X59403

	(glyceraldehyde 3-phosphate dehydrogenase)	Journal of Bacteriology 174:6076-6086(1992)	
gap2	Glyceraldehyde 3-Phosphate Dehydrogenase EC 1.2.1.12 (glyceraldehyde 3-phosphate dehydrogenase 2)	EP1108790 WO0100844	AX127146 AX064939
gdh	Glutamate Dehydrogenase EC 1.4.1.4 (glutamate dehydrogenase)	EP1108790 WO0100844 Boermann et al., Molecular Microbiology 6:317-326 (1992); Guyonvarch et al., NCBI	AX127150 AX063811 X59404  X72855
gnd	6-Phosphogluconate Dehydrogenase EC 1.1.1.44 (6-phosphogluconate dehydrogenase)	EP1108790 WO0100844	AX127147 AX121689 AX065125
hom	Homoserine Dehydrogenase EC 1.1.1.3 (homoserine dehydrogenase)	Peoples et al., Molecular Microbiology 2:63-72 (1988)	Y00546
hom <sup>FBR</sup>	Homoserine Dehydrogenase feedback resistant (fbr) EC 1.1.1.3 (homoserine dehydrogenase fbr)	Reinscheid et al., Journal of Bacteriology 173:3228-30 (1991)	
lysC	Aspartate Kinase EC 2.7.2.4 (aspartate kinase)	EP1108790 WO0100844 Kalinowski et al., Molecular Microbiology 5:1197-204 (1991)	AX120365 AX063743 X57226
lysC <sup>FBR</sup>	Aspartate Kinase feedback resistant (fbr) EC 2.7.2.4 (aspartate kinase fbr)	see Table 2	
msiK	Sugar Importer (multiple sugar import protein)	EP1108790	AX120892
opcA	Glucose 6-Phosphate Dehydrogenase (subunit of glucose 6-phosphate dehydrogenase)	WO0104325	AX076272
oxyR	Transcription Regulator (transcriptional regulator)	EP1108790	AX122198 AX127149
ppc <sup>FBR</sup>	Phosphoenol Pyruvate Carboxylase feedback resistant EC 4.1.1.31 (phosphoenol pyruvate carboxylase feedback resistant)	EP0723011 WO0100852	
ppc	Phosphoenol Pyruvate Carboxylase EC 4.1.1.31 (phosphoenol pyruvate carboxylase)	EP1108790 O'Reagan et al., Gene 77(2):237-251(1989)	AX127148 AX123554 M25819

pgk	Phosphoglycerate Kinase EC 2.7.2.3 (phosphoglycerate kinase)	EP1108790  WO0100844 Eikmanns, Journal of Bacteriology 174:6076-6086 (1992)	AX121838 AX127148 AX064943 X59403
pknA	Protein Kinase A (protein kinase A)	EP1108790	AX120131 AX120085
pknB	Protein Kinase B (protein kinase B)	EP1108790	AX120130 AX120085
pknD	Protein Kinase D (protein kinase D)	EP1108790	AX127150 AX122469 AX122468
pknG	Protein Kinase G (protein kinase G)	EP1108790	AX127152 AX123109
ppsA	Phosphoenol Pyruvate Synthase EC 2.7.9.2 (phosphoenol pyruvate synthase)	EP1108790	AX127144 AX120700 AX122469
ptsH	Phosphotransferase System Protein H EC 2.7.1.69 (phosphotransferase system component H)	EP1108790  WO0100844	AX122210 AX127149 AX069154
ptsI	Phosphotransferase System Enzyme I EC 2.7.3.9 (phosphotransferase system enzyme I)	EP1108790	AX122206 AX127149
ptsM	Glucose-specific Phosphotransferase System Enzyme II EC 2.7.1.69 (glucose phosphotransferase-system enzyme II)	Lee et al., FEMS Microbiology Letters 119 (1-2):137-145 (1994)	L18874
pyc	Pyruvate Carboxylase EC 6.4.1.1 (pyruvate carboxylase)	WO9918228 Peters-Wendisch et al., Microbiology 144:915-927 (1998)	A97276 Y09548
pyc P458S	Pyruvate Carboxylase EC 6.4.1.1 (pyruvate carboxylase) amino acid exchange P458S	EP1108790	
sigC	Sigma Factor C EC 2.7.7.6 (extracytoplasmic function alternative sigma factor C)	EP1108790	AX120368 AX120085
sigD	RNA Polymerase Sigma Factor D EC 2.7.7.6 (RNA polymerase sigma factor)	EP1108790	AX120753 AX127144
sigE	Sigma Factor E EC 2.7.7.6 (extracytoplasmic function alternative sigma factor E)	EP1108790	AX127146 AX121325
sigH	Sigma Factor H EC 2.7.7.6 (sigma factor SigH)	EP1108790	AX127145 AX120939
sigM	Sigma Factor M	EP1108790	AX123500

	EC 2.7.7.6 (sigma factor SigM)		AX127153
tal	Transaldolase EC 2.2.1.2 (transaldolase)	WO0104325	AX076272
thrB	Homoserine Kinase EC 2.7.1.39 (homoserine kinase)	Peoples et al., Molecular Microbiology 2:63-72 (1988)	Y00546
thrC	Threonine Synthase EC 4.2.99.2 (threonine synthase)	Han et al., Molecular Microbiology 4:1693-1702 (1990)	X56037
thrE	Threonine Exporter (threonine export carrier)	EP1085091	AX137526
thyA	Thymidylate Synthase EC 2.1.1.45 (thymidylate synthase)	EP1108790	AX121026 AX127145
tkt	Transketolase EC 2.2.1.1 (transketolase)	Ikeda et al., NCBI	AB023377
tpi	Triose phosphate Isomerase EC 5.3.1.1 (triose phosphate isomerase)	Eikmanns, Journal of Bacteriology 174:6076-6086 (1992)	X59403
zwa1	Cell Growth Factor 1 (growth factor 1)	EP1111062	AX133781
zwf	Glucose 6-Phosphate 1-Dehydrogenase EC 1.1.1.49 (glucose 6-phosphate 1- dehydrogenase)	EP1108790  WO0104325	AX127148 AX121827 AX076272
zwf A213T	Glucose 6-Phosphate 1-Dehydrogenase EC 1.1.1.49 (glucose 6-phosphate 1- dehydrogenase) amino acid exchange A213T	EP1108790	



Table 7

Target sites for integration of open reading frames, genes  
and alleles of threonine production

Gene name	Description of the coded enzyme or protein	Reference	Access Number
ccpA1	Catabolite Control Protein (catabolite control protein A1)	WO0100844 EP1108790	AX065267 AX127147
ccpA2	Catabolite Control Protein (catabolite control protein A2)	WO0100844 EP1108790	AX065267 AX121594
citA	Sensor Kinase Cita (sensor kinase Cita)	EP1108790	AX120161
citB	Transcription Regulator CitB (transcription regulator CitB)	EP1108790	AX120163
citE	Citrate Lyase EC 4.1.3.6 (citrate lyase)	WO0100844 EP1108790	AX065421 AX127146
ddh	Diaminopimelate Dehydrogenase EC 1.4.1.16 (diaminopimelate dehydrogenase)	Ishino et al., Nucleic Acids Research 15: 3917 (1987) EP1108790	S07384 AX127152
gluA	Glutamate Transport ATP-binding Protein (glutamate transport ATP-binding protein)	Kronmeyer et al., Journal of Bacteriology 177(5):1152-8 (1995)	X81191
gluB	Glutamate-binding Protein (glutamate-binding protein)	Kronmeyer et al., Journal of Bacteriology 177(5):1152-8 (1995)	X81191
gluC	Glutamate Transport Permease (glutamate transport system permease)	Kronmeyer et al., Journal of Bacteriology 177(5):1152-8 (1995)	X81191
gluD	Glutamate Transport Permease (glutamate transport system permease)	Kronmeyer et al., Journal of Bacteriology 177(5):1152-8 (1995)	X81191
glyA	Glycine Hydroxymethyltransferase EC 2.1.2.1 (glycine hydroxymethyltransferase)	WO0100843	AX063861 AF327063
ilvA	Threonine Dehydratase EC 4.2.1.16 (threonine dehydratase)	Möckel et al., Journal of Bacteriology 174 (24), 8065-8072 (1992) EP1108790	A47044 L01508 AX127150
ilvBN	Acetolactate Synthase EC 4.1.3.18	Keilhauer et al., Journal of Bacteriology	L09232

	(acetolactate synthase)	175 (17):5595-603 (1993) EP1108790	AX127147
ilvC	Reductoisomerase EC 1.1.1.86 (ketol-acid reductoisomerase)	Keilhauer et al., Journal of Bacteriology 175 (17):5595-603 (1993) EP1108790	C48648 AX127147
ilvD	Dihydroxy-acid Dehydratase EC 4.2.1.9 (dihydroxy-acid dehydratase)	EP1006189	AX136925
luxR	Transcription Regulator LuxR (transcription regulator LuxR)	WO0100842 EP1108790	AX065953 AX123320
luxS	Histidine Kinase LuxS (histidine kinase LuxS)	EP1108790	AX123323 AX127153
lysR1	Transcription Regulator LysR1 (transcription regulator LysR1)	EP1108790	AX064673 AX127144
lysR2	Transcription Activator LysR2 (transcription regulator LysR2)	EP1108790	AX123312
lysR3	Transcription Regulator LysR3 (transcription regulator LysR3)	WO0100842 EP1108790	AX065957 AX127150
mdh	Malate Dehydrogenase EC 1.1.1.37 (malate dehydrogenase)	WO0100844	AX064895
menE	O-Succinylbenzoic Acid CoA Ligase EC 6.2.1.26 (O-succinylbenzoate CoA ligase)	WO0100843 EP1108790	AX064599 AX064193 AX127144
metaA	Homoserine O- Acetyltransferase EC 2.3.1.31 (homoserine O- acetyltransferase)	Park et al., Molecular Cells 30;8(3):286-94 (1998) WO0100843 EP1108790	AX063895 AX127145
metD	Transcription Regulator MetD (transcription regulator MetD)	EP1108790	AX123327 AX127153
pck	Phosphoenol Pyruvate Carboxykinase (phosphoenol pyruvate carboxykinase)	WO0100844	AJ269506 AX065053
poxB	Pyruvate Oxidase EC 1.2.3.3 (pyruvate oxidase)	WO0100844 EP1096013	AX064959 AX137665
sigB	RNA Polymerase Transcription Factor (RNA polymerase transcription factor)	EP1108790	AX127149

zwa2	Cell Growth Factor 2 (growth factor 2)	EP1106693 EP1108790	AX113822 AX127146
------	---	------------------------	----------------------

The invention accordingly also provides a process for the production of coryneform bacteria which produce L-methionine and/or L-threonine, which comprises

- 5 a) isolating the nucleotide sequence of at least one desired ORF, gene or allele of methionine production or threonine production, optionally including the expression and/or regulation signals,
- 10 b) providing the 5' and the 3' end of the ORF, gene or allele with nucleotide sequences of the target site,
- c) preferably incorporating the nucleotide sequence of the desired ORF, gene or allele provided with nucleotide sequences of the target site into a vector which does not replicate or replicates to only a  
15 limited extent in coryneform bacteria,
- d) transferring the nucleotide sequence according to b) or c) into coryneform bacteria, and
- 20 e) isolating coryneform bacteria in which the nucleotide sequence according to a) is incorporated at the target site, no nucleotide sequence which is capable of/enables episomal replication in microorganisms, no nucleotide sequence which is capable of/enables transposition and no nucleotide sequence which imparts resistance to antibiotics remaining at the target  
25 site.

The invention furthermore provides coryneform bacteria, in particular of the genus *Corynebacterium*, which produce L-valine, wherein these have, in addition to at least one of the copy of an open reading frame (ORF), gene or allele of  
30 valine production present at the natural site (locus), in each case a second, optionally third or fourth copy of the

open reading frame (ORF), gene or allele in question at in  
each case a second, optionally third or fourth site in  
integrated form, no nucleotide sequence which is capable  
of/enables episomal replication in microorganisms, no  
5 nucleotide sequence which is capable of/enables  
transposition and no nucleotide sequence which imparts  
resistance to antibiotics being present at the particular  
second, optionally third or fourth site.

The invention also furthermore provides a process for the  
10 preparation of L-valine, which comprises the following  
steps:

a) fermentation of coryneform bacteria, in particular  
Corynebacterium glutamicum, characterized in that  
these have, in addition to at least one of the copy of  
15 an open reading frame (ORF), gene or allele of valine  
production present at the natural site (locus), in  
each case a second, optionally third or fourth copy of  
the open reading frame (ORF), gene or allele in  
question at in each case a second, optionally third or  
20 fourth site in integrated form, no nucleotide sequence  
which is capable of/enables episomal replication in  
microorganisms, no nucleotide sequence which is  
capable of/enables transposition and no nucleotide  
sequence which imparts resistance to antibiotics being  
25 present at the particular second, optionally third or  
fourth site,

under conditions which allow expression of the said  
open reading frames (ORF), genes or alleles,

30 b) concentration of the L-valine in the fermentation  
broth,  
c) isolation of the L-valine from the fermentation broth,  
optionally

- d) with constituents from the fermentation broth and/or the biomass to the extent of > (greater than) 0 to 100%.

5 A "copy of an open reading frame (ORF), gene or allele of valine production" is to be understood as meaning all the open reading frames, genes or alleles of which enhancement/over-expression can have the effect of improving valine production.

10 These include, inter alia, the following open reading frames, genes or alleles: brnE, brnF, brnEF, cstA, cysD, dps, eno, fda, gap, gap2, gdh, ilvB, ilvN, ilvBN, ilvC, ilvD, ilvE, msik, pgk, ptsH, ptsI, ptsM, sigC, sigD, sigE, sigH, sigM, tpi, zwal. These are summarized and explained in Table 8. These include in particular the acetolactate  
15 synthase which codes for a valine-resistant.

The second, optionally third or fourth copy of the open reading frame (ORF), gene or allele of threonine production in question can be integrated at in each case a second, optionally third or fourth site. The following open reading  
20 frames, genes or nucleotide sequences, inter alia, can be used for this: aecD, ccpA1, ccpA2, citA, citB, citE, ddh, gluA, gluB, gluC, gluD, glyA, ilvA, luxR, lysR1, lysR2, lysR3, panB, panC, poxB and zwa2. These are summarized and explained in Table 9.

25 The sites mentioned include, of course, not only the coding regions of the open reading frames or genes mentioned, but also the regions or nucleotide sequences lying upstream which are responsible for expression and regulation, such as, for example, ribosome binding sites, promoters, binding  
30 sites for regulatory proteins, binding sites for regulatory ribonucleic acids and attenuators. These regions in general lie in a range of 1-800, 1-600, 1-400, 1-200, 1-100 or 1-50 nucleotides upstream of the coding region. In the same way, regions lying downstream, such as, for example,

transcription terminators, are also included. These regions in general lie in a range of 1-400, 1-200, 1-100, 1-50 or 1-25 nucleotides downstream of the coding region.

5 Intergenic regions in the chromosome, that is to say nucleotide sequences without a coding function, can furthermore be used. Finally, prophages or defective phages contained in the chromosome can be used for this.

Table 8

Open reading frames, genes and alleles of valine production

Name	Description of the coded enzyme or protein	Reference	Access Number
brnEF	Export of branched-chain amino acids (branched chain amino acid export)	EP1096010 Kennerknecht et al., NCBI	AF454053
cstA	Carbon Starvation Protein A (carbon starvation protein A)	EP1108790 WO0100804	AX120811 AX066109
dps	DNA Protection Protein (protection during starvation protein)	EP1108790	AX127153
eno	Enolase EC 4.2.1.11 (enolase)	EP1108790 WO0100844 EP1090998 Hermann et al., Electrophoresis 19:3217-3221 (1998)	AX127146 AX064945 AX136862
fda	Fructose Bisphosphate Aldolase EC 4.1.2.13 (fructose bisphosphate aldolase)	van der Osten et al., Molecular Microbiology 3:1625-1637 (1989)	X17313
gap	Glyceraldehyde 3-Phosphate Dehydrogenase EC 1.2.1.12 (glyceraldehyde 3-phosphate dehydrogenase)	EP1108790 WO0100844 Eikmanns et al., Journal of Bacteriology 174:6076-6086 (1992)	AX127148 AX064941 X59403
gap2	Glyceraldehyde 3-Phosphate Dehydrogenase EC 1.2.1.12 (glyceraldehyde 3-phosphate dehydrogenase 2)	EP1108790 WO0100844	AX127146 AX064939
gdh	Glutamate Dehydrogenase EC 1.4.1.4 (glutamate dehydrogenase)	EP1108790 WO0100844 Boermann et al., Molecular Microbiology 6:317-326 (1992); Guyonvarch et al., NCBI	AX127150 AX063811 X59404 X72855
ilvBN	Acetolactate Synthase EC 4.1.3.18 (acetolactate synthase)	Keilhauer et al., Journal of Bacteriology 175(17):5595-603 (1993) EP1108790	L09232 AX127147
ilvC	Isomeroreductase EC 1.1.1.86	Keilhauer et al., Journal of	C48648 AX127147

	(acetohydroxy acid isomeroreductase)	Bacteriology 175 (17) : 5595-603 (1993) EP1108790	
ilvD	Dihydroxy-acid Dehydratase EC 4.2.1.9 (dihydroxy acid dehydratase)	EP1006189	AX136925
ilvE	Transaminase B EC 2.6.1.42 (transaminase B)	EP1108790	AX127150 AX122498
msiK	Sugar Importer (multiple sugar import protein)	EP1108790	AX120892
pgk	Phosphoglycerate Kinase EC 2.7.2.3 (phosphoglycerate kinase)	EP1108790  WO0100844 Eikmanns, Journal of Bacteriology 174:6076-6086 (1992)	AX121838 AX127148 AX064943 X59403
ptsH	Phosphotransferase System Protein H EC 2.7.1.69 (phosphotransferase system component H)	EP1108790  WO0100844	AX122210 AX127149 AX069154
ptsI	Phosphotransferase System Enzyme I EC 2.7.3.9 (phosphotransferase system enzyme I)	EP1108790	AX122206 AX127149
ptsM	Glucose-specific Phosphotransferase System Enzyme II EC 2.7.1.69 (glucose phosphotransferase-system enzyme II)	Lee et al., FEMS Microbiology Letters 119 (1-2):137-145 (1994)	L18874
sigC	Sigma Factor C EC 2.7.7.6 (extracytoplasmic function alternative sigma factor C)	EP1108790	AX120368 AX120085
sigD	RNA Polymerase Sigma Factor D EC 2.7.7.6 (RNA polymerase sigma factor)	EP1108790	AX120753 AX127144
sigE	Sigma Factor E EC 2.7.7.6 (extracytoplasmic function alternative sigma factor E)	EP1108790	AX127146 AX121325
sigH	Sigma Factor H EC 2.7.7.6 (sigma factor SigH)	EP1108790	AX127145 AX120939
sigM	Sigma Factor M EC 2.7.7.6 (sigma factor SigM)	EP1108790	AX123500 AX127153
tpi	Triose Phosphate Isomerase EC 5.3.1.1 (triose phosphate isomerase)	Eikmanns, Journal of Bacteriology 174:6076-6086 (1992)	X59403
zwa1	Cell Growth Factor 1 (growth factor 1)	EP1111062	AX133781



Table 9

Target sites for integration of open reading frames, genes  
and alleles of valine production

Gene name	Description of the coded enzyme or protein	Reference	Access Number
aecD	beta C-S Lyase EC 2.6.1.1 (beta C-S lyase)	Rossol et al., Journal of Bacteriology 174(9):2968-77 (1992)	M89931
ccpA1	Catabolite Control Protein (catabolite control protein A1)	WO0100844 EP1108790	AX065267 AX127147
ccpA2	Catabolite Control Protein (catabolite control protein A2)	WO0100844 EP1108790	AX065267 AX121594
citA	Sensor Kinase CitA (sensor kinase CitA)	EP1108790	AX120161
citB	Transcription Regulator CitB (transcription regulator CitB)	EP1108790	AX120163
citE	Citrate Lyase EC 4.1.3.6 (citrate lyase)	WO0100844 EP1108790	AX065421 AX127146
ddh	Diaminopimelate Dehydrogenase EC 1.4.1.16 (diaminopimelate dehydrogenase)	Ishino et al., Nucleic Acids Research 15: 3917 (1987) EP1108790	S07384 AX127152
gluA	Glutamate Transport ATP- binding Protein (glutamate transport ATP- binding protein)	Kronemeyer et al., Journal of Bacteriology 177(5):1152-8 (1995)	X81191
gluB	Glutamate-binding Protein (glutamate-binding protein)	Kronemeyer et al., Journal of Bacteriology 177(5):1152-8 (1995)	X81191
gluC	Glutamate Transport Permease (glutamate transport system permease)	Kronemeyer et al., Journal of Bacteriology 177(5):1152-8 (1995)	X81191
gluD	Glutamate Transport Permease (glutamate transport system permease)	Kronemeyer et al., Journal of Bacteriology 177(5):1152-8 (1995)	X81191
glyA	Glycine Hydroxymethyltransferase EC 2.1.2.1 (glycine hydroxymethyltransferase)	WO0100843	AX063861 AF327063
ilvA	Threonine Dehydratase EC 4.2.1.16 (threonine dehydratase)	Möckel et al., Journal of Bacteriology 174 (24), 8065-8072 (1992)	A47044 L01508 AX127150

		EP1108790	
luxR	Transcription Regulator LuxR (transcription regulator LuxR)	WO0100842 EP1108790	AX065953 AX123320
lysR1	Transcription Regulator LysR1 (transcription regulator LysR1)	EP1108790	AX064673 AX127144
lysR2	Transcription Activator LysR2 (transcription regulator LysR2)	EP1108790	AX123312
lysR3	Transcription Regulator LysR3 (transcription regulator LysR3)	WO0100842 EP1108790	AX065957 AX127150
panB	Ketopantoate Hydroxymethyltransferase EC 2. 1. 2. 11 (ketopantoate hydroxymethyltransferase)	US6177264	X96580
panC	Pantothenate Synthetase EC 6.3.2.1 (pantothenate synthetase)	US6177264	X96580
poxB	Pyruvate Oxidase EC 1.2.3.3 (pyruvate oxidase)	WO0100844 EP1096013	AX064959 AX137665
zwa2	Cell Growth Factor 2 (growth factor 2)	EP1106693 EP1108790	AX113822 AX127146

The invention accordingly also provides a process for the production of coryneform bacteria which produce L-valine, which comprises

- 5 a) isolating the nucleotide sequence of at least one desired ORF, gene or allele of valine production, optionally including the expression and/or regulation signals,
- 10 b) providing the 5' and the 3' end of the ORF, gene or allele with nucleotide sequences of the target site,
- c) preferably incorporating the nucleotide sequence of the desired ORF, gene or allele provided with nucleotide sequences of the target site into a vector

which does not replicate or replicates to only a limited extent in coryneform bacteria,

- d) transferring the nucleotide sequence according to b) or c) into coryneform bacteria, and
- 5 e) isolating coryneform bacteria in which the nucleotide sequence according to a) is incorporated at the target site, no nucleotide sequence which is capable of/enables episomal replication in microorganisms, no nucleotide sequence which is capable of/enables  
10 transposition and no nucleotide sequence which imparts resistance to antibiotics remaining at the target site.

During work on the present invention, it was possible to incorporate a second copy of an  $\text{lysC}^{\text{FBR}}$  allele into the  $\text{gluB}$   
15 gene of *Corynebacterium glutamicum* such that no nucleotide sequence which is capable of/enables episomal replication in microorganisms, no nucleotide sequence which is capable of/enables transposition and no nucleotide sequence which imparts resistance to antibiotics remained at the  $\text{gluB}$  gene  
20 site. This strain, which is called  $\text{DSM13994glu::lysC}$ , carries the  $\text{lysC}^{\text{FBR}}$  allele  $\text{lysC T311I}$  at its natural  $\text{lysC}$  site and a second copy of the  $\text{lysC}^{\text{FBR}}$  allele  $\text{lysC T311I}$  at a second site (target site), namely the  $\text{gluB}$  gene. A plasmid with the aid of which the incorporation of the  $\text{lysC}^{\text{FBR}}$   
25 allele into the  $\text{gluB}$  gene can be achieved is shown in Figure 1. It carries the name  $\text{pK18mobsacBglu1\_1}$ .

During work on the present invention, it was furthermore possible to incorporate a copy of an  $\text{lysC}^{\text{FBR}}$  allele into the target site of the  $\text{gluB}$  gene of *Corynebacterium glutamicum*  
30 such that no nucleotide sequence which is capable of/enables episomal replication in microorganisms, no nucleotide sequence which is capable of/enables transposition and no nucleotide sequence which imparts resistance to antibiotics remained at the  $\text{gluB}$  gene site.

This strain, which is called DSM12866glu::lysC, carries the wild-type form of the lysC gene at its natural lysC site and a second copy of the lysC gene in the form of the lysC<sup>FBR</sup> allele lysC T311I at a second site (target site),  
5 namely the gluB gene. It has been deposited under number DSM15039 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (German Collection of Microorganisms and Cell Cultures). A plasmid with the aid of which the incorporation of the lysC<sup>FBR</sup> allele into the gluB gene can  
10 be achieved is shown in Figure 1. It carries the name pK18mobsacBglu1\_1.

During work on the present invention, it was furthermore possible to incorporate a copy of an lysC<sup>FBR</sup> allele into the target site of the aecD gene of Corynebacterium glutamicum  
15 such that no nucleotide sequence which is capable of/enables episomal replication in microorganisms, no nucleotide sequence which is capable of/enables transposition and no nucleotide sequence which imparts resistance to antibiotics remained at the aecD gene site.  
20 This strain, which is called DSM12866aecD::lysC, carries the wild-type form of the lysC gene at its natural lysC site and a second copy of the lysC gene in the form of the lysC<sup>FBR</sup> allele lysC T311I at a second site (target site), namely the aecD gene. A plasmid with the aid of which the  
25 incorporation of the lysC<sup>FBR</sup> allele into the aecD gene can be achieved is shown in Figure 2. It carries the name pK18mobsacBaecD1\_1.

During work on the present invention, it was furthermore possible to incorporate a copy of an lysC<sup>FBR</sup> allele into the  
30 target site of the pck gene of Corynebacterium glutamicum such that no nucleotide sequence which is capable of/enables episomal replication in microorganisms, no nucleotide sequence which is capable of/enables transposition and no nucleotide sequence which imparts  
35 resistance to antibiotics remained at the pck gene site.

This strain, which is called DSM12866pck::lysC, carries the wild-type form of the lysC gene at its natural lysC site and a second copy of the lysC gene in the form of the lysC<sup>FBR</sup> allele lysC T311I at a second site (target site),  
5 namely the pck gene. A plasmid with the aid of which the incorporation into the pck gene can be achieved is shown in Figure 3. It carries the name pK18mobsacBpck1\_1.

During work on the present invention, it was furthermore possible to incorporate a copy of the ddh gene into the  
10 target site of the gluB gene of Corynebacterium glutamicum such that no nucleotide sequence which is capable of/enables episomal replication in microorganisms, no nucleotide sequence which is capable of/enables transposition and no nucleotide sequence which imparts  
15 resistance to antibiotics remained at the gluB gene site. This strain, which is called DSM12866glu::ddh, carries a copy of the ddh gene at its natural ddh site and a second copy of the ddh gene at a second site (target site), namely the gluB gene. A plasmid with the aid of which the  
20 incorporation of the ddh gene into the gluB gene can be achieved is shown in Figure 4. It carries the name pK18mobsacBgluB2\_1.

During work on the present invention, it was furthermore possible to incorporate a copy of the dapA gene into the  
25 target site of the aecD gene of Corynebacterium glutamicum such that no nucleotide sequence which is capable of/enables episomal replication in microorganisms, no nucleotide sequence which is capable of/enables transposition and no nucleotide sequence which imparts  
30 resistance to antibiotics remained at the aecD gene site. This strain, which is called DSM12866aecD::dapA, carries a copy of the dapA gene at its natural dapA site and a second copy of the dapA gene at a second site (target site), namely the aecD gene. A plasmid with the aid of which the  
35 incorporation of the dapA gene into the aecD gene can be

achieved is shown in Figure 5. It carries the name pK18mobsacBaecD2\_1.

During work on the present invention, it was furthermore possible to incorporate a copy of a pyc allele into the target site of the pck gene of *Corynebacterium glutamicum* such that no nucleotide sequence which is capable of/enables episomal replication in microorganisms, no nucleotide sequence which is capable of/enables transposition and no nucleotide sequence which imparts resistance to antibiotics remained at the pck gene site. This strain, which is called DSM12866pck::pyc, carries a copy of the wild-type form of the pyc gene at its natural pyc site and a second copy of the pyc gene in the form of the pyc allele pyc P458S at a second site (target site), namely the pck gene. A plasmid with the aid of which the incorporation of the pyc allele into the pck gene can be achieved is shown in Figure 6. It carries the name pK18mobsacBpck1\_3.

The coryneform bacteria produced according to the invention can be cultured continuously or discontinuously in the batch process (batch culture) or in the fed batch (feed process) or repeated fed batch process (repetitive feed process) for the purpose of production of chemical compounds. A summary of known culture methods is described in the textbook by Chmiel (Bioprozesstechnik 1. Einführung in die Bioverfahrenstechnik (Gustav Fischer Verlag, Stuttgart, 1991)) or in the textbook by Storhas (Bioreaktoren und periphere Einrichtungen (Vieweg Verlag, Braunschweig/Wiesbaden, 1994)).

The culture medium to be used must meet the requirements of the particular strains in a suitable manner. Descriptions of culture media for various microorganisms are contained in the handbook "Manual of Methods for General Bacteriology" of the American Society for Bacteriology (Washington D.C., USA, 1981).

Sugars and carbohydrates, such as e.g. glucose, sucrose, lactose, fructose, maltose, molasses, starch and cellulose, oils and fats, such as e.g. soya oil, sunflower oil, groundnut oil and coconut fat, fatty acids, such as e.g. 5 palmitic acid, stearic acid and linoleic acid, alcohols, such as e.g. glycerol and ethanol, and organic acids, such as e.g. acetic acid or lactic acid, can be used as the source of carbon. These substances can be used individually or as a mixture.

10 Organic nitrogen-containing compounds, such as peptones, yeast extract, meat extract, malt extract, corn steep liquor, soya bean flour and urea, or inorganic compounds, such as ammonium sulfate, ammonium chloride, ammonium phosphate, ammonium carbonate and ammonium nitrate, can be 15 used as the source of nitrogen. The sources of nitrogen can be used individually or as a mixture.

Phosphoric acid, potassium dihydrogen phosphate or dipotassium hydrogen phosphate or the corresponding sodium-containing salts can be used as the source of phosphorus.

20 The culture medium must furthermore comprise salts of metals, such as e. g. magnesium sulfate or iron sulfate, which are necessary for growth. Finally, essential growth substances, such as amino acids and vitamins, can be employed in addition to the above-mentioned substances.

25 Suitable precursors can moreover be added to the culture medium. The starting substances mentioned can be added to the culture in the form of a single batch, or can be fed in during the culture in a suitable manner.

Basic compounds, such as sodium hydroxide, potassium 30 hydroxide, ammonia or aqueous ammonia, or acid compounds, such as phosphoric acid or sulfuric acid, can be employed in a suitable manner to control the pH of the culture. Antifoams, such as e.g. fatty acid polyglycol esters, can be employed to control the development of foam. Suitable 35 substances having a selective action, such as e.g.

antibiotics, can be added to the medium to maintain the stability of plasmids. To maintain aerobic conditions, oxygen or oxygen-containing gas mixtures, such as e.g. air, are introduced into the culture. The temperature of the culture is usually 20°C to 45°C, and preferably 25°C to 40°C. Culturing is continued until a maximum of the desired chemical compound has formed. This target is usually reached within 10 hours to 160 hours.

It has been found that the coryneform bacteria according to the invention, in particular the coryneform bacteria which produce L-lysine, have an unexpectedly high stability. They were stable for at least 10-20, 20-30, 30-40, 40-50, preferably at least 50-60, 60-70, 70-80 and 80-90 generations or cell division cycles.

The following microorganisms have been deposited:

The strain *Corynebacterium glutamicum* DSM12866glu::lysc was deposited in the form of a pure culture on 5th June 2002 under number DSM15039 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ = German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) in accordance with the Budapest Treaty.

The plasmid pK18mobsacBglu1\_1 was deposited in the form of a pure culture of the strain *E. coli* DH5 $\alpha$ mcr/pK18mobsacBglu1\_1 (= DH5 $\alpha$ lphamcr/pK18mobsacBglu1\_1) on 20th April 2001 under number DSM14243 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany) in accordance with the Budapest Treaty.

The plasmid pK18mobsacBaecD1\_1 was deposited in the form of a pure culture of the strain *E. coli* DH5 $\alpha$ mcr/pK18mobsacBaecD1\_1 (= DH5 $\alpha$ lphamcr/pK18mobsacBaecD1\_1) on 5th June 2002 under number DSM15040 at the Deutsche Sammlung für



Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany) in accordance with the Budapest Treaty.

#### Example 1

5 Incorporation of a second copy of the  $lysC^{FBR}$  allele into the chromosome of the strain DSM13994 and of the strain DSM12866

10 The *Corynebacterium glutamicum* strain DSM13994 was produced by multiple, non-directed mutagenesis, selection and mutant selection from *C. glutamicum* ATCC13032. The strain is resistant to the lysine analogue S-(2-aminoethyl)-L-cysteine and has a feed back-resistant aspartate kinase which is insensitive to inhibition by a mixture of lysine and threonine (in each case 25 mM). The nucleotide sequence of the  $lysC^{FBR}$  allele of this strain is shown as SEQ ID  
15 NO:3. It is also called *lysC* T311I in the following. The amino acid sequence of the aspartate kinase protein coded is shown as SEQ ID NO:4. A pure culture of this strain was deposited on 16th January 2001 at the Deutsche Sammlung für  
20 Mikroorganismen und Zellkulturen (DSMZ = German Collection of Microorganisms and Cell Cultures, Braunschweig, Germany) in accordance with the Budapest Treaty.

The strain DSM12866 was produced from *C. glutamicum* ATCC13032 by non-directed mutagenesis and selection of the mutants with the best L-lysine accumulation. It is  
25 methionine-sensitive. Growth on minimal medium comprising L-methionine can be re-established by addition of threonine. This strain has the wild-type form of the *lysC* gene shown as SEQ ID NO:1. The corresponding amino acid sequence of the wild-type aspartate kinase protein is shown  
30 as SEQ ID NO:2. A pure culture of this strain was deposited on 10th June 1999 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany) in accordance with the Budapest Treaty.

### 1.1 Isolation and sequencing of the DNA of the *lysC* allele of strain DSM13994

From the strain DSM13994, chromosomal DNA is isolated by the conventional methods (Eikmanns et al., Microbiology 140: 1817 - 1828 (1994)). With the aid of the polymerase chain reaction, a DNA section which carries the *lysC* gene or allele is amplified. On the basis of the sequence of the *lysC* gene known for *C. glutamicum* (Kalinowski et al., Molecular Microbiology, 5 (5), 1197 - 1204 (1991); Accession Number X57226), the following primer oligonucleotides were chosen for the PCR:

*lysC*1beg (SEQ ID No: 5):

5' TA(G GAT CC)T CCG GTG TCT GAC CAC GGT G 3'

*lysC*2end: (SEQ ID NO: 6):

5' AC(G GAT CC)G CTG GGA AAT TGC GCT CTT CC 3'

The primers shown are synthesized by MWG Biotech and the PCR reaction is carried out by the standard PCR method of Innis et al. (PCR Protocols. A Guide to Methods and Applications, 1990, Academic Press). The primers allow amplification of a DNA section of approx. 1.7 kb in length, which carries the *lysC* gene or allele. The primers moreover contain the sequence for a cleavage site of the restriction endonuclease BamHI, which is marked by parentheses in the nucleotide sequence shown above.

The amplified DNA fragment of approx. 1.7 kb in length which carries the *lysC* allele of the strain DSM13994 is identified by electrophoresis in a 0.8% agarose gel, isolated from the gel and purified by conventional methods (QIAquick Gel Extraction Kit, Qiagen, Hilden).

Ligation of the fragment is then carried out by means of the Topo TA Cloning Kit (Invitrogen, Leek, The Netherlands, Cat. Number K4600-01) in the vector pCRII-TOPO. The ligation batch is transformed in the *E. coli* strain TOP10.

(Invitrogen, Leek, The Netherlands). Selection of plasmid-carrying cells is made by plating out the transformation batch on kanamycin (50 mg/l)-containing LB agar with X-Gal (5-bromo-4-chloro-3-indolyl  $\beta$ -D-galactopyranoside, 5 64 mg/l).

The plasmid obtained is checked by means of restriction cleavage, after isolation of the DNA, and identified in agarose gel. The resulting plasmid is called pCRIITOPolysC.

The nucleotide sequence of the amplified DNA fragment or 10 PCR product is determined by the dideoxy chain termination method of Sanger et al. (Proceedings of the National Academy of Sciences USA, 74:5463-5467 (1977)) using the "ABI Prism 377" sequencing apparatus of PE Applied Biosystems (Weiterstadt, Germany). The sequence of the 15 coding region of the PCR product is shown in SEQ ID No:3. The amino acid sequence of the associated aspartate kinase protein is shown in SEQ ID NO:4.

The base thymine is found at position 932 of the nucleotide sequence of the coding region of the lysC<sup>FBR</sup> allele of 20 strain DSM13994 (SEQ ID NO:3). The base cytosine is found at the corresponding position of the wild-type gene (SEQ ID NO:1).

The amino acid isoleucine is found at position 311 of the amino acid sequence of the aspartate kinase protein of 25 strain DSM13994 (SEQ ID No:4). The amino acid threonine is found at the corresponding position of the wild-type protein (SEQ ID No:2).

The lysC allele, which contains the base thymine at position 932 of the coding region and accordingly codes for 30 an aspartate kinase protein which contains the amino acid isoleucine at position 311 of the amino acid sequence, is called the lysC<sup>FBR</sup> allele or lysC T311I in the following.

The plasmid pCRIITOPolysC, which carries the lysC<sup>FBR</sup> allele lysC T311I, was deposited in the form of a pure culture of the strain E. coli TOP 10/pCRIITOPolysC under number DSM14242 on 20th April 2001 at the Deutsche Sammlung für  
5 Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany) in accordance with the Budapest Treaty.

## 1.2 Construction of the replacement vector pK18mobsacBglu1\_1

The *Corynebacterium glutamicum* strain ATCC13032 is used as  
10 the donor for the chromosomal DNA. From the strain ATCC13032, chromosomal DNA is isolated using the conventional methods (Eikmanns et al., Microbiology 140: 1817 - 1828 (1994)). With the aid of the polymerase chain reaction, a DNA fragment which carries the gluB gene and  
15 surrounding regions is amplified. On the basis of the sequence of the gluABCD gene cluster known for C. glutamicum (Kronemeyer et al., Journal of Bacteriology, 177: 1152 - 1158 (1995)) (Accession Number X81191), the following primer oligonucleotides are chosen for the PCR:

20 gluBg11 (SEQ ID NO: 7):

5' TA(A GAT CT)G TGT TGG ACG TCA TGG CAA G 3'

gluBg12 (SEQ ID NO: 8):

5' AC(A GAT CT)T GAA GCC AAG TAC GGC CAA G 3'

The primers shown are synthesized by MWG Biotech and the  
25 PCR reaction is carried out by the standard PCR method of Innis et al. (PCR Protocols. A Guide to Methods and Applications, 1990, Academic Press). The primers allow amplification of a DNA fragment of approx 1.7 kb in size, which carries the gluB gene and surrounding regions. The  
30 surrounding regions are a sequence section approx. 0.33 kb in length upstream of the gluB gene, which represents the 3' end of the gluA gene, and a sequence section approx. 0.44 kb in length downstream of the gluB gene, which

represents the 5' end of the *gluC* gene. The primers moreover contain the sequence for the cleavage site of the restriction endonuclease *Bgl*II, which is marked by parentheses in the nucleotide sequence shown above.

- 5 The amplified DNA fragment of approx. 1.7 kb in length which carries the *gluB* gene and surrounding regions is identified by means of electrophoresis in a 0.8% agarose gel and isolated from the gel and purified by conventional methods (QIAquick Gel Extraction Kit, Qiagen, Hilden).
- 10 Ligation of the fragment is then carried out by means of the TOPO TA Cloning Kit (Invitrogen, Leek, The Netherlands, Cat. Number K4600-01) in the vector pCRII-TOPO. The ligation batch is transformed in the *E. coli* strain TOP10 (Invitrogen, Leek, The Netherlands). Selection of plasmid-
- 15 carrying cells is made by plating out the transformation batch on kanamycin (50 mg/l)-containing LB agar with X-Gal (5-bromo-4-chloro-3-indolyl  $\beta$ -D-galactopyranoside, 64 mg/l).

- The plasmid obtained is checked by means of restriction
- 20 cleavage, after isolation of the DNA, and identified in agarose gel. The resulting plasmid is called pCRII-TOPOglu.

- The plasmid pCRII-TOPOglu is cleaved with the restriction enzyme *Bgl*II (Amersham-Pharmacia, Freiburg, Germany) and after separation in an agarose gel (0.8%) with the aid of
- 25 the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) the *gluB* fragment of approx. 1.7 kb is isolated from the agarose gel and employed for ligation with the mobilizable cloning vector pK18mobsacB described by Schäfer et al. (Gene 14: 69-73 (1994)). This is cleaved beforehand with
- 30 the restriction enzyme *Bam*HI and dephosphorylated with alkaline phosphatase (Alkaline Phosphatase, Boehringer Mannheim), mixed with the *gluB* fragment of approx. 1.7 kb, and the mixture is treated with T4 DNA Ligase (Amersham-Pharmacia, Freiburg, Germany).

- The E. coli strain DH5 $\alpha$  (Grant et al.; Proceedings of the National Academy of Sciences USA, 87 (1990) 4645-4649) is then transformed with the ligation batch (Hanahan, In. DNA Cloning. A Practical Approach. Vol. 1, IRL-Press, Cold Spring Harbor, New York, 1989). Selection of plasmid-carrying cells is made by plating out the transformation batch on LB agar (Sambrook et al., Molecular Cloning: A Laboratory Manual. 2<sup>nd</sup> Ed., Cold Spring Harbor, New York, 1989), which is supplemented with 50 mg/l kanamycin.
- 10 Plasmid DNA is isolated from a transformant with the aid of the QIAprep Spin Miniprep Kit from Qiagen and checked by restriction cleavage and subsequent agarose gel electrophoresis. The plasmid is called pK18mobsacBglu1.
- Plasmid DNA was isolated from the strain DSM14242 (see Example 1.1), which carries the plasmid pCRIITOPolysC, and cleaved with the restriction enzyme BamHI (Amersham-Pharmacia, Freiburg, Germany), and after separation in an agarose gel (0.8%) with the aid of the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) the lysC<sup>FBR</sup>-
- 20 containing DNA fragment of approx. 1.7 kb in length was isolated from the agarose gel and employed for ligation with the vector pK18mobsacBglu1 described above. This is cleaved beforehand with the restriction enzyme BamHI, dephosphorylated with alkaline phosphatase (Alkaline Phosphatase, Boehringer Mannheim, Germany), mixed with the
- 25 lysC<sup>FBR</sup> fragment of approx. 1.7 kb and the mixture is treated with T4 DNA Ligase (Amersham-Pharmacia, Freiburg, Germany).
- The E. coli strain DH5 $\alpha$ mcr (Life Technologies GmbH, Karlsruhe, Germany) is then transformed with the ligation batch (Hanahan, In: DNA Cloning. A Practical Approach. Vol. 1, IRL-Press, Cold Spring Harbor, New York, 1989).
- Selection of plasmid-carrying cells is made by plating out the transformation batch on LB agar (Sambrook et al.,
- 35 Molecular Cloning: A Laboratory Manual. 2<sup>nd</sup> Ed., Cold

Spring Harbor, New York, 1989), which was supplemented with 50 mg/l kanamycin.

Plasmid DNA is isolated from a transformant with the aid of the QIAprep Spin Miniprep Kit from Qiagen and checked by  
5 restriction cleavage and subsequent agarose gel electrophoresis. The plasmid is called pK18mobsacBglu1\_1. A map of the plasmid is shown in Figure 1.

The plasmid pK18mobsacBglu1\_1 was deposited in the form of a pure culture of the strain E. coli

10 DH5 $\alpha$ mcr/pK18mobsacBglu1\_1 (= DH5 $\alpha$ phamcr/pK18mobsacBglu1\_1) under number DSM14243 on 20.04.2001 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany) in accordance with the Budapest Treaty.

15 1.3 Incorporation of a second copy of the lysC<sup>FBR</sup> allele lysC T311I into the chromosome (target site: gluB gene) of the strain DSM13994 by means of the replacement vector pK18mobsacBglu1\_1

The vector pK18mobsacBglu1\_1 described in Example 1.2 is  
20 transferred by the protocol of Schäfer et al. (Journal of Microbiology 172: 1663-1666 (1990)) into the C. glutamicum strain DSM13994 by conjugation. The vector cannot replicate independently in DSM13994 and is retained in the cell only if it has integrated into the chromosome. Selection of  
25 clones or transconjugants with integrated pK18mobsacBglu1\_1 is made by plating out the conjugation batch on LB agar (Sambrook et al., Molecular Cloning: A Laboratory Manual. 2<sup>nd</sup> Ed., Cold Spring Harbor, New York, 1989), which is supplemented with 15 mg/l kanamycin and 50 mg/l nalidixic  
30 acid. Kanamycin-resistant transconjugants are plated out on LB agar plates with 25 mg/l kanamycin and incubated for 48 hours at 33°C.

For selection of mutants in which excision of the plasmid has taken place as a consequence of a second recombination event, the clones are cultured for 20 hours in LB liquid medium and then plated out on LB agar with 10% sucrose and  
5 incubated for 48 hours.

The plasmid pK18mobsacBglu1\_1, like the starting plasmid pK18mobsacB, contains, in addition to the kanamycin resistance gene, a copy of the sacB gene which codes for  
10 levan sucrase from *Bacillus subtilis*. The expression which can be induced by sucrose leads to the formation of levan sucrase, which catalyses the synthesis of the product levan, which is toxic to *C. glutamicum*. Only those clones in which the integrated pK18mobsacBglu1\_1 has excised as  
15 the consequence of a second recombination event therefore grow on LB agar. Depending on the position of the second recombination event, after the excision the second copy of the *lysC*<sup>FBR</sup> allele manifests itself in the chromosome at the *gluB* locus, or the original *gluB* locus of the host remains.

Approximately 40 to 50 colonies are tested for the  
20 phenotype "growth in the presence of sucrose" and "non-growth in the presence of kanamycin". Approximately 20 colonies which show the phenotype "growth in the presence of sucrose" and "non-growth in the presence of kanamycin" are investigated with the aid of the polymerase chain  
25 reaction. A DNA fragment which carries the *gluB* gene and surrounding regions is amplified here from the chromosomal DNA of the colonies. The same primer oligonucleotides as are described in Example 1.2 for the construction of the integration plasmid are chosen for the PCR.

30 *gluBg11* (SEQ ID NO: 7):

5' TA(A GAT CT)G TGT TGG ACG TCA TGG CAA G 3'

*gluBg12* (SEQ ID NO: 8):

5' AC(A GAT CT)T GAA GCC AAG TAC GGC CAA G 3'



The primers allow amplification of a DNA fragment approx. 1.7 kb in size in control clones with the original gluB locus. In clones with a second copy of the lysC<sup>FBR</sup> allele in the chromosome at the gluB locus, DNA fragments with a size of approx. 3.4 kb are amplified.

The amplified DNA fragments are identified by means of electrophoresis in a 0.8% agarose gel.

A clone which, in addition to the copy present at the lysC locus, has a second copy of the lysC<sup>FBR</sup> allele lysC T311I at the gluB locus in the chromosome was identified in this manner. This clone was called strain DSM13994glu::lysC.

1.4 Incorporation of a second copy of the lysC gene in the form of the lysC<sup>FBR</sup> allele lysC T311I into the chromosome (target site: gluB gene) of the strain DSM12866 by means of the replacement vector pK18mobsacBglu1\_1

As described in Example 1.3, the plasmid pK18mobsacBglu1\_1 is transferred into the C. glutamicum strain DSM12866 by conjugation. A clone which, in addition to the copy of the wild-type gene present at the lysC locus, has a second copy of the lysC gene in the form of the lysC<sup>FBR</sup> allele lysC T311I at the gluB locus in the chromosome was identified in the manner described in 1.3. This clone was called strain DSM12866glu::lysC.

The Corynebacterium glutamicum strain according to the invention which carries a second copy of an lysC<sup>FBR</sup> allele in the gluB gene was deposited in the form of a pure culture of the strain Corynebacterium glutamicum DSM12866glu::lysC on 5th June 2002 under number DSM15039 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany) in accordance with the Budapest Treaty.

### 1.5 Construction of the replacement vector pK18mobsacBpck1\_1

The *Corynebacterium glutamicum* strain ATCC13032 is used as the donor for the chromosomal DNA. From the strain  
5 ATCC13032, chromosomal DNA is isolated using the conventional methods (Eikmanns et al., Microbiology 140: 1817 - 1828 (1994)). With the aid of the polymerase chain reaction, a DNA fragment which carries the pck gene and surrounding regions is amplified. On the basis of the  
10 sequence of the pck gene known for *C. glutamicum* (EP1094111 and Riedel et al., Journal of Molecular and Microbiological Biotechnology 3:573-583 (2001)) (Accession Number AJ269506), the following primer oligonucleotides are chosen for the PCR:

15 pck\_beg (SEQ ID NO: 9):  
5' TA(A GAT CT) G CCG GCA TGA CTT CAG TTT 3'

pck\_end (SEQ ID NO: 10):  
5' AC(A GAT CT) G GTG GGA GCC TTT CTT GTT ATT3'

The primers shown are synthesized by MWG Biotech and the  
20 PCR reaction is carried out by the standard PCR method of Innis et al. (PCR Protocols. A Guide to Methods and Applications, 1990, Academic Press). The primers allow amplification of a DNA fragment of approx. 2.9 kb in size, which carries the pck gene and adjacent regions. The  
25 primers moreover contain the sequence for the cleavage site of the restriction endonuclease BglII, which is marked by parentheses in the nucleotide sequence shown above.

The amplified DNA fragment of approx. 2.9 kb in length which carries the pck gene and surrounding regions is  
30 identified by means of electrophoresis in a 0.8% agarose gel and isolated from the gel and purified by conventional methods (QIAquick Gel Extraction Kit, Qiagen, Hilden).

Ligation of the fragment is then carried out by means of the TOPO TA Cloning Kit (Invitrogen, Leek, The Netherlands, Cat. Number K4600-01) in the vector pCRII-TOPO. The ligation batch is transformed in the E. coli strain TOP10 (Invitrogen, Leek, The Netherlands). Selection of plasmid-carrying cells is made by plating out the transformation batch on kanamycin (50 mg/l)-containing LB agar with X-Gal (64 mg/l).

The plasmid obtained is checked by means of restriction cleavage, after isolation of the DNA, and identified in agarose gel. The resulting plasmid is called pCRII-TOPOpck.

The plasmid pCRII-TOPOpck is cleaved with the restriction enzyme BglII (Amersham-Pharmacia, Freiburg, Germany) and after separation in an agarose gel (0.8%) with the aid of the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) the pck fragment of approx. 2.9 kb is isolated from the agarose gel and employed for ligation with the mobilizable cloning vector pK18mobsacB described by Schäfer et al. (Gene 14: 69-73 (1994)). This is cleaved beforehand with the restriction enzyme BamHI and dephosphorylated with alkaline phosphatase (Alkaline Phosphatase, Boehringer Mannheim), mixed with the pck fragment of approx. 2.9 kb, and the mixture is treated with T4 DNA Ligase (Amersham-Pharmacia, Freiburg, Germany).

The E. coli Strain DH5 $\alpha$  (Grant et al.; Proceedings of the National Academy of Sciences USA, 87 (1990) 4645-4649) is then transformed with the ligation batch (Hanahan, In. DNA Cloning. A Practical Approach. Vol. 1, IRL-Press, Cold Spring Harbor, New York, 1989) Selection of plasmid-carrying cells is made by plating out the transformation batch on LB agar (Sambrook et al., Molecular Cloning: A Laboratory Manual. 2<sup>nd</sup> Ed., Cold Spring Harbor, New York, 1989), which is supplemented with 50 mg/l kanamycin.

Plasmid DNA is isolated from a transformant with the aid of the QIAprep Spin Miniprep Kit from Qiagen and checked by restriction cleavage and subsequent agarose gel electrophoresis. The plasmid is called pK18mobsacBpck1.

- 5 Plasmid DNA was isolated from the strain DSM14242 (see Example 1.1), which carries the plasmid pCRIITOPolysC, and cleaved with the restriction enzyme BamHI (Amersham-Pharmacia, Freiburg, Germany), and after separation in an agarose gel (0.8%) with the aid of the QIAquick Gel  
10 Extraction Kit (Qiagen, Hilden, Germany) the lysC<sup>FBR</sup>-containing DNA fragment approx. 1.7 kb long was isolated from the agarose gel and employed for ligation with the vector pK18mobsacBpck1 described above. This is cleaved beforehand with the restriction enzyme BamHI,  
15 dephosphorylated with alkaline phosphatase (Alkaline Phosphatase, Boehringer Mannheim, Germany), mixed with the lysC<sup>FBR</sup> fragment of approx. 1.7 kb and the mixture is treated with T4 DNA Ligase (Amersham-Pharmacia, Freiburg, Germany).
- 20 The E. coli strain DH5 $\alpha$ mc<sup>r</sup> (Life Technologies GmbH, Karlsruhe, Germany) is then transformed with the ligation batch (Hanahan, In: DNA Cloning. A Practical Approach. Vol. 1, IRL-Press, Cold Spring Harbor, New York, 1989). Selection of plasmid-carrying cells is made by plating out  
25 the transformation batch on LB agar (Sambrook et al., Molecular Cloning: A Laboratory Manual. 2<sup>nd</sup> Ed., Cold Spring Harbor, New York, 1989), which was supplemented with 50 mg/l kanamycin.

- Plasmid DNA is isolated from a transformant with the aid of  
30 the QIAprep Spin Miniprep Kit from Qiagen and checked by restriction cleavage and subsequent agarose gel electrophoresis. The plasmid is called pK18mobdsacBpck1\_1. A map of the plasmid is shown in Figure 3.

- 1.6 Incorporation of a second copy of the *lysC* gene in the form of the *lysC*<sup>FBR</sup> allele *lysC* T311I into the chromosome (target site: *pck* gene) of the strain DSM12866 by means of the replacement vector
- 5 *pK18mobsacBpck1\_1*

- As described in Example 1.3, the plasmid *pK18mobsacBpck1\_1* described in Example 1.5 is transferred into the *C. glutamicum* strain DSM12866 by conjugation. Selection is made for targeted recombination events in the chromosome of
- 10 *C. glutamicum* DSM12866 as described in Example 1.3. Depending on the position of the second recombination event, after the excision the second copy of the *lysC*<sup>FBR</sup> allele manifests itself in the chromosome at the *pck* locus, or the original *pck* locus of the host remains.
- 15 Approximately 40 to 50 colonies are tested for the phenotype "growth in the presence of sucrose" and "non-growth in the presence of kanamycin". Approximately 20 colonies which show the phenotype "growth in the presence of sucrose" and "non-growth in the presence of kanamycin"
- 20 are investigated with the aid of the polymerase chain reaction. A DNA fragment which carries the *pck* gene and surrounding regions is amplified here from the chromosomal DNA of the colonies. The same primer oligonucleotides as are described in Example 1.5 for the construction of the
- 25 integration plasmid are chosen for the PCR.

*pck\_beg* (SEQ ID NO: 9):

5' TA(A GAT CT) G CCG GCA TGA CTT CAG TTT 3'

*pck\_end* (SEQ ID NO: 10):

5' AC(A GAT CT) G GTG GGA GCC TTT CTT GTT ATT3'

- 30 The primers allow amplification of a DNA fragment approx. 2.9 kb in size in control clones with the original *pck* locus. In clones with a second copy of the *lysC*<sup>FBR</sup> allele in

the chromosome at the pck locus, DNA fragments with a size of approx. 4.6 kb are amplified.

The amplified DNA fragments are identified by means of electrophoresis in a 0.8% agarose gel.

- 5 A clone which, in addition to the copy of the wild-type gene present at the lysC locus, has a second copy of the lysC gene in the form of the lysC<sup>FBR</sup> allele lysC T311I at the pck locus in the chromosome was identified in this manner. This clone was called strain DSM12866pck::lysC.

10 1.7 Construction of the replacement vector  
pK18mobsacBaecD1\_1

The *Corynebacterium glutamicum* strain ATCC13032 is used as the donor for the chromosomal DNA. From the strain ATCC13032, chromosomal DNA is isolated using the  
15 conventional methods (Eikmanns et al., Microbiology 140: 1817 - 1828 (1994)). With the aid of the polymerase chain reaction, a DNA fragment which carries the aecD gene and surrounding regions is amplified. On the basis of the sequence of the aecD gene known for *C. glutamicum* (Rossol  
20 et al., Journal of Bacteriology 174:2968-2977 (1992)) (Accession Number M89931), the following primer oligonucleotides are chosen for the PCR:

aecD\_beg (SEQ ID NO: 11):

5' GAA CTT ACG CCA AGC TGT TC 3'

25 aecD\_end (SEQ ID NO: 12):

5' AGC ACC ACA ATC AAC GTG AG 3'

The primers shown are synthesized by MWG Biotech and the PCR reaction is carried out by the standard PCR method of Innis et al. (PCR Protocols. A Guide to Methods and  
30 Applications, 1990, Academic Press). The primers allow amplification of a DNA fragment of approx 2.1 kb in size, which carries the aecD gene and adjacent regions.

The amplified DNA fragment of approx. 2.1 kb in length is identified by means of electrophoresis in a 0.8% agarose gel and isolated from the gel and purified by conventional methods (QIAquick Gel Extraction Kit, Qiagen, Hilden).

- 5 The DNA fragment purified is cleaved with the restriction enzyme BamHI and EcoRV (Amersham Pharmacia, Freiburg, Germany). The ligation of the fragment in the vector pUC18 then takes place (Norranders et al., Gene 26:101-106 (1983)). This is cleaved beforehand with the restriction  
10 enzymes BglII and SmaI, dephosphorylated, mixed with the aecD-carrying fragment of approx. 1.5 kb, and the mixture is treated with T4 DNA Ligase (Amersham-Pharmacia, Freiburg, Germany). The ligation batch is transformed in the E. coli strain TOP10 (Invitrogen, Leek, The  
15 Netherlands). Selection of plasmid-carrying cells is made by plating out the transformation batch on kanamycin (50 mg/l)-containing LB agar with X-Gal (64 mg/l).

The plasmid obtained is checked by means of restriction cleavage, after isolation of the DNA, and identified in  
20 agarose gel. The resulting plasmid is called pUC18aecD.

- Plasmid DNA was isolated from the strain DSM14242 (see Example 1.1) which carries the plasmid pCRIITOPolysC and cleaved with the restriction enzyme BamHI (Amersham-Pharmacia, Freiburg, Germany) and then treated with Klenow  
25 polymerase. After separation in an agarose gel (0.8%) with the aid of the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) the lysC<sup>FBR</sup>-containing DNA fragment approx. 1.7 kb in length is isolated from the agarose gel and employed for ligation with the vector pUC18aecD described above. This is  
30 cleaved beforehand with the restriction enzyme StuI, dephosphorylated with alkaline phosphatase (Alkaline Phosphatase, Boehringer Mannheim, Germany), mixed with the lysC<sup>FBR</sup> fragment of approx. 1.7 kb and the mixture is treated with T4 DNA Ligase (Amersham-Pharmacia, Freiburg,  
35 Germany).

The E. coli strain DH5 $\alpha$ mc $\alpha$ r (Life Technologies GmbH, Karlsruhe, Germany) is then transformed with the ligation batch (Hanahan, In: DNA Cloning. A Practical Approach. Vol. 1, IRL-Press, Cold Spring Harbor, New York, 1989).

- 5 Selection of plasmid-carrying cells is made by plating out the transformation batch on LB agar (Sambrook et al., Molecular Cloning: A Laboratory Manual. 2<sup>nd</sup> Ed., Cold Spring Harbor, New York, 1989), which was supplemented with 50 mg/l kanamycin.
- 10 Plasmid DNA is isolated from a transformant with the aid of the QIAprep Spin Miniprep Kit from Qiagen and checked by restriction cleavage and subsequent agarose gel electrophoresis. The plasmid is called pUC18aecd1.

- 15 The plasmid pUC18aecd1 is cleaved with the restriction enzyme KpnI and then treated with Klenow polymerase. The plasmid is then cleaved with the restriction enzyme SalI (Amersham-Pharmacia, Freiburg, Germany) and after separation in an agarose gel (0.8%) with the aid of the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) the
- 20 fragment of approx. 3.2 kb which carries aecD and lysC is isolated from the agarose gel and employed for ligation with the mobilizable cloning vector pK18mobsacB described by Schäfer et al. (Gene 14: 69-73 (1994)). This is cleaved beforehand with the restriction enzymes SmaI and SalI and
- 25 dephosphorylated with alkaline phosphatase (Alkaline Phosphatase, Boehringer Mannheim), mixed with the fragment of approx. 3.2 kb which carries aecD and lysC, and the mixture is treated with T4 DNA Ligase (Amersham-Pharmacia, Freiburg, Germany).

- 30 The E. coli strain DH5 $\alpha$  (Grant et al.; Proceedings of the National Academy of Sciences USA, 87 (1990) 4645-4649) is then transformed with the ligation batch (Hanahan, In: DNA Cloning. A Practical Approach. Vol. 1, IRL-Press, Cold Spring Harbor, New York, 1989). Selection of plasmid-
- 35 carrying cells is made by plating out the transformation



batch on LB agar (Sambrook et al., Molecular Cloning: A Laboratory Manual. 2<sup>nd</sup> Ed., Cold Spring Harbor, New York, 1989), which is supplemented with 50 mg/l kanamycin.

5 Plasmid DNA is isolated from a transformant with the aid of the QIAprep Spin Miniprep Kit from Qiagen and checked by restriction cleavage and subsequent agarose gel electrophoresis. The plasmid is called pK18mobsacBaecD1\_1. A map of the plasmid is shown in Figure 2.

10 The plasmid pK18mobsacBaecD1\_1 was deposited in the form of a pure culture of the strain E. coli DH5 $\alpha$ mcr/pK18mobsacBaecD1\_1 (= DH5 $\alpha$ lphamcr/pK18mobsacBaecD1\_1) on 5th June 2002 under number DSM15040 at the Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, 15 Germany) in accordance with the Budapest Treaty.

1.8 Incorporation of a second copy of the lysC gene as the lysC<sup>FBR</sup> allele into the chromosome (target site: aecD gene) of the strain DSM12866 by means of the replacement vector pK18mobsacBaecD1\_1

20 As described in Example 1.3, the plasmid pK18mobsacBaecD1\_1 described in Example 1.4 is transferred into the C. glutamicum strain DSM12866 by conjugation. Selection is made for targeted recombination events in the chromosome of C. glutamicum DSM12866 as described in Example 1.3.

25 Depending on the position of the second recombination event, after the excision the second copy of the lysC<sup>FBR</sup> allele manifests itself in the chromosome at the aecD locus, or the original aecD locus of the host remains.

30 Approximately 40 to 50 colonies are tested for the phenotype "growth in the presence of sucrose" and "non-growth in the presence of kanamycin". Approximately 20 colonies which show the phenotype "growth in the presence of sucrose" and "non-growth in the presence of kanamycin"

are investigated with the aid of the polymerase chain reaction. A DNA fragment which carries the aecD gene and surrounding regions is amplified here from the chromosomal DNA of the colonies. The same primer oligonucleotides as  
5 are described in Example 1.7 for the construction of the integration plasmid are chosen for the PCR.

aecD\_beg (SEQ ID NO: 11):

5' GAA CTT ACG CCA AGC TGT TC 3'

aecD\_end (SEQ ID NO: 12):

10 5' AGC ACC ACA ATC AAC GTG AG 3'

The primers allow amplification of a DNA fragment approx. 2.1 kb in size in control clones with the original aecD locus. In clones with a second copy of the lysC<sup>FBR</sup> allele in the chromosome at the aecD locus, DNA fragments with a size  
15 of approx. 3.8 kb are amplified.

The amplified DNA fragments are identified by means of electrophoresis in a 0.8% agarose gel.

A clone which, in addition to the copy of the wild-type gene present at the lysC locus, has a second copy of the  
20 lysC gene in the form of the lysC<sup>FBR</sup> allele lysC T311I at the aecD locus in the chromosome was identified in this manner. This clone was called strain DSM12866aecD::lysC.

### Example 2

Incorporation of a second copy of the ddh gene into the  
25 chromosome (target site: gluB gene) of the strain DSM12866

#### 2.1 Construction of the replacement vector pK18mobsacBglu2\_1

The *Corynebacterium glutamicum* strain ATCC13032 is used as the donor for the chromosomal DNA. From the strain  
30 ATCC13032, chromosomal DNA is isolated using the conventional methods (Eikmanns et al., Microbiology 140:

1817 - 1828 (1994)). With the aid of the polymerase chain reaction, a DNA fragment which carries the *gluB* gene and surrounding regions is amplified. On the basis of the sequence of the *gluABCD* gene cluster known for *C.*

- 5 *glutamicum* (Kronmeyer et al., Journal of Bacteriology, 177: 1152 - 1158 (1995); EP1108790) (Accession Number X81191 and AX127149), the following primer oligonucleotides are chosen for the PCR:

*gluA\_beg* (SEQ ID NO: 13):

- 10 5' CAC GGT TGC TCA TTG TAT CC 3'

*gluD\_end* (SEQ ID NO: 14):

5' CGA GGC GAA TCA GAC TTC TT 3'

- The primers shown are synthesized by MWG Biotech and the PCR reaction is carried out by the standard PCR method of  
15 Innis et al. (PCR Protocols. A Guide to Methods and Applications, 1990, Academic Press). The primers allow amplification of a DNA fragment of approx 4.4 kb in size, which carries the *gluB* gene and surrounding regions.

- The amplified DNA fragment is identified by means of  
20 electrophoresis in a 0.8% agarose gel and isolated from the gel and purified by conventional methods (QIAquick Gel Extraction Kit, Qiagen, Hilden).

- Ligation of the fragment is then carried out by means of the TOPO TA Cloning Kit (Invitrogen, Leek, The Netherlands,  
25 Cat. Number K4600-01) in the vector pCRII-TOPO. The ligation batch is transformed in the *E. coli* strain TOP10 (Invitrogen, Leek, The Netherlands). Selection of plasmid-carrying cells is made by plating out the transformation batch on kanamycin (50 mg/l)-containing LB agar with X-Gal  
30 (64 mg/l).

The plasmid obtained is checked by means of restriction cleavage, after isolation of the DNA, and identified in

agarose gel. The resulting plasmid is called pCRII-TOPOglu2.

The plasmid pCRII-TOPOglu2 is cleaved with the restriction enzymes EcoRI and SalI (Amersham-Pharmacia, Freiburg, Germany) and after separation in an agarose gel (0.8%) with the aid of the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) the gluB fragment of approx. 3.7 kb is isolated from the agarose gel and employed for ligation with the mobilizable cloning vector pK18mobsacB described by Schäfer et al. (Gene 14, 69-73 (1994)). This is cleaved beforehand with the restriction enzymes EcoRI and SalI and dephosphorylated with alkaline phosphatase (Alkaline Phosphatase, Boehringer Mannheim), mixed with the gluB fragment of approx. 3.7 kb, and the mixture is treated with T4 DNA Ligase (Amersham-Pharmacia, Freiburg, Germany).

The E. coli Strain DH5 $\alpha$  (Grant et al.; Proceedings of the National Academy of Sciences USA, 87 (1990) 4645-4649) is then transformed with the ligation batch (Hanahan, In. DNA Cloning. A Practical Approach. Vol. 1, IRL-Press, Cold Spring Harbor, New York, 1989). Selection of plasmid-carrying cells is made by plating out the transformation batch on LB agar (Sambrook et al., Molecular Cloning: A Laboratory Manual. 2<sup>nd</sup> Ed., Cold Spring Harbor, New York, 1989), which is supplemented with 50 mg/l kanamycin.

Plasmid DNA is isolated from a transformant with the aid of the QIAprep Spin Miniprep Kit from Qiagen and checked by restriction cleavage and subsequent agarose gel electrophoresis. The plasmid is called pK18mobsacBglu2.

As described in Example 2.1, a DNA fragment which carries the ddh gene and surrounding regions is also amplified with the aid of the polymerase chain reaction. On the basis of the sequence of the ddh gene cluster known for C. glutamicum (Ishino et al., Nucleic Acids Research 15,

3917(1987)) (Accession Number Y00151), the following primer oligonucleotides are chosen for the PCR:

ddh\_beg (SEQ ID NO: 15):

5' CTG AAT CAA AGG CGG ACA TG 3'

5 ddh\_end (SEQ ID NO: 16):

5' TCG AGC TAA ATT AGA CGT CG 3'

The primers shown are synthesized by MWG Biotech and the PCR reaction is carried out by the standard PCR method of Innis et al. (PCR Protocols. A Guide to Methods and  
10 Applications, 1990, Academic Press). The primers allow amplification of a DNA fragment of approx 1.6 kb in size, which carries the ddh gene.

The amplified DNA fragment of approx. 1.6 kb in length, which the ddh gene, is identified by means of  
15 electrophoresis in a 0.8% agarose gel and isolated from the gel and purified by conventional methods (QIAquick Gel Extraction Kit, Qiagen, Hilden).

After purification, the fragment carrying the ddh gene is employed for ligation in the vector pK18mobsacBglu2  
20 described. This is partly cleaved beforehand with the restriction enzyme BamHI. By treatment of the vector with a Klenow polymerase (Amersham-Pharmacia, Freiburg, Germany), the overhangs of the cleaved ends are completed to blunt ends, the vector is then mixed with the DNA fragment of  
25 approx. 1.6 kb which carries the ddh gene and the mixture is treated with T4 DNA ligase (Amersham-Pharmacia, Freiburg, Germany). By using Vent Polymerase (New England Biolabs, Frankfurt, Germany) for the PCR reaction, a ddh-carrying DNA fragment which has blunt ends and is suitable  
30 for ligation in the pretreated vector pK18mobsacBglu2 is generated.

The E. coli strain DH5 $\alpha$ mc<sup>r</sup> (Life Technologies GmbH, Karlsruhe, Germany) is then transformed with the ligation

batch (Hanahan, In: DNA Cloning. A Practical Approach. Vol. 1, ILR-Press, Cold Spring Harbor, New York, 1989).

Selection of plasmid-carrying cells is made by plating out the transformation batch on LB agar (Sambrook et al.,  
5 Molecular Cloning: A Laboratory Manual. 2<sup>nd</sup> Ed., Cold Spring Harbor, New York, 1989), which was supplemented with 50 mg/l kanamycin.

Plasmid DNA is isolated from a transformant with the aid of the QIAprep Spin Miniprep Kit from Qiagen and checked by  
10 restriction cleavage and subsequent agarose gel electrophoresis. The plasmid is called pK18mobsacBglu2\_1. A map of the plasmid is shown in Figure 4.

2.2 Incorporation of a second copy of the ddh gene into the chromosome (target site: gluB gene) of the strain  
15 DSM12866 by means of the replacement vector pK18mobsacBglu2\_1

As described in Example 1.3, the plasmid pK18mobsacBglu2\_1 described in Example 2.1 is transferred into the C. glutamicum strain DSM12866 by conjugation. Selection is  
20 made for targeted recombination events in the chromosome of C. glutamicum DSM12866 as described in Example 1.3. Depending on the position of the second recombination event, after the excision the second copy of the ddh gene manifests itself in the chromosome at the gluB locus, or  
25 the original gluB locus of the host remains.

Approximately 40 to 50 colonies are tested for the phenotype "growth in the presence of sucrose" and "non-growth in the presence of kanamycin". Approximately 20 colonies which show the phenotype "growth in the presence  
30 of sucrose" and "non-growth in the presence of kanamycin" are investigated with the aid of the polymerase chain reaction. A DNA fragment which carries the glu region described is amplified here from the chromosomal DNA of the colonies. The same primer oligonucleotides as are described

in Example 2.1 for the construction of the replacement plasmid are chosen for the PCR.

gluA\_beg (SEQ ID NO: 13):

5' CAC GGT TGC TCA TTG TAT CC 3'

5 gluD\_end (SEQ ID NO: 14):

5' CGA GGC GAA TCA GAC TTC TT 3'

The primers allow amplification of a DNA fragment approx. 4.4 kb in size in control clones with the original glu locus. In clones with a second copy of the ddh gene in the chromosome at the gluB locus, DNA fragments with a size of approx. 6 kb are amplified.

The amplified DNA fragments are identified by means of electrophoresis in a 0.8% agarose gel.

A clone which, in addition to the copy present at the ddh locus, has a second copy of the ddh gene at the gluB locus in the chromosome was identified in this manner. This clone was called strain DSM12866glu::ddh.

### Example 3

Incorporation of a second copy of the dapA gene into the chromosome (target site: aecD gene) of the strain DSM12866

#### 3.1 Construction of the replacement vector pK18mobsacBaecD2\_1

The *Corynebacterium glutamicum* strain ATCC13032 is used as the donor for the chromosomal DNA. From the strain ATCC13032, chromosomal DNA is isolated using the conventional methods (Eikmanns et al., Microbiology 140: 1817 - 1828 (1994)). With the aid of the polymerase chain reaction, a DNA fragment which carries the aecD gene and surrounding regions is amplified. On the basis of the sequence of the aecD gene known for *C. glutamicum* (Rossol et al., Journal of Bacteriology 174:2968-2977 (1992))

(Accession Number M89931), the following primer oligonucleotides are chosen for the PCR:

aecD\_beg (SEQ ID NO: 11):

5` GAA CTT ACG CCA AGC TGT TC 3`

5 aecD\_end (SEQ ID NO: 12):

5` AGC ACC ACA ATC AAC GTG AG 3`

The primers shown are synthesized by MWG Biotech and the PCR reaction is carried out by the standard PCR method of Innis et al. (PCR Protocols. A Guide to Methods and  
10 Applications, 1990, Academic Press). The primers allow amplification of a DNA fragment of approx 2.1 kb in size, which carries the aecD gene and adjacent regions.

The amplified DNA fragment of approx. 2.1 kb in length is identified by means of electrophoresis in a 0.8% agarose  
15 gel and isolated from the gel and purified by conventional methods (QIAquick Gel Extraction Kit, Qiagen, Hilden).

The DNA fragment purified is cleaved with the restriction enzyme BglII and EcoRV (Amersham Pharmacia, Freiburg, Germany). The ligation of the fragment in the vector pUC18  
20 then takes place (Norranders et al., Gene 26:101-106 (1983)). This is cleaved beforehand with the restriction enzymes BamHI and SmaI and dephosphorylated, mixed with the aecD-carrying fragment of approx. 1.5 kb, and the mixture is treated with T4 DNA Ligase (Amersham-Pharmacia,  
25 Freiburg, Germany). The ligation batch is transformed in the E. coli strain TOP10 (Invitrogen, Leek, The Netherlands). Selection of plasmid-carrying cells is made by plating out the transformation batch on kanamycin (50 mg/l)-containing LB agar with X-Gal (64 mg/l).

30 The plasmid obtained is checked by means of restriction cleavage, after isolation of the DNA, and identified in agarose gel. The resulting plasmid is called pUC18aecD.



With the aid of the polymerase chain reaction, a further DNA fragment which carries the *dapA* gene and surrounding regions is amplified. On the basis of the sequence of the *dapA* gene known for *C. glutamicum* (Bonassi et al., Nucleic  
5 Acids Research 18:6421 (1990)) (Accession Number X53993 and AX127149), the following primer oligonucleotides are chosen for the PCR:

*dapA\_beg* (SEQ ID NO: 17):

5' CGA GCC AGT GAA CAT GCA GA 3'

10 *dapA\_end* (SEQ ID NO: 18):

5' CTT GAG CAC CTT GCG CAG CA 3'

The primers shown are synthesized by MWG Biotech and the PCR reaction is carried out by the standard PCR method of Innis et al. (PCR Protocols. A Guide to Methods and  
15 Applications, 1990, Academic Press). The primers allow amplification of a DNA fragment of approx. 1.4 kb in size, which carries the *dapA* gene and adjacent regions.

The amplified DNA fragment of approx. 1.4 kb in length is identified by means of electrophoresis in a 0.8% agarose  
20 gel and isolated from the gel and purified by conventional methods (QIAquick Gel Extraction Kit, Qiagen, Hilden).

After purification, the *dapA*-containing DNA fragment approx. 1.4 kb in length is employed for ligation with the vector pUC18a<sub>ecD</sub> described above. This is cleaved  
25 beforehand with the restriction enzyme *StuI*, mixed with the DNA fragment of approx. 1.4 kb, and the mixture is treated with T4 DNA Ligase (Amersham-Pharmacia, Freiburg, Germany).

The *E. coli* strain DH5 $\alpha$ mc<sub>r</sub> (Life Technologies GmbH, Karlsruhe, Germany) is then transformed with the ligation  
30 batch (Hanahan, In: DNA Cloning. A Practical Approach. Vol. 1, IRL-Press, Cold Spring Harbor, New York, 1989). Selection of plasmid-carrying cells is made by plating out the transformation batch on LB agar (Sambrook et al.,

Molecular Cloning: A Laboratory Manual. 2<sup>nd</sup> Ed., Cold Spring Harbor, New York, 1989), which was supplemented with 50 mg/l kanamycin.

5 Plasmid DNA is isolated from a transformant with the aid of the QIAprep Spin Miniprep Kit from Qiagen and checked by restriction cleavage and subsequent agarose gel electrophoresis. The plasmid is called pUC18aecD2.

10 The plasmid pUC18aecD2 is cleaved with the restriction enzyme SalI and partly with EcoRI (Amersham-Pharmacia, Freiburg, Germany) and after separation in an agarose gel (0.8%) with the aid of the QIAquick Gel Extraction Kit (Qiagen, Hilden, Germany) the fragment of approx. 2.7 kb which carries aecD and dapA is isolated from the agarose gel and employed for ligation with the mobilizable cloning  
15 vector pK18mobsacB described by Schäfer et al. (Gene 14: 69-73 (1994)). This is cleaved beforehand with the restriction enzymes EcoRI and with SalI and dephosphorylated with alkaline phosphatase (Alkaline Phosphatase, Boehringer Mannheim), mixed with the fragment  
20 of approx. 2.7 kb which carries aecD and dapA, and the mixture is treated with T4 DNA Ligase (Amersham-Pharmacia, Freiburg, Germany).

The E. coli strain DH5 $\alpha$  (Grant et al.; Proceedings of the National Academy of Sciences USA, 87 (1990) 4645-4649) is  
25 then transformed with the ligation batch (Hanahan, In. DNA Cloning. A Practical Approach. Vol. 1, IRL-Press, Cold Spring Harbor, New York, 1989). Selection of plasmid-carrying cells is made by plating out the transformation batch on LB agar (Sambrook et al., Molecular Cloning: A  
30 Laboratory Manual. 2<sup>nd</sup> Ed., Cold Spring Harbor, New York, 1989), which is supplemented with 50 mg/l kanamycin.

Plasmid DNA is isolated from a transformant with the aid of the QIAprep Spin Miniprep Kit from Qiagen and checked by restriction cleavage and subsequent agarose gel

electrophoresis. The plasmid is called pK18mobsacBaecD2\_1. A map of the plasmid is shown in Figure 5.

3.2 Incorporation of a second copy of the *dapA* gene into the chromosome (target site: *aecD* gene) of the strain  
5 DSM12866 by means of the replacement vector  
pK18mobsacBaecD2\_1

As described in Example 1.3, the plasmid pK18mobsacBaecD2\_1 described in Example 3.1 is transferred into the *C. glutamicum* strain DSM12866 by conjugation. Selection is  
10 made for targeted recombination events in the chromosome of *C. glutamicum* DSM12866 as described in Example 1.3. Depending on the position of the second recombination event, after the excision the second copy of the *dapA* gene manifests itself in the chromosome at the *aecD* locus, or  
15 the original *aecD* locus of the host remains.

Approximately 40 to 50 colonies are tested for the phenotype "growth in the presence of sucrose" and "non-growth in the presence of kanamycin". Approximately 20 colonies which show the phenotype "growth in the presence  
20 of sucrose" and "non-growth in the presence of kanamycin" are investigated with the aid of the polymerase chain reaction. A DNA fragment which carries the *aecD* gene and surrounding regions is amplified here from the chromosomal DNA of the colonies. The same primer oligonucleotides as  
25 are described in Example 3.1 for the construction of the integration plasmid are chosen for the PCR.

*aecD\_beg* (SEQ ID NO: 11):

5' GAA CTT ACG CCA AGC TGT TC 3'

*aecD\_end* (SEQ ID NO: 12):

30 5' AGC ACC ACA ATC AAC GTG AG 3'

The primers allow amplification of a DNA fragment approx. 2.1 kb in size in control clones with the original *aecD* locus. In clones with a second copy of the *dapA* gene in the

chromosome at the aecD locus, DNA fragments with a size of approx. 3.6 kb are amplified.

The amplified DNA fragments are identified by means of electrophoresis in a 0.8% agarose gel.

- 5 A clone which, in addition to the copy present at the dapA locus, has a second copy of the dapA gene at the aecD locus in the chromosome was identified in this manner. This clone was called strain DSM12866aecD::dapA.

#### Example 4

- 10 Incorporation of a second copy of the pyc gene in the form of the pyc allele pycP458S into the chromosome (target site: pck gene) of the strain DSM12866

#### 4.1 Construction of the replacement vector pK18mobsacBpck1\_3

- 15 The replacement vector pK18mobsacBpck1 described in Example 1.5 is used as the base vector for insertion of the pyc allele.

As described in Example 2.1, a DNA fragment which carries the pyc gene and surrounding regions is also amplified with  
20 the aid of the polymerase chain reaction. On the basis of the sequence of the pyc gene cluster known for *C. glutamicum* (Peters-Wendisch et al., Journal of Microbiology 144: 915-927 (1998)) (Accession Number Y09548), the following primer oligonucleotides are chosen for the PCR:

- 25 pyc\_beg (SEQ ID NO: 19):  
5' TC(A CGC GT)C TTG AAG TCG TGC AGG TCA G 3'  
  
pyc\_end (SEQ ID NO: 20):  
5' TC(A CGC GT)C GCC TCC TCC ATG AGG AAG A 3'

- The primers shown are synthesized by MWG Biotech and the  
30 PCR reaction is carried out by the standard PCR method of

Innis et al. (PCR Protocols. A Guide to Methods and Applications, 1990, Academic Press). The primers allow amplification of a DNA fragment of approx 3.6 kb in size, which carries the pyc gene. The primers moreover contain  
5 the sequence for the cleavage site of the restriction endonuclease MluI, which is marked by parentheses in the nucleotide sequence shown above.

The amplified DNA fragment of approx. 3.6 kb in length, which carries the pyc gene, is cleaved with the restriction  
10 endonuclease MluI, identified by means of electrophoresis in a 0.8% agarose gel and isolated from the gel and purified by conventional methods (QIAquick Gel Extraction Kit, Qiagen, Hilden).

After purification, the fragment carrying the pyc gene is  
15 employed for ligation in the vector pK18mobsacBpck1 described. This is cleaved beforehand with the restriction enzyme BssHII, dephosphorylated with alkaline phosphatase (Alkaline Phosphatase, Boehringer Mannheim, Germany), mixed with the DNA fragment of approx. 3.6 kb which carries the  
20 pyc gene, and the mixture is treated with T4 DNA Ligase (Amersham-Pharmacia, Freiburg, Germany).

The E. coli strain DH5 $\alpha$ mcr (Life Technologies GmbH, Karlsruhe, Germany) is then transformed with the ligation batch (Hanahan, In: DNA Cloning. A Practical Approach. Vol.  
25 1, IRL-Press, Cold Spring Harbor, New York, 1989). Selection of plasmid-carrying cells is made by plating out the transformation batch on LB agar (Sambrook et al., Molecular Cloning: A Laboratory Manual. 2<sup>nd</sup> Ed., Cold Spring Harbor, New York, 1989), which was supplemented with  
30 50 mg/l kanamycin.

Plasmid DNA is isolated from a transformant with the aid of the QIAprep Spin Miniprep Kit from Qiagen and checked by restriction cleavage and subsequent agarose gel electrophoresis. The plasmid is called pK18mobsacBpck1\_2.

#### 4.2 Construction of the pyc allele pyc P458S by means of site-specific mutagenesis of the wild-type pyc gene

The site-directed mutagenesis is carried out with the QuikChange Site-Directed Mutagenesis Kit (Stratagene, La Jolla, USA). EP-A-1108790 describes a point mutation in the pyc gene for *C. glutamicum* which allows improved L-lysine production. On the basis of the point mutation in the nucleotide sequence of cytosine to thymine in the pyc gene at position 1372, replacement in the amino acid sequence derived therefrom of proline for serine at position 458 results. The allele is called pyc P458S. To generate the mutation described, the following primer oligonucleotides are chosen for the linear amplification:

P458S-1 (SEQ ID NO: 21):  
15 5' GGATTCATTGCCGATCAC (TCG) CACCTCCTTCAGGCTCCA 3'  
  
P458S-2 (SEQ ID NO: 22):  
5'GTGGAGGAAGTCCGAGGT (CGA) GTGATCGGCAATGAATCC 3'

The primers shown are synthesized by MWG Biotech. The codon for serine, which is to replace the proline at position 458, is marked by parentheses in the nucleotide sequence shown above. The plasmid pK18mobsacBpck1\_2 described in Example 4.1 is employed with the two primers, which are each complementary to a strand of the plasmid, for linear amplification by means of Pfu Turbo DNA polymerase. By this lengthening of the primers, a mutated plasmid with broken circular strands is formed. The product of the linear amplification is treated with DpnI - this endonuclease cleaves the methylated and half-methylated template DNA specifically. The newly synthesized broken, mutated vector DNA is transformed in the *E. coli* strain XL1 Blue (Bullock, Fernandez and Short, *BioTechniques* (5) 376-379 (1987)). After the transformation, the XL1 Blue cells repair the breaks in the mutated plasmids. Selection of the transformants was carried out on LB medium with kanamycin

50 mg/l. The plasmid obtained is checked by means of restriction cleavage, after isolation of the DNA, and identified in agarose gel. The DNA sequence of the mutated DNA fragment is checked by sequencing. The sequence of the PCR product coincides with the sequence described Ohnishi et al. (2002). The resulting plasmid is called pK18mobsacBpck1\_3. A map of the plasmid is shown in Figure 6.

- 4.3 Incorporation of a second copy of the pyc gene in the form of the pyc allele pycP458S into the chromosome (target site pck gene) of the strain DSM12866 by means of the replacement vector pK18mobsacBpck1\_3

The plasmid pK18mobsacBpck1\_3 described in Example 4.2 is transferred as described in Example 1.3 into the C. glutamicum strain DSM12866 by conjugation. Selection is made for targeted recombination events in the chromosome of C. glutamicum DSM12866 as described in Example 1.3. Depending on the position of the second recombination event, after the excision the second copy of the pyc allele manifests itself in the chromosome at the pck locus, or the original pck locus of the host remains.

Approximately 40 to 50 colonies are tested for the phenotype "growth in the presence of sucrose" and "non-growth in the presence of kanamycin". Approximately 20 colonies which show the phenotype "growth in the presence of sucrose" and "non-growth in the presence of kanamycin" are investigated with the aid of the polymerase chain reaction. A DNA fragment which carries the pck gene and surrounding regions is amplified here from the chromosomal DNA of the colonies. The same primer oligonucleotides as are described in Example 1.5 for the construction of the replacement plasmid are chosen for the PCR.

pck\_beg (SEQ ID NO: 9):

5' TA(A GAT CT) G CCG GCA TGA CTT CAG TTT 3'

pck\_end (SEQ ID NO: 10):

5' AC(A GAT CT) G GTG GGA GCC TTT CTT GTT ATT3'

The primers allow amplification of a DNA fragment approx. 2.9 kb in size in control clones with the original pck locus. In clones with a second copy of the pyc allele in the chromosome at the pck locus, DNA fragments with a size of approx. 6.5 kb are amplified.

The amplified DNA fragments are identified by means of electrophoresis in a 0.8% agarose gel.

10 A clone which, in addition to the copy of the wild-type gene present at the pyc locus, has a second copy of the pyc gene in the form of the pyc allele pycP458S at the pck locus in the chromosome was identified in this manner. This clone was called strain DSM12866pck::pyc.

15 Example 5

Preparation of Lysine

The *C. glutamicum* strains DSM13994glu::lysC, DSM12866glu::lysC, DSM12866pck::lysC, DSM12866aecD::lysC, DSM12866glu::ddh, DSM12866aecD::dapA and DSM12866pck::pyc obtained in Example 1, 2, 3 and 4 are cultured in a nutrient medium suitable for the production of lysine and the lysine content in the culture supernatant was determined.

For this, the cultures are first incubated on a brain-heart agar plate (Merck, Darmstadt, Germany) for 24 hours at 33°C. Starting from this agar plate culture, a preculture is seeded (10 ml medium in a 100 ml conical flask). The medium MM is used as the medium for the preculture. The preculture is incubated for 24 hours at 33°C at 240 rpm on a shaking machine. A main culture is seeded from this preculture such that the initial OD (660 nm) of the main



culture is 0.1 OD. The Medium MM is also used for the main culture.

#### Medium MM

CSL	5 g/l
MOPS	20 g/l
Glucose (autoclaved separately)	50 g/l
Salts:	
(NH <sub>4</sub> ) <sub>2</sub> SO <sub>4</sub>	25 g/l
KH <sub>2</sub> PO <sub>4</sub>	0.1 g/l
MgSO <sub>4</sub> * 7 H <sub>2</sub> O	1.0 g/l
CaCl <sub>2</sub> * 2 H <sub>2</sub> O	10 mg/l
FeSO <sub>4</sub> * 7 H <sub>2</sub> O	10 mg/l
MnSO <sub>4</sub> * H <sub>2</sub> O	5.0 mg/l
Biotin (sterile-filtered)	0.3 mg/l
Thiamine * HCl (sterile-filtered)	0.2 mg/l
CaCO <sub>3</sub>	25 g/l

- The CSL (corn steep liquor), MOPS
- 5 (morpholinopropanesulfonic acid) and the salt solution are brought to pH 7 with aqueous ammonia and autoclaved. The sterile substrate and vitamin solutions, as well as the CaCO<sub>3</sub> autoclaved in the dry state, are then added.

- Culturing is carried out in a 10 ml volume in a 100 ml
- 10 conical flask with baffles. Culturing is carried out at 33°C and 80% atmospheric humidity.

After 48 hours, the OD is determined at a measurement wavelength of 660 nm with a Biomek 1000 (Beckmann Instruments GmbH, Munich). The amount of lysine formed is determined with an amino acid analyzer from Eppendorf-  
5 BioTronik (Hamburg, Germany) by ion exchange chromatography and post-column derivation with ninhydrin detection.

The result of the experiment is shown in Table 10.

Table 10

Strain	OD (660 nm)	Lysine HCl g/l
DSM13994	12.0	19.1
DSM13994glu::lysC	9.9	20.0
DSM12866	12.5	14.9
DSM15039	11.4	16.2
DSM12866pck::lysC	12.6	16.5
DSM12866aecD::lysC	12.0	15.9
DSM12866glu::ddh	11.0	15.5
DSM12866aecD::dapA	11.1	16.2
DSM12866pck::pyc	10.9	16.9

## Brief Description of the Figures:

- 5 The base pair numbers stated are approximate values obtained in the context of reproducibility of measurements.

Figure 1: Map of the plasmid pK18mobsacBglu1\_1.

The abbreviations and designations used have the following meaning:

KanR: Kanamycin resistance gene

HindIII:	Cleavage site of the restriction enzyme HindIII
BamHI:	Cleavage site of the restriction enzyme BamHI
lysC:	lysC <sup>FBR</sup> allele, lysC T311I
'gluA:	3' terminal fragment of the gluA gene
gluB':	5' terminal fragment of the gluB gene
'gluB:	3' terminal fragment of the gluB gene
gluC':	5' terminal fragment of the gluC gene
sacB:	sacB gene
RP4mob:	mob region with the replication origin for the transfer (oriT)
oriV:	Replication origin V

Figure 2: Map of the plasmid pK18mobsacBaecD1\_1.

The abbreviations and designations used have the following meaning:

KanR:	Kanamycin resistance gene
SalI:	Cleavage site of the restriction enzyme SalI
lysC:	lysC <sup>FBR</sup> allele, lysC T311I
aecD':	5' terminal fragment of the aecD gene
'aecD:	3' terminal fragment of the aecD gene
sacB:	sacB gene
RP4mob:	mob region with the replication origin for the transfer (oriT)

oriV:                    Replication origin V

Figure 3:    Map of the plasmid pK18mobsacBpck1\_1.

The abbreviations and designations used have the following meaning:

KanR:                    Kanamycin resistance gene

BamHI:                   Cleavage site of the restriction enzyme  
BamHI

lysC:                    lysC<sup>FBR</sup> allele, lysC T311I

pck':                    5' terminal fragment of the pck gene

'pck:                    3' terminal fragment of the pck gene

sacB:                    sacB gene

RP4mob:                   mob region with the replication origin for  
the transfer (oriT)

oriV:                    Replication origin V

Figure 4:    Map of the plasmid pK18mobsacBgluB2\_1.

5    The abbreviations and designations used have the following meaning:

KanR:                    Kanamycin resistance gene

SalI                      Cleavage site of the restriction enzyme SalI

EcoRI                    Cleavage site of the restriction enzyme  
EcoRI

BamHI:                   Cleavage site of the restriction enzyme  
BamHI

ddh:                    ddh gene

gluA	gluA gene
gluB':	5' terminal fragment of the gluB gene
'gluB:	3' terminal fragment of the gluB gene
gluC	gluC gene
gluD':	5' terminal fragment of the gluD gene
sacB:	sacB gene
RP4mob:	mob region with the replication origin for the transfer (oriT)
oriV:	Replication origin V

Figure 5: Map of the plasmid pK18mobsacBaecD2\_1.

The abbreviations and designations used have the following meaning:

KanR:	Kanamycin resistance gene
EcoRI	Cleavage site of the restriction enzyme EcoRI
SalI:	Cleavage site of the restriction enzyme SalI
dapA:	dapA gene
aecD':	5' terminal fragment of the aecD gene
'aecD:	3' terminal fragment of the aecD gene
sacB:	sacB gene
RP4mob:	mob region with the replication origin for the transfer (oriT)
oriV:	Replication origin V

Figure 6: Map of the plasmid pK18mobsacBpck1\_3.

The abbreviations and designations used have the following meaning:

KanR:	Kanamycin resistance gene
pyc:	pyc allele, pyc P458S
pck':	5' terminal fragment of the pck gene
'pck:	3' terminal fragment of the pck gene
sacB:	sacB gene
RP4mob:	mob region with the replication origin for the transfer (oriT)
oriV:	Replication origin V

BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

PCT/EP02/08464

**DSMZ**Deutsche Sammlung von  
Mikroorganismen und  
Zellkulturen GmbH

## INTERNATIONAL FORM

Degussa AG

Kantstr. 2

33790 Halle (Westf.)

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

<b>I. IDENTIFICATION OF THE MICROORGANISM</b>	
Identification reference given by the DEPOSITOR: DSM12866glu::lysC	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 15039
<b>II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION</b>	
The microorganism identified under I. above was accompanied by:  (X) a scientific description (X) a proposed taxonomic designation (Mark with a cross where applicable).	
<b>III. RECEIPT AND ACCEPTANCE</b>	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 2002-06-05 (Date of the original deposit) <sup>1</sup> .	
<b>IV. RECEIPT OF REQUEST FOR CONVERSION</b>	
The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).	
<b>V. INTERNATIONAL DEPOSITARY AUTHORITY</b>	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH  Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):    Date: 2002-06-06

<sup>1</sup> Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.



BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

**DSMZ**

Deutsche Sammlung von  
Mikroorganismen und  
Zellkulturen GmbH



INTERNATIONAL FORM

Degussa AG  
Kantstr. 2  
33790 Halle (Westf.)

VIABILITY STATEMENT  
issued pursuant to Rule 10.2 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

I. DEPOSITOR	II. IDENTIFICATION OF THE MICROORGANISM
Name: Degussa AG Kantstr. 2 Address: 33790 Halle (Westf.)	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 15039  Date of the deposit or the transfer <sup>1</sup> :  2002-06-05
III. VIABILITY STATEMENT	
The viability of the microorganism identified under II above was tested on 2002-06-05 On that date, the said microorganism was  <input checked="" type="checkbox"/> viable <input type="checkbox"/> no longer viable	
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED <sup>4</sup>	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH  Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):    Date: 2002-06-06

- <sup>1</sup> Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).  
<sup>2</sup> In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.  
<sup>3</sup> Mark with a cross the applicable box.  
<sup>4</sup> Fill in if the information has been requested and if the results of the test were negative.

BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

## INTERNATIONAL FORM

Degussa AG  
Kantstr. 2  
33790 Halle (Westf.)

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

<b>I. IDENTIFICATION OF THE MICROORGANISM</b>	
Identification reference given by the DEPOSITOR: DH5alphamcr/pK18mobsacBaecD1_1	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 15040
<b>II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION</b>	
The microorganism identified under I. above was accompanied by:  ( <input checked="" type="checkbox"/> ) a scientific description ( <input checked="" type="checkbox"/> ) a proposed taxonomic designation (Mark with a cross where applicable).	
<b>III. RECEIPT AND ACCEPTANCE</b>	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 2002-06-05 (Date of the original deposit) <sup>1</sup> .	
<b>IV. RECEIPT OF REQUEST FOR CONVERSION</b>	
The microorganism identified under I above was received by this International Depositary Authority on _____ (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on _____ (date of receipt of request for conversion).	
<b>V. INTERNATIONAL DEPOSITARY AUTHORITY</b>	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH  Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):    Date: 2002-06-06

<sup>1</sup> Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.

BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE**DSMZ**Deutsche Sammlung von  
Mikroorganismen und  
Zellkulturen GmbH

## INTERNATIONAL FORM

Degussa AG  
Kantstr. 2  
33790 Halle (Westf.)VIABILITY STATEMENT  
issued pursuant to Rule 10.2 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

<b>I. DEPOSITOR</b>		<b>II. IDENTIFICATION OF THE MICROORGANISM</b>	
Name: Degussa AG Kantstr. 2 Address: 33790 Halle (Westf.)		Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 15040  Date of the deposit or the transfer <sup>1</sup> :  2002-06-05	
<b>III. VIABILITY STATEMENT</b>			
The viability of the microorganism identified under II above was tested on 2002-06-05 On that date, the said microorganism was  (x) <sup>2</sup> viable ( ) <sup>2</sup> no longer viable			
<b>IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED<sup>4</sup></b>			
<b>V. INTERNATIONAL DEPOSITARY AUTHORITY</b>			
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH Address: Mascheroder Weg 1b D-38124 Braunschweig		Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):   Date: 2002-06-06	


<sup>1</sup> Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).<sup>2</sup> In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.<sup>3</sup> Mark with a cross the applicable box.<sup>4</sup> Fill in if the information has been requested and if the results of the test were negative.

BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

## INTERNATIONAL FORM

Degussa AG  
Kantstr. 2  
33790 Halle/Künsebeck

RECEIPT IN THE CASE OF AN ORIGINAL DEPOSIT  
Issued pursuant to Rule 7.1 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

I. IDENTIFICATION OF THE MICROORGANISM	
Identification reference given by the DEPOSITOR: DH5alphamcr/ pK18mobsacBglu1_1	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY:  DSM 14243
II. SCIENTIFIC DESCRIPTION AND/OR PROPOSED TAXONOMIC DESIGNATION	
<p>The microorganism identified under I. above was accompanied by:</p> <p>(X) a scientific description (X) a proposed taxonomic designation</p> <p>(Mark with a cross where applicable).</p>	
III. RECEIPT AND ACCEPTANCE	
This International Depositary Authority accepts the microorganism identified under I. above, which was received by it on 2001-04-20 (Date of the original deposit) <sup>1</sup> .	
IV. RECEIPT OF REQUEST FOR CONVERSION	
The microorganism identified under I above was received by this International Depositary Authority on (date of original deposit) and a request to convert the original deposit to a deposit under the Budapest Treaty was received by it on (date of receipt of request for conversion).	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH  Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):    Date: 2001-04-26

<sup>1</sup> Where Rule 6.4 (d) applies, such date is the date on which the status of international depositary authority was acquired.


BUDAPEST TREATY ON THE INTERNATIONAL  
RECOGNITION OF THE DEPOSIT OF MICROORGANISMS  
FOR THE PURPOSES OF PATENT PROCEDURE

## INTERNATIONAL FORM

Degussa AG  
Kantstr. 2  
33790 Halle/Künsebeck

## VIABILITY STATEMENT

Issued pursuant to Rule 10.2 by the  
INTERNATIONAL DEPOSITARY AUTHORITY  
identified at the bottom of this page

I. DEPOSITOR	II. IDENTIFICATION OF THE MICROORGANISM
Name: Degussa AG Kantstr. 2 Address: 33790 Halle/Künsebeck	Accession number given by the INTERNATIONAL DEPOSITARY AUTHORITY: DSM 14243  Date of the deposit or the transfer <sup>1</sup> : 2001-04-20
III. VIABILITY STATEMENT	
The viability of the microorganism identified under II above was tested on 2001-04-20 <sup>2</sup> . On that date, the said microorganism was  <input checked="" type="checkbox"/> viable  <input type="checkbox"/> no longer viable	
IV. CONDITIONS UNDER WHICH THE VIABILITY TEST HAS BEEN PERFORMED <sup>4</sup>	
V. INTERNATIONAL DEPOSITARY AUTHORITY	
Name: DSMZ-DEUTSCHE SAMMLUNG VON MIKROORGANISMEN UND ZELLKULTUREN GmbH  Address: Mascheroder Weg 1b D-38124 Braunschweig	Signature(s) of person(s) having the power to represent the International Depositary Authority or of authorized official(s):    Date: 2001-04-26

<sup>1</sup> Indicate the date of original deposit or, where a new deposit or a transfer has been made, the most recent relevant date (date of the new deposit or date of the transfer).

<sup>2</sup> In the cases referred to in Rule 10.2(a) (ii) and (iii), refer to the most recent viability test.

<sup>3</sup> Mark with a cross the applicable box.

<sup>4</sup> Fill in if the information has been requested and if the results of the test were negative.

**What is claimed is:**

1. Coryneform bacteria which produce chemical compounds, wherein these have, in addition to at least one copy, present at the natural site (locus), of an open reading  
5 frame (ORF), gene or allele which codes for the synthesis of a protein or an RNA, a second, optionally third or fourth copy of the open reading frame (ORF), gene or allele in question at a second, optionally third or fourth site in a form integrated into the  
10 chromosome, no nucleotide sequence which is capable of/enables episomal replication or transposition in microorganisms and no nucleotide sequence(s) which impart(s) resistance to antibiotics being present at the second, optionally third or fourth site, and the  
15 second, optionally third or fourth site not relating to open reading frames (ORF), genes or alleles which are essential for the growth of the bacteria and the production of the desired compound.
2. Coryneform bacteria according to claim 1 which produce  
20 chemical compounds, wherein the coryneform bacteria belong to the genus *Corynebacterium*.
3. Coryneform bacteria of the genus *Corynebacterium* according to claim 2 which produce chemical compounds, wherein these belong to the species *Corynebacterium*  
25 *glutamicum*.
4. Coryneform bacteria according to claim 1 which produce chemical compounds, wherein the chemical compound is a compound chosen from the group consisting of L-amino acids, vitamins, nucleosides and nucleotides.
- 30 5. Coryneform bacteria according to claim 1 which produce chemical compounds, wherein the chemical compound is one or more L-amino acids chosen from the group consisting of L-aspartic acid, L-asparagine, L-

- threonine, L-serine, L-glutamic acid, L-glutamine,  
glycine, L-alanine, L-cysteine, L-valine, L-methionine,  
L-isoleucine, L-leucine, L-tyrosine, L-phenylalanine,  
L-histidine, L-lysine, L-tryptophan, L-proline and L-  
arginine.
6. Coryneform bacteria according to claims 1 and 4 which  
produce chemical compounds, wherein the L-amino acid is  
L-lysine, and these bacteria have, in addition to at  
least one copy of an open reading frame (ORF), gene  
or allele of lysine production present at the natural  
site (locus), in each case a second, optionally third  
or fourth copy of the open reading frame (ORF), gene or  
allele of lysine production in question at in each case  
a second, optionally third or fourth site in a form  
integrated into the chromosome.
7. Coryneform bacteria according to claim 6 which produce  
L-lysine, wherein the coryneform bacteria belong to the  
genus *Corynebacterium*.
8. Coryneform bacteria of the genus *Corynebacterium*  
according to claim 7 which produce L-lysine, wherein  
these belong to the species *Corynebacterium glutamicum*.
9. Coryneform bacteria according to claim 6 which produce  
L-lysine, wherein the open reading frame (ORF), gene or  
allele of lysine production is one or more open reading  
frame(s), one or more gene(s) or allele(s) chosen from  
the group consisting of accBC, accDA, cstA, cysD, cysE,  
cysH, cysK, cysN, cysQ, dapA, dapB, dapC, dapD, dapE,  
dapF, ddh, dps, eno, gap, gap2, gdh, gnd, lysC, lysC<sup>FBR</sup>,  
lyeE, msik, opca, oxyR, ppc, ppc<sup>FBR</sup>, pgk, pknA, pknB,  
pknD, pknG, ppsA, ptsH, ptsI, ptsM, pyc, pyc P458S,  
sigC, sigD, sigE, sigH, sigM, tal, thyA, tkt, tpi,  
zwa1, zwf and zwf A213T.

10. Coryneform bacteria according to claim 6 which produce L-lysine, wherein the open reading frame, gene or allele of lysine production is one or more gene(s) or allele(s) chosen from the group consisting of dapA, ddh, lysC<sup>FBR</sup> and pyc P458S.
11. Coryneform bacteria according to claim 6 which produce L-lysine, wherein the open reading frame, gene or allele of lysine production is a lysC<sup>FBR</sup> allele which codes for a feed back resistant form of aspartate kinase.
12. Coryneform bacteria according to claim 11 which produce L-lysine, wherein the feed back resistant form of aspartate kinase coded by the lysC<sup>FBR</sup> allele contains an amino acid sequence according to SEQ ID NO:2, SEQ ID NO:2 containing one or more amino acid replacements chosen from the group consisting of A279T, A279V, S301F, T308I, S301Y, G345D, R320G, T311I and S381F.
13. Coryneform bacteria according to claim 11 which produce L-lysine, wherein the feed back resistant form of aspartate kinase coded by the lysC<sup>FBR</sup> allele includes an amino acid sequence according to SEQ ID NO:4.
14. Coryneform bacteria according to claim 11 which produce L-lysine, wherein the coding region of the lysC<sup>FBR</sup> allele includes the nucleotide sequence of SEQ ID NO:3.
15. Coryneform bacteria according to claim 6 which produce L-lysine, wherein the particular second, optionally third or fourth site is a gene chosen from the group consisting of aecD, ccpA1, ccpA2, cita, citB, cite, fda, gluA, gluB, gluC, gluD, luxR, luxS, lysR1, lysR2, lysR3, menE, mqo, pck, pgi and poxB.
16. Coryneform bacteria according to claim 6 which produce L-lysine, wherein the particular second, optionally third or fourth site is a site chosen from the group



consisting of intergenic regions of the chromosome, prophages contained in the chromosome and defective phages contained in the chromosome.

17. Coryneform bacteria according to claim 15 which produce  
5 L-lysine, wherein the particular second, optionally third or fourth site is the aecD gene site.
18. Coryneform bacteria according to claim 15 which produce L-lysine, wherein the particular second, optionally third or fourth site is the gluB gene site.
- 10 19. Coryneform bacteria according to claim 15 which produce L-lysine, wherein the particular second, optionally third or fourth site is the pck gene site.
20. Process for the preparation of chemical compounds by fermentation of coryneform bacteria, in which the  
15 following steps are carried out:
  - a) fermentation of coryneform bacteria, which
  - a1) which have, in addition to at least one copy, present at the natural site (locus), of an open reading frame (ORF), gene or allele which codes  
20 for the synthesis of a protein or an RNA, a second, optionally third or fourth copy of this open reading frame (ORF), gene or allele at a second, optionally third or fourth site in a form integrated into the chromosome, no nucleotide  
25 sequence which is capable of/enables episomal replication or transposition in microorganisms and no nucleotide sequence(s) which impart(s) resistance to antibiotics being present at the second, optionally third or fourth site, and the  
30 second, optionally third or fourth site not relating to open reading frames (ORF), genes or alleles which are essential for the growth of the

bacteria and the production of the desired compound, and

- 5 a2) in which the intracellular activity of the corresponding protein is increased, in particular the nucleotide sequence which codes for this protein is over-expressed,
- c) concentration of the chemical compound(s) in the fermentation broth and/or in the cells of the bacteria,
- 10 d) isolation of the chemical compound(s), optionally
- e) with constituents from the fermentation broth and/or the biomass to the extent of > (greater than) 0 to 100 wt.%.
- 15 21. Process according to claim 20, wherein the coryneform bacteria belong to the genus *Corynebacterium*.
22. Process according to claim 20, wherein the coryneform bacteria of the genus *Corynebacterium* belong to the species *Corynebacterium glutamicum*.
- 20 23. Process according to claim 20, wherein the chemical compound is a compound chosen from the group consisting of L-amino acids, vitamins, nucleosides and nucleotides.
- 25 24. Process according to claim 20, wherein the chemical compound is one or more L-amino acids chosen from the group consisting of L-aspartic acid, L-asparagine, L-threonine, L-serine, L-glutamic acid, L-glutamine, glycine, L-alanine, L-cysteine, L-valine, L-methionine, L-isoleucine, L-leucine, L-tyrosine, L-phenylalanine, L-histidine, L-lysine, L-tryptophan, L-proline and L-
- 30 arginine.

25. Process according to claim 24, wherein the chemical compound is L-lysine.

26. Process for the preparation of L-lysine, which comprises the following steps:

5       a) fermentation of coryneform bacteria which have, in addition to at least one copy of an open reading frame (ORF), gene or allele of lysine production present at the natural site (locus), in each case a second, optionally third or fourth copy of the open  
10       reading frame (ORF), gene or allele of lysine production in question at in each case a second, optionally third or fourth site in a form integrated into the chromosome

15       under conditions which allow expression of the said open reading frames (ORF), genes or alleles mentioned.

27. Process for the preparation of L-lysine according to claim 26, wherein the open reading frame (ORF), gene or  
20       allele of lysine production is an open reading frame, a gene or allele chosen from the group consisting of accBC, accDA, cstA, cysD, cyse, cysh, cysK, cysN, cysQ, dapA, dapB, dapC, dapD, dapE, dapF, ddh, dps, eno, gap, gap2, gdh, gnd, lysC, lysC<sup>FBR</sup>, lyse, msik, opca, oxyR,  
25       ppc, ppc<sup>FBR</sup>, pgk, pknA, pknB, pknD, pknG, ppsA, ptsH, ptsI, ptsM, pyc, pyc P458S, sigC, sigD, sigE, sigH, sigM, tal, thyA, tkt, tpi, zwal, zwf and zwf A213T.

28. Process for the preparation of L-lysine according to claim 26, wherein the open reading frame (ORF), gene  
30       or allele of lysine production is a gene or allele chosen from the group consisting of dapA, ddh, lysC<sup>FBR</sup> and pyc P458S.

29. Process for the preparation of L-lysine according to claim 26, wherein the open reading frame (ORF), gene or allele of lysine production is a  $lysC^{FBR}$  allele which codes for a feed back resistant form of aspartate kinase.
30. Process for the preparation of L-lysine according to claim 29, wherein the feed back resistant form of aspartate kinase coded by the  $lysC^{FBR}$  allele contains an amino acid sequence according to SEQ ID NO:2, SEQ ID NO:2 containing one or more amino acid replacements chosen from the group consisting of A279T, A279V, S301F, T308I, S301Y, G345D, R320G, T311I and S381F.
31. Process for the preparation of L-lysine according to claim 29, wherein the feed back resistant form of aspartate kinase coded by the  $lysC^{FBR}$  allele includes an amino acid sequence according to SEQ ID NO:4.
32. Process for the preparation of L-lysine according to claim 29, wherein the coding region of the  $lysC^{FBR}$  allele includes the nucleotide sequence of SEQ ID NO:3.
33. Process for the preparation of L-lysine according to claim 26, wherein the particular second, optionally third or fourth site is a site chosen from the group consisting of aecD, ccpA1, ccpA2, citA, citB, citE, fda, gluA, gluB, gluC, gluD, luxR, luxS, lysR1, lysR2, lysR3, menE, mqo, pck, pgi and poxB.
34. Process for the preparation of L-lysine according to claim 26, wherein the second, optionally third or fourth site is the aecD gene site.
35. Process for the preparation of L-lysine according to claim 26, wherein the second, optionally third or fourth site is the gluB gene site.

36. Process for the preparation of L-lysine according to claim 26, wherein the second, optionally third or fourth site is the pck gene site.
37. Process for the production of coryneform bacteria which produce one or more chemical compounds, which comprises
- a) isolating the nucleotide sequence of at least one desired ORF, gene or allele which codes for a protein or an RNA, optionally including the expression and/or regulation signals, preferably from coryneform bacteria,
  - b) providing the 5' and the 3' end of the ORF, gene or allele with nucleotide sequences of the target site,
  - c) preferably incorporating the nucleotide sequence of the desired ORF, gene or allele provided with nucleotide sequences of the target site into a vector which does not replicate or replicates to only a limited extent in coryneform bacteria,
  - d) transferring the nucleotide sequences according to b) or c) into coryneform bacteria, and
  - e) isolating coryneform bacteria in which the nucleotide sequence(s) according to a) is incorporated at the target site, no nucleotide sequence(s) which is(are) capable of/enable(s) episomal replication or transposition in microorganisms, and no nucleotide sequence(s) which impart(s) resistance to antibiotics remaining at the target site.
38. Plasmid pK18mobsacBglu1\_1 shown in Figure 1 and deposited in the form of a pure culture of the strain E. coli DH5 $\alpha$ mcr/pK18mobsacBglu1\_1 (= DH5 $\alpha$ lac mcr/pK18mobsacBglu1\_1) under number DSM14243.

39. Plasmid pK18mobsacBaecD1\_1 shown in Figure 2 and deposited in the form of a pure culture of the strain E. coli DH5 $\alpha$ mcr/pK18mobsacBaecD1\_1 (= DH5 $\alpha$ lphamcr/pK18mobsacBaecD1\_1) under number DSM15040.
- 5 40. Corynebacterium glutamicum strain DSM12866glu::lysC deposited in the form of a pure culture under number DSM15039.

Figure 1: Plasmid pK18mobsacBglu1\_1




Figure 2: Plasmid pK18mobsacBaecD1\_1






Figure 3: Plasmid pK18mobsacBpck1\_1




Figure 4: Plasmid pK18mobsacBglu2\_1




Figure 5: Plasmid pK18mobsacBaecD2\_1





Figure 6: Plasmid pK18mobsacBpck1\_3



## SEQUENCE LISTING

5 <110> Degussa AG

<120> Coryneform bacteria which produce chemical compounds I

<130> 010301 BT

10 <160> 22

<170> PatentIn version 3.1

15 <210> 1

<211> 1263

<212> DNA

<213> Corynebacterium glutamicum

20 <220>

<221> CDS

<222> (1)..(1263)

<223> lysC wild-type gene

25 <400> 1

gtg gcc ctg gtc gta cag aaa tat ggc ggt tcc tcg ctt gag agt gcg 48

Met Ala Leu Val Val Gln Lys Tyr Gly Gly Ser Ser Leu Glu Ser Ala

1 5 10 15

30 gaa cgc att aga aac gtc gct gaa cgg atc gtt gcc acc aag aag gct 96

Glu Arg Ile Arg Asn Val Ala Glu Arg Ile Val Ala Thr Lys Lys Ala

20 25 30

35 gga aat gat gtc gtg gtt gtc tgc tcc gca atg gga gac acc acg gat 144

Gly Asn Asp Val Val Val Val Cys Ser Ala Met Gly Asp Thr Thr Asp

35 40 45

40 gaa ctt cta gaa ctt gca gcg gca gtg aat ccc gtt ccg cca gct cgt 192

Glu Leu Leu Glu Leu Ala Ala Val Asn Pro Val Pro Pro Ala Arg

50 55 60

45 gaa atg gat atg ctc ctg act gct ggt gag cgt att tct aac gct ctc 240

Glu Met Asp Met Leu Leu Thr Ala Gly Glu Arg Ile Ser Asn Ala Leu

65 70 75 80

50 gtc gcc atg gct att gag tcc ctt ggc gca gaa gcc caa tct ttc acg 288

Val Ala Met Ala Ile Glu Ser Leu Gly Ala Glu Ala Gln Ser Phe Thr

85 90 95

55 ggc tct cag gct ggt gtg ctc acc acc gag cgc cac gga aac gca cgc 336

Gly Ser Gln Ala Gly Val Leu Thr Thr Glu Arg His Gly Asn Ala Arg

100 105 110

60 att gtt gat gtc act cca ggt cgt gtg cgt gaa gca ctc gat gag ggc 384

Ile Val Asp Val Thr Pro Gly Arg Val Arg Glu Ala Leu Asp Glu Gly

115 120 125

aag atc tgc att gtt gct ggt ttc cag ggt gtt aat aaa gaa acc cgc 432

Lys Ile Cys Ile Val Ala Gly Phe Gln Gly Val Asn Lys Glu Thr Arg

130 135 140

	gat gtc acc acg ttg ggt cgt ggt ggt tct gac acc act gca gtt gcg	480
	Asp Val Thr Thr Leu Gly Arg Gly Gly Ser Asp Thr Thr Ala Val Ala	
	145 150 155 160	
5	ttg gca gct gct ttg aac gct gat gtg tgt gag att tac tcg gac gtt	528
	Leu Ala Ala Ala Leu Asn Ala Asp Val Cys Glu Ile Tyr Ser Asp Val	
	165 170 175	
10	gac ggt gtg tat acc gct gac ccg cgc atc gtt cct aat gca cag aag	576
	Asp Gly Val Tyr Thr Ala Asp Pro Arg Ile Val Pro Asn Ala Gln Lys	
	180 185 190	
15	ctg gaa aag ctc agc ttc gaa gaa atg ctg gaa ctt gct gct gtt ggc	624
	Leu Glu Lys Leu Ser Phe Glu Glu Met Leu Glu Leu Ala Ala Val Gly	
	195 200 205	
20	tcc aag att ttg gtg ctg cgc agt gtt gaa tac gct cgt gca ttc aat	672
	Ser Lys Ile Leu Val Leu Arg Ser Val Glu Tyr Ala Arg Ala Phe Asn	
	210 215 220	
	gtg cca ctt cgc gta cgc tcg tct tat agt aat gat ccc ggc act ttg	720
	Val Pro Leu Arg Val Arg Ser Ser Tyr Ser Asn Asp Pro Gly Thr Leu	
	225 230 235 240	
25	att gcc ggc tct atg gag gat att cct gtg gaa gaa gca gtc ctt acc	768
	Ile Ala Gly Ser Met Glu Asp Ile Pro Val Glu Glu Ala Val Leu Thr	
	245 250 255	
30	ggt gtc gca acc gac aag tcc gaa gcc aaa gta acc gtt ctg ggt att	816
	Gly Val Ala Thr Asp Lys Ser Glu Ala Lys Val Thr Val Leu Gly Ile	
	260 265 270	
35	tcc gat aag cca ggc gag gct gcg aag gtt ttc cgt gcg ttg gct gat	864
	Ser Asp Lys Pro Gly Glu Ala Ala Lys Val Phe Arg Ala Leu Ala Asp	
	275 280 285	
40	gca gaa atc aac att gac atg gtt ctg cag aac gtc tct tct gta gaa	912
	Ala Glu Ile Asn Ile Asp Met Val Leu Gln Asn Val Ser Ser Val Glu	
	290 295 300	
	gac ggc acc acc gac atc acc ttc acc tgc cct cgt tcc gac ggc cgc	960
	Asp Gly Thr Thr Asp Ile Thr Phe Thr Cys Pro Arg Ser Asp Gly Arg	
	305 310 315 320	
45	cgc gcg atg gag atc ttg aag aag ctt cag gtt cag ggc aac tgg acc	1008
	Arg Ala Met Glu Ile Leu Lys Lys Leu Gln Val Gln Gly Asn Trp Thr	
	325 330 335	
50	aat gtg ctt tac gac gac cag gtc ggc aaa gtc tcc ctc gtg ggt gct	1056
	Asn Val Leu Tyr Asp Asp Gln Val Gly Lys Val Ser Leu Val Gly Ala	
	340 345 350	
55	ggc atg aag tct cac cca ggt gtt acc gca gag ttc atg gaa gct ctg	1104
	Gly Met Lys Ser His Pro Gly Val Thr Ala Glu Phe Met Glu Ala Leu	
	355 360 365	
60	cgc gat gtc aac gtg aac atc gaa ttg att tcc acc tct gag att cgt	1152
	Arg Asp Val Asn Val Asn Ile Glu Leu Ile Ser Thr Ser Glu Ile Arg	
	370 375 380	

att tcc gtg ctg atc cgt gaa gat gat ctg gat gct gct gca cgt gca 1200  
 Ile Ser Val Leu Ile Arg Glu Asp Asp Leu Asp Ala Ala Ala Arg Ala  
 385 390 395 400

5 ttg cat gag cag ttc cag ctg ggc ggc gaa gac gaa gcc gtc gtt tat 1248  
 Leu His Glu Gln Phe Gln Leu Gly Gly Glu Asp Glu Ala Val Val Tyr  
 405 410 415

10 gca ggc acc gga cgc 1263  
 Ala Gly Thr Gly Arg  
 420

15 <210> 2  
 <211> 421  
 <212> PRT  
 <213> *Corynebacterium glutamicum*  
 <400> 2

20 Met Ala Leu Val Val Gln Lys Tyr Gly Gly Ser Ser Leu Glu Ser Ala  
 1 5 10 15  
 Glu Arg Ile Arg Asn Val Ala Glu Arg Ile Val Ala Thr Lys Lys Ala  
 20 25 30

25 Gly Asn Asp Val Val Val Val Cys Ser Ala Met Gly Asp Thr Thr Asp  
 35 40 45

30 Glu Leu Leu Glu Leu Ala Ala Ala Val Asn Pro Val Pro Pro Ala Arg  
 50 55 60  
 Glu Met Asp Met Leu Leu Thr Ala Gly Glu Arg Ile Ser Asn Ala Leu  
 65 70 75 80

35 Val Ala Met Ala Ile Glu Ser Leu Gly Ala Glu Ala Gln Ser Phe Thr  
 85 90 95  
 Gly Ser Gln Ala Gly Val Leu Thr Thr Glu Arg His Gly Asn Ala Arg  
 100 105 110

40 Ile Val Asp Val Thr Pro Gly Arg Val Arg Glu Ala Leu Asp Glu Gly  
 115 120 125

45 Lys Ile Cys Ile Val Ala Gly Phe Gln Gly Val Asn Lys Glu Thr Arg  
 130 135 140  
 Asp Val Thr Thr Leu Gly Arg Gly Gly Ser Asp Thr Thr Ala Val Ala  
 145 150 155 160

50 Leu Ala Ala Ala Leu Asn Ala Asp Val Cys Glu Ile Tyr Ser Asp Val  
 165 170 175  
 Asp Gly Val Tyr Thr Ala Asp Pro Arg Ile Val Pro Asn Ala Gln Lys  
 180 185 190

55 Leu Glu Lys Leu Ser Phe Glu Glu Met Leu Glu Leu Ala Ala Val Gly  
 195 200 205

60 Ser Lys Ile Leu Val Leu Arg Ser Val Glu Tyr Ala Arg Ala Phe Asn  
 210 215 220

Val Pro Leu Arg Val Arg Ser Ser Tyr Ser Asn Asp Pro Gly Thr Leu  
 225 230 235 240  
 5 Ile Ala Gly Ser Met Glu Asp Ile Pro Val Glu Glu Ala Val Leu Thr  
 245 250 255  
 Gly Val Ala Thr Asp Lys Ser Glu Ala Lys Val Thr Val Leu Gly Ile  
 260 265 270  
 10 Ser Asp Lys Pro Gly Glu Ala Ala Lys Val Phe Arg Ala Leu Ala Asp  
 275 280 285  
 15 Ala Glu Ile Asn Ile Asp Met Val Leu Gln Asn Val Ser Ser Val Glu  
 290 295 300  
 Asp Gly Thr Thr Asp Ile Thr Phe Thr Cys Pro Arg Ser Asp Gly Arg  
 305 310 315 320  
 20 Arg Ala Met Glu Ile Leu Lys Lys Leu Gln Val Gln Gly Asn Trp Thr  
 325 330 335  
 Asn Val Leu Tyr Asp Asp Gln Val Gly Lys Val Ser Leu Val Gly Ala  
 340 345 350  
 25 Gly Met Lys Ser His Pro Gly Val Thr Ala Glu Phe Met Glu Ala Leu  
 355 360 365  
 30 Arg Asp Val Asn Val Asn Ile Glu Leu Ile Ser Thr Ser Glu Ile Arg  
 370 375 380  
 Ile Ser Val Leu Ile Arg Glu Asp Asp Leu Asp Ala Ala Ala Arg Ala  
 385 390 395 400  
 35 Leu His Glu Gln Phe Gln Leu Gly Gly Glu Asp Glu Ala Val Val Tyr  
 405 410 415  
 Ala Gly Thr Gly Arg  
 420  
 40 <210> 3  
 <211> 1263  
 <212> DNA  
 <213> Corynebacterium glutamicum  
 45 <220>  
 <221> CDS  
 <222> (1)..(1263)  
 <223> lysC-fbr allele lysC T3111  
 50 <400> 3  
 gtg gcc ctg gtc gta cag aaa tat ggc ggt tcc tcg ctt gag agt gcg 48  
 Met Ala Leu Val Val Gln Lys Tyr Gly Gly Ser Ser Leu Glu Ser Ala  
 1 5 10 15  
 55 gaa cgc att aga aac gtc gct gaa cgg atc gtt gcc acc aag aag gct 96  
 Glu Arg Ile Arg Asn Val Ala Glu Arg Ile Val Ala Thr Lys Lys Ala  
 20 25 30  
 60 gga aat gat gtc gtg gtt gtc tgc tcc gca atg gga gac acc acg gat 144  
 Gly Asn Asp Val Val Val Val Cys Ser Ala Met Gly Asp Thr Thr Asp  
 35 40 45



	gaa ctt cta gaa ctt gca gcg gca gtg aat ccc gtt ccg cca gct cgt	192
	Glu Leu Leu Glu Leu Ala Ala Ala Val Asn Pro Val Pro Pro Ala Arg	
	50 55 60	
5	gaa atg gat atg ctc ctg act gct ggt gag cgt att tct aac gct ctc	240
	Glu Met Asp Met Leu Thr Ala Gly Glu Arg Ile Ser Asn Ala Leu	
	65 70 75 80	
10	gtc gcc atg gct att gag tcc ctt ggc gca gaa gcc caa tct ttc acg	288
	Val Ala Met Ala Ile Glu Ser Leu Gly Ala Glu Ala Gln Ser Phe Thr	
	85 90 95	
15	ggc tct cag gct ggt gtg ctc acc acc gag cgc cac gga aac gca cgc	336
	Gly Ser Gln Ala Gly Val Leu Thr Thr Glu Arg His Gly Asn Ala Arg	
	100 105 110	
20	att gtt gat gtc act cca ggt cgt gtg cgt gaa gca ctc gat gag ggc	384
	Ile Val Asp Val Thr Pro Gly Arg Val Arg Glu Ala Leu Asp Glu Gly	
	115 120 125	
25	aag atc tgc att gtt gct ggt ttc cag ggt gtt aat aaa gaa acc cgc	432
	Lys Ile Cys Ile Val Ala Gly Phe Gln Gly Val Asn Lys Glu Thr Arg	
	130 135 140	
30	gat gtc acc acg ttg ggt cgt ggt ggt tct gac acc act gca gtt gcg	480
	Asp Val Thr Thr Leu Gly Arg Gly Gly Ser Asp Thr Thr Ala Val Ala	
	145 150 155 160	
35	ttg gca gct gct ttg aac gct gat gtg tgt gag att tac tcg gac gtt	528
	Leu Ala Ala Ala Leu Asn Ala Asp Val Cys Glu Ile Tyr Ser Asp Val	
	165 170 175	
40	gac ggt gtg tat acc gct gac ccg cgc atc gtt cct aat gca cag aag	576
	Asp Gly Val Tyr Thr Ala Asp Pro Arg Ile Val Pro Asn Ala Gln Lys	
	180 185 190	
45	ctg gaa aag ctc agc ttc gaa gaa atg ctg gaa ctt gct gct gtt ggc	624
	Leu Glu Lys Leu Ser Phe Glu Glu Met Leu Glu Leu Ala Ala Val Gly	
	195 200 205	
50	tcc aag att ttg gtg ctg cgc agt gtt gaa tac gct cgt gca ttc aat	672
	Ser Lys Ile Leu Val Leu Arg Ser Val Glu Tyr Ala Arg Ala Phe Asn	
	210 215 220	
55	gtg cca ctt cgc gta cgc tcg tct tat agt aat gat ccc ggc act ttg	720
	Val Pro Leu Arg Val Arg Ser Ser Tyr Ser Asn Asp Pro Gly Thr Leu	
	225 230 235 240	
60	att gcc ggc tct atg gag gat att cct gtg gaa gaa gca gtc ctt acc	768
	Ile Ala Gly Ser Met Glu Asp Ile Pro Val Glu Glu Ala Val Leu Thr	
	245 250 255	
65	ggc gtc gca acc gac aag tcc gaa gcc aaa gta acc gtt ctg ggt att	816
	Gly Val Ala Thr Asp Lys Ser Glu Ala Lys Val Thr Val Leu Gly Ile	
	260 265 270	
70	tcc gat aag cca ggc gag gct gcg aag gtt ttc cgt gcg ttg gct gat	864
	Ser Asp Lys Pro Gly Glu Ala Ala Lys Val Phe Arg Ala Leu Ala Asp	
	275 280 285	

	gca gaa atc aac att gac atg gtt ctg cag aac gtc tct tct gta gaa	912
	Ala Glu Ile Asn Ile Asp Met Val Leu Gln Asn Val Ser Ser Val Glu	
	290 295 300	
5	gac ggc acc acc gac atc atc ttc acc tgc cct cgt tcc gac ggc cgc	960
	Asp Gly Thr Thr Asp Ile Ile Phe Thr Cys Pro Arg Ser Asp Gly Arg	
	305 310 315 320	
10	cgc gcg atg gag atc ttg aag aag ctt cag gtt cag ggc aac tgg acc	1008
	Arg Ala Met Glu Ile Leu Lys Lys Leu Gln Val Gln Gly Asn Trp Thr	
	325 330 335	
15	aat gtg ctt tac gac gac cag gtc ggc aaa gtc tcc ctc gtg ggt gct	1056
	Asn Val Leu Tyr Asp Asp Gln Val Gly Lys Val Ser Leu Val Gly Ala	
	340 345 350	
20	ggc atg aag tct cac cca ggt gtt acc gca gag ttc atg gaa gct ctg	1104
	Gly Met Lys Ser His Pro Gly Val Thr Ala Glu Phe Met Glu Ala Leu	
	355 360 365	
25	cgc gat gtc aac gtg aac atc gaa ttg att tcc acc tct gag att cgt	1152
	Arg Asp Val Asn Val Asn Ile Glu Leu Ile Ser Thr Ser Glu Ile Arg	
	370 375 380	
30	att tcc gtg ctg atc cgt gaa gat gat ctg gat gct gct gca cgt gca	1200
	Ile Ser Val Leu Ile Arg Glu Asp Asp Leu Asp Ala Ala Ala Arg Ala	
	385 390 395 400	
35	ttg cat gag cag ttc cag ctg ggc ggc gaa gac gaa gcc gtc gtt tat	1248
	Leu His Glu Gln Phe Gln Leu Gly Gly Glu Asp Glu Ala Val Val Tyr	
	405 410 415	
40	gca ggc acc gga cgc	1263
	Ala Gly Thr Gly Arg	
	420	
	<210> 4	
	<211> 421	
	<212> PRT	
	<213> Corynebacterium glutamicum	
	<400> 4	
45	Met Ala Leu Val Val Gln Lys Tyr Gly Gly Ser Ser Leu Glu Ser Ala	
	1 5 10 15	
	Glu Arg Ile Arg Asn Val Ala Glu Arg Ile Val Ala Thr Lys Lys Ala	
	20 25 30	
50	Gly Asn Asp Val Val Val Val Cys Ser Ala Met Gly Asp Thr Thr Asp	
	35 40 45	
55	Glu Leu Leu Glu Leu Ala Ala Ala Val Asn Pro Val Pro Pro Ala Arg	
	50 55 60	
60	Glu Met Asp Met Leu Leu Thr Ala Gly Glu Arg Ile Ser Asn Ala Leu	
	65 70 75 80	
	Val Ala Met Ala Ile Glu Ser Leu Gly Ala Glu Ala Gln Ser Phe Thr	
	85 90 95	



<210> 5  
<211> 28  
<212> DNA  
5 <213> Artificial sequence

<220>  
<221> misc\_feature  
<222> (1)..(28)  
10 <223> Primer lysC1beg

<400> 5  
taggatcctc cgggtgtctga ccacggtg 28

15 <210> 6  
<211> 29  
<212> DNA  
<213> Artificial sequence

20 <220>  
<221> misc\_feature  
<222> (1)..(29)  
<223> Primer lysC2end

25 <400> 6  
acggatccgc tgggaaattg cgctcttcc 29

<210> 7  
<211> 28  
30 <212> DNA  
<213> Artificial sequence

<220>  
<221> misc\_feature  
35 <222> (1)..(28)  
<223> Primer gluBgl1

<400> 7  
taagatctgt gttggacgtc atggcaag 28

40 <210> 8  
<211> 28  
<212> DNA  
<213> Artificial sequence

45 <220>  
<221> misc\_feature  
<222> (1)..(28)  
<223> Primer gluBgl2

50 <400> 8  
acagatcttg aagccaagta cggccaag 28

<210> 9  
55 <211> 27  
<212> DNA  
<213> Artificial sequence

<220>  
60 <221> misc\_feature  
<222> (1)..(27)  
<223> Primer pck\_beg

<400> 9  
taagatctgc cggcatgact tcagttt 27

5 <210> 10  
<211> 30  
<212> DNA  
<213> Artificial sequence

10 <220>  
<221> misc\_feature  
<222> (1)..(30)  
<223> Primer pck\_end

15 <400> 10  
acagatctgg tgggagcett tcttggtatt 30

20 <210> 11  
<211> 20  
<212> DNA  
<213> Corynebacterium glutamicum

25 <220>  
<221> misc\_feature  
<222> (1)..(20)  
<223> Primer aecD\_beg

30 <400> 11  
gaacttacgc caagctgttc 20

35 <210> 12  
<211> 20  
<212> DNA  
<213> Corynebacterium glutamicum

40 <220>  
<221> misc\_feature  
<222> (1)..(20)  
<223> Primer aecD\_end

45 <400> 12  
agcaccacaa tcaacgtgag 20

50 <210> 13  
<211> 20  
<212> DNA  
<213> Corynebacterium glutamicum

55 <220>  
<221> misc\_feature  
<222> (1)..(20)  
<223> Primer gluA\_beg

60 <400> 13  
cacggttgct cattgtatcc 20

<210> 14  
<211> 20  
<212> DNA  
<213> Corynebacterium glutamicum

5 <220>  
<221> misc\_feature  
<222> (1)..(20)  
<223> Primer gluD\_end  
  
<400> 14  
cgaggcgaat cagacttctt 20

10 <210> 15  
<211> 20  
<212> DNA  
<213> Corynebacterium glutamicum

15 <220>  
<221> misc\_feature  
<222> (1)..(20)  
<223> Primer ddh\_beg

20 <400> 15  
ctgaatcaaa ggcggacatg 20

25 <210> 16  
<211> 20  
<212> DNA  
<213> Corynebacterium glutamicum

30 <220>  
<221> misc\_feature  
<222> (1)..(20)  
<223> Primer ddh\_end

<400> 16  
tcgagctaaa ttagacgtcg 20

35 <210> 17  
<211> 20  
<212> DNA  
<213> Corynebacterium glutamicum

40 <220>  
<221> misc\_feature  
<222> (1)..(20)  
<223> Primer dapA\_beg

45 <400> 17  
cgagccagtg aacatgcaga 20

50 <210> 18  
<211> 20  
<212> DNA  
<213> Corynebacterium glutamicum

55 <220>  
<221> misc\_feature  
<222> (1)..(20)  
<223> Primer dapA\_end

60 <400> 18  
cttgagcacc ttgcgcagca 20

5 <210> 19  
<211> 28  
<212> DNA  
<213> Artificial sequence

10 <220>  
<221> misc\_feature  
<222> (1)..(28)  
<223> Primer pyc\_beg

<400> 19  
tcacgcgtct tgaagtcgtg caggtcag 28

15 <210> 20  
<211> 28  
<212> DNA  
<213> Artificial sequence

20 <220>  
<221> misc\_feature  
<222> (1)..(28)  
<223> Primer pyc\_end

25 <400> 20  
tcacgcgtcg cctcctccat gaggaaga 28

30 <210> 21  
<211> 39  
<212> DNA  
<213> Corynebacterium glutamicum

35 <220>  
<221> misc\_feature  
<222> (1)..(39)  
<223> Primer P458S-1

<400> 21  
ggattcattg ccgatcactc gcacctcctt caggtcca 39

40 <210> 22  
<211> 39  
<212> DNA  
<213> Corynebacterium glutamicum

45 <220>  
<221> misc\_feature  
<222> (1)..(39)  
<223> Primer P458S-2

50 <400> 22  
gtggaggaag tccgaggtcg agtgatcggc aatgaatcc 39

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
15 May 2003 (15.05.2003)

PCT

(10) International Publication Number  
**WO 03/040373 A3**

(51) International Patent Classification<sup>7</sup>: **C12N 15/52**,  
15/53, 15/54, 15/60, C12P 13/08, C12N 1/21 // (C12P  
13/08, C12R 1:15)

(21) International Application Number: **PCT/EP02/08464**

(22) International Filing Date: **30 July 2002 (30.07.2002)**

(25) Filing Language: **English**

(26) Publication Language: **English**

(30) Priority Data:  
**60/309,878** **6 August 2001 (06.08.2001)** **US**

(71) Applicant (for all designated States except US): **DE-  
GUSSA AG** [DE/DE]; Bennigsenplatz 1, 40474 Düssel-  
dorf (DE).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **BATHE,**

**Brigitte** [DE/DE]; Twieten 1, 33154 Salzkotten (DE).  
**KREUTZER, Caroline** [DE/DE]; Poststrasse 16, 49326  
Melle (DE). **MÖCKEL, Bettina** [DE/DE]; Benrode-  
strasse 35, 40597 Düsseldorf (DE). **THIERBACH, Georg**  
[DE/DE]; Gunststrasse 21, 33613 Bielefeld (DE).


(74) Common Representative: **DEGUSSA AG**; Intellectual  
Property Management, Patents And Trademarks, Location  
Hanau, P.O. Box 13 45, 63403 Hanau (DE).

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,  
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,  
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,  
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,  
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,  
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG,  
SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,  
VN, YU, ZA, ZM, ZW.

(84) Designated States (*regional*): ARIPO patent (GH, GM,  
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),  
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),

[Continued on next page]

(54) Title: **PRODUCTION OF L-LYSINE BY GENETICALLY MODIFIED CORYNEBACTERIUM GLUTAMICUM STRAINS**



(57) Abstract: The invention relates to coryneform bacteria which have, in addition to at least one copy, present at the natural site (locus), of an open reading frame (ORF), gene or allele which codes for the synthesis of a protein or an RNA, in each case a second, optionally third or fourth copy of this open reading frame (ORF), gene or allele at in each case a second, optionally third or fourth site in a form integrated into the chromosome and processes for the preparation of chemical compounds by fermentation of these bacteria.





European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

(AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG)

— of inventorship (Rule 4.17(iv)) for US only

**Declarations under Rule 4.17:**

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) for the following designations AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW, ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent

**Published:**

— with international search report

**(88) Date of publication of the international search report:**

18 December 2003

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 02/08464

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C12N15/52 C12N15/53 C12N15/54 C12N15/60 C12P13/08  
C12N1/21 //(C12P13/08,C12R1:15)

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C12N C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, SEQUENCE SEARCH, BIOSIS, EMBASE

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	KRONMEYER, W. ET AL.: "Structure of the gluABCD Cluster Encoding the Glutamate Uptake System of Corynebacterium glutamicum" JOURNAL OF BACTERIOLOGY, vol. 177, no. 5, March 1995 (1995-03), pages 1152-1158, XP002935147 cited in the application abstract page 1154; figure 2 page 1157, column 1, line 9 - line 13 ----- -/--	1-38,40



Further documents are listed in the continuation of box C.



Patent family members are listed in annex.

## \* Special categories of cited documents:

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*G\* document member of the same patent family

Date of the actual completion of the international search

25 July 2003

Date of mailing of the international search report

08.08.2003

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Fuchs, U

## INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/EP 02/08464

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	ISHINO, S. ET AL.: "Nucleotide sequence of the meso-diaminopimelate D-dehydrogenase gene from Corynebacterium glutamicum" NUCLEIC ACIDS RESEARCH, vol. 15, no. 9, 11 May 1987 (1987-05-11), page 3917 XP001056569 cited in the application the whole document	1-37
A	EP 1 094 111 A (DEGUSSA-HÜLS AG) 25 April 2001 (2001-04-25) cited in the application the whole document see especially: page 9 -page 10; examples 5,6; tables 2,3	1-37
A	EP 1 067 192 A (DEGUSSA-HÜLS AG; FORSCHUNGSZENTRUM JÜLICH GMBH) 10 January 2001 (2001-01-10) the whole document see especially: page 12 -page 13; examples 12-15 and page 19; claims 1,7-9,11-15,19,20	1-40
A	EP 1 108 790 A (KYOWA HAKKO KOGYO CO., LTD.) 20 June 2001 (2001-06-20) cited in the application the whole document see especially: page 224 -page 228; examples 2,3	1-40
A	WO 00 63388 A (KYOWA HAKKO KOGYO CO., LTD.) 26 October 2000 (2000-10-26) cited in the application abstract SEQ ID NOS: 17 and 18 page 24 -page 28	1-40
P,A	-& EP 1 172 437 A (KYOWA HAKKO KOGYO CO., LTD) 16 January 2002 (2002-01-16) the whole document	1-40
A	SCHÄFER, A. ET AL.: "Small mobilizable multi-purpose cloning vectors derived from the Escherichia coli plasmids pK18 and pK19: selection of defined deletions in the chromosome of Corynebacterium glutamicum" GENE, vol. 145, no. 1, 22 July 1994 (1994-07-22), pages 69-73, XP001093898 cited in the application the whole document	1-40

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/EP 02/08464

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☒ Claims Nos.: 1-37  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:  
see FURTHER INFORMATION sheet PCT/ISA/210
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☒ No protest accompanied the payment of additional search fees.

**FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210**

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-37 partially and 38, 40 completely

Corynebacterium glutamicum strains DSM13994glu::lysC (see example 1.3), DSM12866glu::lysC (see example 1.4) and DSM12866glu::ddh (see example 2.2), a process for the preparation of lysine involving said strains, a process for the production of said strains, plasmid pK18mobsacBglu1\_1;

2. Claims: 1-37 partially

Corynebacterium glutamicum strains DSM12866pck::lysC (see example 1.6) and DSM12866pck::pyc (see example 4.3), a process for the preparation of lysine involving said strains, a process for the production of said strains;

3. Claims: 1-37 partially and 39 completely

Corynebacterium glutamicum strain DSM12866aecD::lysC (see example 1.8), a process for the preparation of lysine involving said strain, a process for the production of said strain, plasmid pK18mobsacSaecD1\_1;

4. Claims: 1-37 partially

Corynebacterium glutamicum strain DSM12866aecD::dapA (see example 3.2), a process for the preparation of lysine involving said strain, a process for the production of said strain.

## FURTHER INFORMATION CONTINUED FROM PCT/SA/ 210

Continuation of Box I.2

Claims Nos.: 1-37

Present claims 1-19 relate to coryneform bacteria defined by reference to desirable characteristics or properties, namely "which produce chemical compounds", "wherein these have, in addition to at least one copy, present at the natural site (locus), of an open reading frame (ORF), gene or allele which codes for the synthesis of a protein or an RNA, a second, optionally third or fourth copy of the open reading frame (ORF), gene or allele in question", "at a second, optionally third or fourth site in a form integrated into the chromosome ... and the second, optionally third or fourth site not relating to open reading frames (ORF), genes or alleles which are essential for the growth of the bacteria and the production of the desired compound". Furthermore, claim 37 relates to a process for the production of such bacteria.

The claims cover all coryneform bacteria having these characteristic or properties, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such bacteria. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the bacteria by reference to results to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the *Corynebacterium glutamicum* strains produced in examples 1.2-4.3.

The same applies to claims 20-36 relating to a process for the preparation of chemical compounds involving such bacteria. Again, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to the preparation of lysine as described in example 5.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 02/08464

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
EP 1094111	A	25-04-2001	DE 19950409 A1	26-04-2001
			AU 6410400 A	26-04-2001
			BR 0004957 A	29-05-2001
			CA 2322555 A1	20-04-2001
			CN 1308125 A	15-08-2001
			EP 1094111 A2	25-04-2001
			HU 0004115 A2	28-09-2002
			JP 2001149086 A	05-06-2001
			PL 343339 A1	23-04-2001
			SK 15292000 A3	03-12-2001
			US 2003003548 A1	02-01-2003
			US 2002065403 A1	30-05-2002
EP 1067192	A	10-01-2001	DE 19931317 A1	11-01-2001
			AU 4509900 A	11-01-2001
			BR 0002655 A	05-06-2001
			CA 2310870 A1	07-01-2001
			CN 1280184 A	17-01-2001
			EP 1067192 A1	10-01-2001
			HU 0002585 A2	28-09-2002
			JP 2001061485 A	13-03-2001
			SK 10142000 A3	09-04-2001
			US 6200785 B1	13-03-2001
			US 2002086371 A1	04-07-2002
EP 1108790	A	20-06-2001	EP 1108790 A2	20-06-2001
			JP 2002191370 A	09-07-2002
			US 2002197605 A1	26-12-2002
WO 0063388	A	26-10-2000	AU 3837400 A	02-11-2000
			CN 1355849 T	26-06-2002
			EP 1172437 A1	16-01-2002
			WO 0063388 A1	26-10-2000